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ABSTRACT 
 
Epstein-Barr virus (EBV) is a gamma herpes virus persistently infecting over 90% of the adult 
population worldwide.  It has been aetiologically linked to a number of human malignancies, 
including more than 90% of post transplant lymphoproliferative disease (PTLD), 50% of Hodgkin’s 
lymphoma (HL), virtually all undifferentiated nasopharyngeal carcinoma (NPC), and approximately 
10% of gastric carcinoma (GC).  As EBV infection in healthy individuals is mainly controlled by 
virus specific cytotoxic T lymphocytes (CTLs), we hypothesise that engineering T cells with chimeric 
T cell receptors (cTCRs) specific for EBV latent membrane proteins (LMPs) will confer on these cells 
the ability to target and kill the malignant cells of cancers associated with Epstein-Barr virus.  Thus, 
the aim of this project was generate these engineered T cells and to set up a severe combined 
immunodeficient (SCID) mouse model in which to test their effectiveness. 
Three EBV-infected cell lines derived from HL, NPC and GC gave rise to tumours in 11 of 12 (92%), 
12 of 12 (100%) and 10 of 10 (100%) SCID mice respectiv ly, when 1x107 cells were injected 
subcutaneously.  Immunohistochemical analysis showed that the HL SCID tumours were CD4-, 
CD15-, CD20+, CD30+, consistent with a HL Reed-Sternb g cell phenotype, and NPC and GC SCID 
tumours expressed the epithelial cell marker cytokeratin.  Furthermore, all tumours expressed EBV-
encoded RNAs (EBERs) and LMP1.  This was identical to parent cell line expression patterns, and 
hence growth in vivo did not affect cell phenotype. 
T cells were successfully transduced with a retroviral vector encoding a CD19-specific cTCR (CD19-
cTCR) with a mean transduction rate of 13%±6%.  Transduced cells were cytotoxic for HL-derived 
L591 cells in vitro, with specific lysis of 24%±11% at an effector to target ratio of 20:1.  This was 
significantly higher than specific lysis seen in mock transduced cells (p>0.05).  At a tumour 
inoculation dose of 5x106, in vivo sc transfer of 5x107 CD19-cTCR transduced cells was able to 
prevent HL tumour development in 6 of 6 (100%) testmice, whereas 17 of 22 (77%) control mice and 
2 of 3 (66%) mice treated with unmodified EBV-specific CTLs developed tumours.  Moreover, iv 
transfer of 5x107 CD19-cTCR transduced cells mediated complete regression of HL SCID tumours in 
3 out of 6 (50%) mice. 
Phage display selection experiments to isolate a single chain antibody fragment (scFv) specific for 
viral LMPs for incorporation in a cTCR were performed.  Linear, biotinylated and cyclised 
biotinylated peptides derived from the external reve se turn loops of LMP2 were used as target 
antigens.  Despite extensive testing, no reactive clones specific for the peptides were identified. 
The ability of CD19-cTCR transduced cells to specifically lyse HL cells in vitro, and clear tumour 
burden in vivo, supports a future role for engineered T cells in the treatment of HL.  Despite the lack 
of success in isolating a scFv for LMP2, the use of viral antigen specific, cTCR redirected T cells 
remains in principle a valuable therapeutic alternative for EBV-associated malignancies.  The SCID 
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The family Herpesviridae contains over 200 species of virus, isolated from a range 
of animal hosts as diverse as humans, birds, turtles and oysters, although the viruses 
are rarely capable of infecting more than one species.  This wide distribution and 
narrow specificity suggests close co-evolution betwe n virus and host.  Indeed, 
herpesviruses are well adapted for survival within their natural host, with virus 
infection persisting for the life of the host and only very rare fatal illness.  Infection 
in heterologous or immunodeficient hosts can however result in serious disease.   
 
Inclusion with in the herpesvirus family has historically been reliant on the 
architecture of the virion (see 1.1.2).  All herpesviruses also share four principal 
biologic properties: 
1. They encode enzymes used in their own nucleic acid metabolism, DNA 
synthesis and protein processing. 
2. Viral DNA synthesis and capsid assembly occurs in the nucleus, and capsids 
acquire an envelope as they bud through the nuclear m mbrane. 
3. The production of progeny virus during lytic replication invariably results in 
host cell death. 
4. They are capable of latent infection in their naturl hosts.  Viral genomes in 
latently infected cells are maintained as circular episomes, and express a 
subset of viral genes (Roizman et al, 1992). 
Despite these common characteristics, herpesviruses also diverge with respect to 
their biologic characteristics.  Host cell range, site and mechanism of latency, and 
length of replication cycle can all differ (Pellett & Roizman, 2007). 
 
1.1.1 Classification 
Herpesviridae is divided into three subfamilies, the alpha-, beta- and 
gammaherpesvirinae.  This classification was based initially on biological 
Chapter 1                                                                                          Introduction 
 2 
characteristics (Roizman et al, 1981), but more recent evaluation of gene content and 
sequence similarities has upheld the divisions (Roizman & Baines, 1991).  Thus far 
eight human herpes viruses (HHV) have been identifid, and are listed in Table 1.1, 
along with the biological properties that define thherpesvirus subfamilies. 
 
 
Table 1.1: Classification of herpes viruses, with human examples. 
Adapted from Brooks et al (2001). 
biologic properties 
growth  cytopathology site of  
subfamily 
 
 cycle   latency 
human herpesvirus 
number & common name 
 
    1 Herpes simplex  
     virus type 1 
alpha short cytolytic sensory neuron 2 Herpes simplex  
 (~18hrs)  ganglia  virus type 2 
    3 Varicella-zoster virus 
 cytomegalic 
salivary glands  
kidneys 5 Cytomegalovirus 




 lymphoproliferative lymphoid tissue 6 Human herpesvirus 6 
    7 Human herpesvirus 7 
    4 Epstein-Barr virus 
gamma variable lymphoproliferative lymphocytes 8 Kaposi's sarcoma  
          associated herpesvirus 
 
 
1.1.2 Virus structure 
All herpesviruses encode genetic information in a linear double-stranded DNA 
(dsDNA) genome, which is contained in the toroid-shaped core of the virion 
(Furlong et al, 1972).  The surrounding protein coat is made up of 162 capsomeres, 
and the diameter of the icosahedral nucleocapsid is approximately 125nm (Pellett & 
Roizman, 2007).  Each virion is enclosed in a host-cell derived envelope containing 
viral glycoproteins.  Between the nucleocapsid and the envelope is an amorphous 
protein tegument, which may be of varying thickness and asymmetrical distribution.  
The diameter of complete herpesvirus virions range from 120 to 260nm, with 
variation largely due to the thickness of the tegument (Pellett & Roizman, 2007).  A 
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schematic diagram illustrating common herpesvirus structural elements is shown in 





Figure 1.1: The herpesvirus virion. 
Schematic diagram of a mature herpesvirus particle, indicating the nucleocapsid, 
tegument, genome, and membrane of the virion (A). Also, an electron micrograph image 
(B) of a herpesvirus virion, with capsid [c] and envelope [e] clearly visible.  Images from 




Herpesvirus DNA is packaged as a linear molecule, but upon release from the capsid 
into the host cell nucleus immediately circularises and is maintained in the cell as a 
circular episome.  Genomes range in size from 120 to 250 kilobase pairs (kb) and 
encode between 70 and 200 genes.  Herpesviruses can contain terminal and/or 
internal repeated sequences, which may vary in copy number, and some family 
members undergo genome rearrangements resulting in DNA isomers, for example 
herpes simplex virus.  The majority of herpesvirus genes consist of a single open 
reading frame, flanked by 5’ and 3’ nontranslated squence, a promoter sequence 
upstream of a TATA box, and a 3’ polyadenylation signal.  Most, although not all, 
are transcribed by RNA polymerase II and are unspliced.  Approximately 40 ‘core’ 
genes are conserved across all herpesvirus subfamilies, and all herpesviruses encode 
at least one gene of host cell origin (Pellett & Roizman, 2007). 
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1.2 Epstein-Barr virus 
Epstein-Barr virus (EBV) was first discovered in 1964 following culture of Burkitt’s 
lymphoma (BL) tumour material.  In the 1950s, Dr Dennis Burkitt, a British surgeon 
working in East Africa, described a childhood malignancy that now bears his name 
(Burkitt, 1958).  He noted a climatically restricted pidemiology for the disease 
across equatorial Africa, which led him to suggest a mosquito vector and 
consequently an infectious origin for the disease (Burkitt, 1962).  This speculation 
caught the attention of British virologist Dr Anthony Epstein, who together with 
Yvonne Barr established the first BL-derived cell lines from tumour samples sent to 
them by Burkitt (Epstein & Barr, 1964).  When examined by electron microscopy, 
herpesvirus-like particles were clearly present in a proportion of cells (Epstein et al, 
1964).  A similar electron micrograph is shown in F gure 1.1 panel B.  EBV has a very 
narrow host range, as it is able to sustain persistnt infection only in humans.  
However, it is transmitted with ease within the human population, with over 90% of 
adults being EBV seropositive (IARC, 1997). 
 
Primary infection with EBV generally occurs in young children, and is normally 
asymptomatic, although infectious mononucleosis (IM) can result when primary 
infection is delayed until adolescence.  EBV has also been aetiologically linked to a 
number of human malignancies, including BL, post transplant lymphoproliferative 
disease (PTLD), Hodgkin’s lymphoma (HL), nasopharyngeal carcinoma (NPC), and 
gastric carcinoma (GC).  EBV disease associations are covered in more depth in 
section 1.3. 
 
1.2.1 EBV genome 
The EBV genome is 184kb in size, has a guanine-cytosine content of 60% and a 
characteristic set of repeat sequences.  There are tandem reiterated 0.5kb terminal 
repeat (TR) sequences at both ends of the genome and the unique region is divided 
by four 3kb reiterated internal repeats (IR) (Kieff & Rickinson, 2007).  The circular 
viral episome is formed by covalent linking of the TRs (Lindahl et al, 1976).  Each 
cell infected with EBV contains multiple copies of the episome (Sugden et al, 1979). 
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The prototype EBV, a laboratory strain designated B95-8, was first isolated in 1973 
(Miller  et al, 1973) and fully sequenced in 1984 (Baer et al, 1984).  Sequencing was 
carried out using a BamHI fragment library, and as a result genes, promoters, open 
reading frames (ORF) and polyadenylation sites are often named with reference to 
the restriction fragment in which transcription begins.  For example, BZLF1 refers to 
a protein situated in the first (1) leftward (L) ORF (F) of the BamHI (B) Z fragment 





Figure 1.2: BamHI fragments of the EBV genome. 
BamHI restriction endonuclease map of the B95-8 EBV genome.  Fragments are 
named by size, with A being the largest and lowercase letters the smallest.  
Areas within the terminal repeats (TR) are designated Nhet due to the 
heterogeneity which results from the variable number of TRs in different virus 
isolates.  Image adapted by permission from Macmillan Publishers Ltd: Young 
LS and Rickinson AB. Nature Reviews Cancer 4:757-768, copyright (2004). 
 
 
EBV is subdivided into Types 1 and 2.  Division is based on genome sequence, with 
differences in the regions encoding EBV nuclear antige s (EBNA)–LP, 2, 3A, 3B 
and 3C.  Type 2 is more common in African populations, while Type 1 is more 
common in Western countries (Zimber t al, 1986), although both types are present 
worldwide.  Type 1 EBV is more efficient than Type 2 at transforming lymphocytes 
in vitro (Rickinson et al, 1987), and delayed infection with Type 1 EBV was 
significantly more likely to result in IM then a Type 2 infection in a recent 
epidemiological study (Crawford et al, 2006). 
 
1.2.2 EBV encoded transcripts and proteins 
There are 84 major unique ORFs contained in the EBV genome (Baer et al, 1984).  
EBV is able to vary the combination of genes expressed in latent and lytic infection 
through the use of different gene promoters. 
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1.2.2.1 EBV encoded latent proteins and RNAs 
Cells latently infected with EBV constituently express up to nine viral proteins.  
These are six EBV nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, 
EBNA3C, and EBNA-LP), and three latent membrane proteins (LMP1, LMP2A, and 
LMP2B).  Also expressed are two types of viral-encoded, but non-translated RNA, 
BARTs (BamHI A rightwards transcripts) and EBERs (EBV-encoded RNA).  





Figure 1.3: The EBV episome. 
The double-stranded DNA episome of EBV, showing the 
location of latent antigens and promoters.  Image adapted by 
permission from Macmillan Publishers Ltd: Young LS and 




The role and function of each latent antigen is summarised below and in Table 1.2, 
and reviewed in several references (Kuppers, 2003; Young & Murray, 2003; Young 
& Rickinson, 2004; Kieff & Rickinson, 2007). 
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Table 1.2: EBV latent transcripts. 
The open reading frame (ORF), requirement for B cell transformation and 
main function of EBV antigens expressed during latency.  Adapted from 
Johannessen & Crawford (1999) and Williams & Crawford (2006). 
protein ORF role in transformation main function 
EBNA1 BKRF1 yes genome maintenance 
EBNA2 BYRF1 yes viral transactivator 
EBNA3A BLFR3/BERF1 yes EBNA2 agonist, disrupts cell cycle 
EBNA3B BERF2A/B no EBNA2 agonist 
EBNA3C BERF3/4 yes EBNA2 agonist, disrupts cell cycle 
EBNA-LP BWRF1 no cooperates with EBNA2 
LMP1 BNLF1 yes viral oncogene, survival factor 
LMP2A BARF1/BNRF1 no survival factor 
LMP2B BNRF1 no survival factor 
EBERs BCRF1 no not known 




Two small, non-polyadenylated RNA transcripts, EBER1 and EBER2, are expressed 
in all forms of EBV latency.  They localise to the nucleus, with approximately 104 to 
105 copies per cell (Howe & Steitz, 1986).  EBERs are not essential for EBV 
transformation of B cells (Swaminathan et al, 1991), however expression in EBV-
negative BL cell lines increases tumourigenicity, promotes cell survival and induces 
interleukin (IL)-10 expression and thus EBERs may play a role in the pathogenesis 
of some EBV-associated malignancies, such as BL (Komano et al, 1999; Kitagawa et 
al, 2000; Ruf et al, 2000). 
 
EBNA1 
EBNA1 is the only viral protein translated in all forms of latency (see 1.2.2.2), and 
also the only EBNA found during lytic infection (Reedman & Klein, 1973).  The 
protein has four components: an internal glycine-alanine repeat flanked by two 
arginine-rich domains, and a carboxy-terminal DNA binding and dimerisation 
domain.  The two arginine-rich domains facilitate th random association of EBNA1 
with chromosomal DNA, whilst the carboxy-terminal binds in a sequence-specific 
manner to the EBV origin of replication (oriP).  These interactions are essential for 
EBV episome maintenance and partitioning of viral DNA into daughter cells during 
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mitosis (Yates et al, 1985; Lee et al, 1999).  Expression of EBNA1 in the B cell 
compartment of transgenic mice leads to development of lymphomas, and thus 
EBNA1 can be considered a viral oncogene (Wilson et al, 1996).  EBNA1 also 
interacts with certain viral promoters, and is thereby involved with transcriptional 
regulation of LMP1 and the EBNAs, including itself (Kieff & Rickinson, 2007).   
 
Despite being expressed in all virus-infected cells and capable of raising an antibody 
response (Dillner et al, 1984), EBNA1 is a relatively poor target for cytotoxic T cells 
(CTL) (Rickinson & Moss, 1997).  Generally, EBV-positive cells expressing only 
EBNA1 are resistant to CTL mediated lysis in vitro (Levitskaya et al, 1995) and CTL 
responses against EBNA1 are absent in vivo (Rickinson & Kieff, 2007).  The internal 
glycine-alanine repeat inhibits degradation of the protein via the 
ubiquitin/proteosome pathway, which prevents endogen us presentation of EBNA1 
peptides by major histocompatibility complex (MHC) class 1 to T cells (Levitskaya 
et al, 1997).  However, EBNA1 processed exogenously is capable of eliciting a 
response from both cluster of differentiation (CD) 4+ and CD8+ T cells, and CTLs 
responsive to EBNA1 have been detected in EBV seropositive individuals (Blake et 
al, 1997; Voo et al, 2002). 
 
EBNA2 
EBNA2 is essential for the transformation of B cells into lymphoblastoid cell lines 
(LCL), inducing proliferation and blocking differentiation (Hammerschmidt & 
Sugden, 1989).  It is a potent transactivator of both cellular and viral genes, 
upregulating expression of the B cell antigens CD21 and CD23 (Cordier et al, 1990; 
Wang et al, 1991), as well as LMP1 and LMP2 (Wang et al, 1990b; Zimber-Strobl et 
al, 1991).  It also transactivates the viral promoter C (Cp), initiating the switch from 
promoter W (Wp) to Cp seen early in B cell infection, and thus plays a role in its 
own transcriptional regulation by this upregulation f its promoter (Puglielli et al, 
1997).  EBNA2 does not bind directly to the transcriptional elements, rather it 
interacts with the cellular sequence specific DNA binding protein recombinant signal 
binding protein (RBP)-Jκ, which is partly responsible for targeting EBNA2 to
promoters (Grossman et al, 1994). 
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EBNA3 
The three members of the EBNA3 family, EBNA3A, 3B and 3C are encoded on 
tandemly located genes and appear to have a common origi .  EBNA3A and 3C are 
essential for B cell transformation, while EBNA3B is not (Tomkinson et al, 1993).  
All three proteins are transcriptional regulators, binding RBP-Jκ and repressing the 
effects of EBNA2 upregulation (Le Roux et al, 1994; Robertson et al, 1996).  
EBNA3B also upregulates the cytoskeletal protein vimentin and the activation 
antigen CD40, but down regulates the BL associated ntigen CD77 in BL cell lines 
(Silins & Sculley, 1994).  EBNA3C upregulates CD21 and acts with EBNA2 to 
coactivate the LMP1 promoter (Allday & Farrell, 1994; Marshall & Sample, 1995).  
EBNA3A and 3C also repress activation of the Cp promoter (Cludts & Farrell, 1998; 
Radkov et al, 1999).  
 
EBNA-LP 
The EBNA leader protein (LP) is so named as its coding sequence is included as the 
leader of each EBNA mRNA transcript (see Figure 1.3).  It is not absolutely required 
for B cell transformation, but it does contribute to the efficient outgrowth of LCLs 
(Allan et al, 1992).  EBNA-LP also interacts with EBNA2, coactiva ng the Cp and 
LMP1 promoters (Harada & Kieff, 1997). 
 
LMP1 
The major transforming protein of EBV, LMP1 is essential for EBV-induced 
transformation of B lymphocytes in vitro (Kaye et al, 1993).  It is an integral 
membrane protein with a short amino terminal domain, six hydrophobic 
transmembrane domains joined by short reverse turns, and a 200 amino acid (aa) 
carboxy terminus signalling domain (Figure 1.4).  The signalling domain contains two 
functional sequences known as C-terminal activation regions (CTARs), identified by 
their ability to activate the nuclear factor (NF)-κB pathway (Huen et al, 1995).  
LMP1 post-translationally inserts into cell membranes, primarily the plasma 
membrane (Hennessy et al, 1984).  Both terminal domains are cytoplasmic, and t 
least one of the three outer reverse turn loops is exposed on the cell surface 
(Liebowitz et al, 1986).  The protein self-aggregates in the plasma membrane, which 
appears to be a property of the multiple transmembrane domains, often forming into 
a single cap-like structure (Liebowitz et al, 1986). 




Figure 1.4: Structure of LMP1. 
Schematic of LMP1, showing orientation within a cell 
membrane.  LMP1 has a cytoplasmic amino-terminal domain, 
six hydrophobic transmembrane domains joined by short reverse 
turns, three of which are extracellular, and a carboxy-terminal 
cytoplasmic signalling domain containing two C-terminal 
activation regions (CTARs).  The sequence highlighted in red 
was used as a target peptide in phage display selections (see 
Figure 5.14).  Image adapted by permission from Macmillan 
Publishers Ltd: Young LS and Rickinson AB. Nature Rviews 




Functional studies have shown LMP1 operates as a member of the tumour necrosis 
factor receptor (TNFR) superfamily.  It resembles CD40, another member of the 
TNFR superfamily, and is able to partially substitute for CD40 in vivo, providing 
activation and differentiation signals to B cells (Uchida et al, 1999).  LMP1 
constituently activates several downstream signalling pathways including the NF-κB 
pathway, JNK/AP-1, p38/MAPK, and JAK/STAT pathways.  It is activation of the 
NF-κB pathway which contributes to many of the phenotypic consequences of LMP1 
expression, such as upregulation of cell surface adhesion molecules (CD11a/CD18, 
CD54, CD58) and activation antigens (CD21, CD23, CD40) (Wang et al, 1990a), 
and induction of anti-apoptotic proteins (bcl-2, A20) (Henderson et al, 1991).  LMP1 
also downregulates the pro-apoptotic genes such as Bax (Dirmeier et al, 2005) and 
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upregulates cytokine production (IL-6, IL-8, IL-10) (Eliopoulos et al, 1999).  The 
LMP1 transmembrane domains, for homoaggregation, and at least one of the two 
CTARs within the carboxy terminus signalling domain, are required for NF-κB 
activation (Huen et al, 1995; Floettmann & Rowe, 1997).  LMP1 also affects the 
growth of EBV infected epithelial cells, inhibiting differentiation and inducing 
morphological changes in some cell lines (Dawson et al, 1990; Fahraeus et al, 1990), 
although it was able to induce tumourigenicity without inhibiting differentiation in 
others (Nicholson et al, 1997).  Expression of LMP1 in the skin of transgenic mice 
also induced epidermal hyperplasia and altered keratin gene expression (Wilson et al, 
1990). 
 
LMP1 is transcribed in lytic as well as latent infection.  During late lytic infection a 
truncated LMP1 containing only the last two transmembrane and the intracellular 
carboxy terminus domain is also transcribed (Hudson et al, 1985).  This truncated 
protein does not have the transforming ability of full length LMP1 (Baichwal & 
Sugden, 1989).  Detection of truncated but not fulllength LMP1 in pure virus 
preparations and also immediately after infection suggests it is incorporated into 
virions and thus may have a role to play in newly infected cells (Erickson & Martin, 
1997).  It has also been suggested that LMP1 functio s in the maintenance of latency 
in vivo, as it has been shown to bind the viral transactivting lytic protein BZLF-1 in 
cells that do not express EBNA2 (Adler t al, 2002).   
 
LMP2 
The LMP2 gene spans the fused terminal repeats of the EBV episome, and thus can 
only be transcribed when the genome is circularised (Laux et al, 1988).  It encodes 
two distinct proteins, LMP2A and LMP2B, which share 12 hydrophobic 
transmembrane domains and a 27 aa cytoplasmic carboxy terminal domain (Figure 
1.5).  LMP2A also contains a 119 aa amino terminal cytoplasmic domain not found 
in LMP2B (Sample et al, 1989).  Neither LMP2A nor LMP2B are essential for B cell 
transformation in vitro, although LMP2A is transforming in epithelial cells (Scholle 
et al, 2000).  Both LMP2s are under the transcriptional control of EBNA2, although 
cellular factors can substitute in its absence. 
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Figure 1.5: The structure of LMP2. 
Schematic of LMP2, showing orientation within a cell membrane.  LMP2 has twelve 
hydrophobic transmembrane domains joined by short reverse turns, six of which are 
extracellular.  The amino-terminal cytoplasmic signalli g domain is unique to LMP2A, 
and not present in LMP2B.  It contains an immunoreceptor tyrosine-based activation 
motif (ITAM) which binds lyn and syk tyrosine kinases.  Tyrosine residues in the 
amino-terminal domain are indicated by circles.  The sequences highlighted in red were 
used as target peptides in phage display selections (see Table 5.2).  Image adapted by 
permission from Macmillan Publishers Ltd: Young LS and Rickinson AB. Nature 
Reviews Cancer 4:757-768, copyright (2004). 
 
The amino terminal cytoplasmic domain unique to LMP2A contains an 
immunoreceptor tyrosine-based activation motif (ITAM) (Miller  et al, 1994).  The 
ITAM binds lyn and syk tyrosine kinases, sequestering them from the B cell receptor 
(BCR) and thus inhibiting antigen stimulated B cell activation and consequently 
EBV progression into lytic replication (Miller et al, 1995).  In the absence of the 
BCR, LMP2A can mimic its actions and provide growth and survival signals to B 
cells (Caldwell et al, 1998; Mancao & Hammerschmidt, 2007).  LMP2 forms 
aggregates in the plasma membrane of B cells, co-localising with LMP1 
(Longnecker & Kieff, 1990).  It has been suggested that the function of LMP2B may 
be to modulate spacing of the LMP2A signalling domains in these plasma membrane 
aggregates (Longnecker & Miller, 1996).   
 
BARTs 
Highly spliced polyadenylated RNAs known as BARTs are bundantly expressed 
during EBV latency.  Their function remains unclear, but they have been identified in 
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NPC (Hitt et al, 1989), BL (Tao et al, 1998) and HL (Deacon et al, 1993), as well as 
in latently infected healthy individuals (Chang et al, 1999) and thus may play a role 
in viral persistence.  BARTs contain three ORFs which could potentially encode 
protein, but reports on translation of BARTs are inco sistent. 
 
1.2.2.2 Latency programs 
Latent infection with EBV is characterised by differential expression of latent 
proteins, which result from the use of alternative promoters.  These expression 
patterns are termed the latency I or latency program, l tency II or default program, 
and latency III or growth program, and are characteristic of certain EBV-associated 
diseases (Rowe t al, 1992).  Latent infection of B cell in healthy seropositive 
individuals is designated latency program 0.  EBV antigen expression, promoter 
usage and disease associations are shown in Table 1.3. 
 
 
Table 1.3: EBV latency programs.  
The gene expression patterns, EBNA1 promoter and human diseases associated with 
EBV latency programs.  Adapted from Crawford (2001), Rickinson & Kieff (2007), and 
Straathof et al (2003).  [*variable EBNA1 expression in healthy seropositive individuals; 
**expression of LMP2A observed in a proportion of GC cases] 
latency      genes EBNA1 disease 
program    expressed promoter association 
Latency 0  EBERs Qp  
  EBNA1*   
  LMP2A   
  BARTs   
Latency I  EBERs Qp Burkitt's lymphoma 
latency   EBNA1  Gastric carcinoma ** 
  BARTs   
Latency II  EBERs Qp Hodgkin's lymphoma 
default  EBNA1  Nasopharyngeal carcinoma 
  LMP1 and/or  T cell lymphomas 
  LMP2A   
  BARTs   
Latency III  EBERs Cp/Wp Lymphoblastoid cell lines in vitro 
growth  EBNA1  Infectious mononucleosis 
  EBNA2  Post transplant lymphoproliferative  
  EBNA3A, 3B, 3C  disease 
  LMP1, 2A, 2B   
  EBNA-LP   
    BARTs     
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1.2.2.3 Lytic replication 
The exact conditions needed in vivo to initiate a switch from latent to lytic infection 
remain unclear.  In vitro, around 2 to 10% of cells in LCL cultures spontaneously 
enter the lytic cycle (Henle & Henle, 1966).  Lytic replication in vitro can also be 
induced by surface immunoglobulin (Ig) crosslinking or phorbol ester treatment.  
During lytic replication, the EBV genome is amplified 100- to 1000-fold 
(Hammerschmidt & Sugden, 1988) and progeny virus is released, resulting in host 
cell death. 
 
EBV lytic replication is controlled by a separate set of genes to those involved with 
latency.  These are expressed consecutively, in groups f immediate early, early and 
late genes, as outlined below. 
 
Immediate early genes 
Immediate early gene products are required for transactivation of lytic replication 
(Cox et al, 1990).  The two principle immediate early genes are BZLF1 and BRLF1.  
Their gene products, the proteins ZEBRA and Rta, coordinately upregulate 
expression from early EBV promoters (Chevallier-Greco t al, 1986).  ZEBRA also 
binds to the lytic origin of replication (oriLyt), inducing viral replication, and can 
downregulate the latency III promoter Cp (Kenney t al, 1989).  Rta activates 
transcription of the viral DNA polymerase, BALF5 (Liu et al, 1996). 
 
Early genes 
EBV early genes encode at least 30 proteins, most of which are enzymes involved in 
genome replication.  BALF2 is a DNA binding protein important in viral DNA 
replication (Fixman et al, 1992).  BHRF1 has homology to the cellular bcl-2 gene, 
and potentially works to prevent apoptosis in lytic infection (Henderson et al, 1993).  
The viral DNA polymerase, which is essential for lytic replication of the EBV 
genome, is also an early gene (Hammerschmidt & Sugden, 1988).  Detection of 
serum antibodies against immediate early and early proteins is used in the diagnosis 
of IM.  Gene products include those of BZLF1, BALF2 and BHRF1, which are 
collectively termed early antigen (EA).  
 
Chapter 1                                                                                          Introduction 
 15 
Late genes 
The EBV late genes encode structural glycoproteins as well as proteins involved in 
cleavage of the progeny virus DNA concatamers, and packaging, envelopment and 
egress of virions.  The major viral structural proteins are the gp350/220 (from ORF 
BLLF1), and the gp85/25/42 (from ORFs BKRF2, BZLF2 and BXLF2) complexes.  
These proteins are also involved in attachment and entry of the virion to the host cell, 
with gp350/220 facilitating virion attachment to B cells via CD21 (Tanner et al, 
1987), and gp85/25/42 mediating viral fusion via human leukocyte antigen (HLA) 
class II molecules (Li et al, 1995).  Detection of serum antibodies against viral capsid 
antigen (VCA), and membrane antigen (MA), are also u ed in the diagnosis of IM.  
VCA is comprised of a range of virus nucleocapsid proteins, while antibodies against 
MA are generally specific for gp350, and to a lesser extent gp220 and gp85. 
 
1.2.3 EBV infection 
1.2.3.1 Cell tropism 
In a healthy human host, EBV exhibits a distinct cell tropism, infecting lymphocytes.  
Lymphocyte infection is generally found in B cells, and although EBV infection of T 
and natural killer (NK) cells has been seen it is generally restricted to disease states 
(Kanegane et al, 1996; Kanegane t al, 1998).  There is also evidence for EBV 
infection of monocytes and macrophages (Shimakage et al, 1999; Savard et al, 
2000).  Circulating infected B cells are rare in healthy carriers, with between 1 and 
50 EBV-positive cells per million B cells (Khan et al, 1996), and are generally of the 
memory phenotype, that is surface Ig-positive but surface IgD-negative (Babcock et 
al, 1998). 
 
Definitive proof for EBV infection of epithelial cells in healthy individuals has yet to 
be found.  Evidence supporting a role for epithelial infection by EBV includes the 
presence of viral DNA, mRNA and protein in explant cultures of tonsils from healthy 
seropositive individuals (Pegtel t al, 2004), and the presence of EBV genomes in 
dysplastic epithelial cells adjacent to gastric adenocarcinomas (Shibata & Weiss, 
1992).  The presence of EBV in NPC cells and oral hairy leucoplakia (OHL) lesions 
demonstrates that EBV is capable of epithelial infection under certain conditions 
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(Klein et al, 1974; Greenspan et al, 1985).  In vitro, primary epithelial cells are 
generally EBV resistant, although some cell lines can be infected. 
 
1.2.3.2 Infection of B cells 
EBV preferentially infects resting B cells, attaching to cells via CD21, also known as 
the C3d complement receptor or complement receptor 2 (Fingeroth et al, 1984; Weis 
et al, 1984).  The EBV envelope glycoprotein complex gp350/220 acts as the CD21 
ligand (Nemerow et al, 1987).  Monoclonal antibodies to CD21 block viral infection 
(Fingeroth et al, 1984), however EBV BLLF1-deletion mutants which lack 
gp350/220 are infectious, albeit with reduced efficien y, indicating that gp350/220-
CD21 binding is not essential for infection with EBV (Janz et al, 2000).  The 
heterotrimer of gp85/25/42 mediates fusion of the virus envelope with the cell 
membrane (Li et al, 1995).  Gp42 is an essential component of the trimer, and its 
association with HLA Class II molecules as coreceptors for fusion plays a critical 
role in infection (Spriggs et al, 1996; Wang & Hutt-Fletcher, 1998; Haan et al, 
2000).  In vitro infection of B cells with EBV results in the establishment of LCLs, 
which are continually cycling and capable of proliferating indefinitely (Pope t al, 
1968; Steel et al, 1977; Tosato et al, 1985). 
 
Circularisation of the EBV genome occurs around 12-16 hours post infection when 
measured during in vitro experiments (Kieff & Rickinson, 2007).  Of the multiple 
linear copies released into the cell, only one copy is circularised, resulting in a clonal 
population of infected cells (Sugden t al, 1979).  Infection drives the resting B cell 
into G1, then S-phase, and the circular episome is r plicated whilst linear copies are 
lost.  EBNA2 and EBNA-LP are the first viral genes to be expressed, with gene 
products detectable by about 12 hours post infection (Alfieri  et al, 1991).  Initially, 
EBNA2 is under the control of the Wp promoter, but a switch to Cp occurs at around 
36 hours, concurrent with expression of the remaining EBNAs and LMP1 
(Woisetschlaeger et al, 1989; Woisetschlaeger t al, 1990).  LMP2A and 2B are not 
detected for up to 70 hours post infection, the time when EBERs transcripts also 
reach substantial levels (Alfieri et al, 1991).  
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Infection of primary B cells with EBV also results in a range of phenotypic changes, 
similar to those seen with antigen activation of cells, including cell clumping, 
increased villous projections and increased vimentin expression.  There is also 
upregulation of the cell surface antigens CD21, CD23, CD39, CD40, CD44, and 
HLA class II; increase in the production of cytokines Il-6, IL-8 and IL-10; and 
increased expression of the adhesion molecules CD11a/CD18 (LFA-1), CD54 
(ICAM-1), and CD58 (LFA-3) (Wang et al, 1988; Eliopoulos et al, 1999; Kieff & 
Rickinson, 2007). 
 
1.2.3.3 Infection of epithelial cells 
Epithelial cells generally do not express CD21, nord  they have HLA class II 
molecules on their surface.  Therefore, entry of EBV into epithelial cells is evidently 
via a different method to B cells, although the exact mechanism remains unclear.  
Using recombinant EBV carrying a neomycin resistant gene, both CD21-dependent 
and -independent infection of epithelial cell lines has been shown in vitro 
(Yoshiyama et al, 1997; Fingeroth et al, 1999).  Infection is reliant on gp85/25 
complexes, which do not include the gp42 component essential for B cell infection 
(Li  et al, 1995; Molesworth et al, 2000).  Interaction between the viral BMRF2 
protein and β1 or α5β1 on the basolateral surface of epithelial cells hasalso been 
suggested as an alternative CD21-independent mediator of viral entry (Tugizov et al, 
2003).  In vitro, efficient cell to cell infection from EBV-infected LCLs to epithelial 
cell lines derived from a range of carcinomas has been described (Imai et al, 1998), 
as has transfer of virus from B cell membranes to epith lial cells (Shannon-Lowe t 
al, 2006).  This process requires cell to cell contact nd is CD21-independent, 
although induction of CD21 expression enhanced infection efficiency (Chang et al, 
1999).  Once the initial infection is achieved, it is possible that cell to cell spread 
amongst epithelial cells occurs (Tugizov et al, 2003). 
 
1.2.4 EBV primary infection and persistence in vivo 
EBV infection usually occurs via the oral route, with nfectious virus particles shed 
in saliva (Gerber et al, 1972).  Primary infection generally occurs in young children, 
with seroprevalence increasing with age until over 90% of adults are seropositive.  
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Primary infection is normally asymptomatic, although a self-limiting disease, IM, 
occurs in 25-50% of cases where primary infection occurs in adolescence 
(Niederman et al, 1970; Sawyer et al, 1971; Crawford et al, 2006).  In IM, primary 
infection is brought under control by a strong CD8+ CTL response to both latent and 
lytic antigens (Khanna & Burrows, 2000).  The production of EBV-specific 
antibodies also helps limit the spread of infectious virus.  These immune responses 
are not able to completely eliminate EBV from the body, and a persistent latent 
infection is established. 
 
The identity of the EBV primary target cell and reservoirs of persistent infection i  
vivo remain controversial.  Two hypothetical cycles of infection have been proposed, 
and are outlined below. 
 
B cell hypothesis 
EBV enters the host in saliva and infects naïve B cells.  Waldeyer’s ring is a band of 
lymphoid tissue in the throat comprising the palatine, lingual and pharyngeal tonsils.  
Here the epithelium of the oropharynx dips deeply into the underlying lymphoid 
tissue to form structures known as crypts, where the epithelial layer is not so tightly 
knit together and lymphoid cells are able to infiltrate (Perry & Whyte, 1998).  This 
allows EBV in saliva direct access to B cells as a primary target for infection 
(Faulkner et al, 2000; Macsween & Crawford, 2003).  Infected naïve B cells undergo 
clonal expansion and express a latency III phenotype (Babcock et al, 2000; Babcock 
& Thorley-Lawson, 2000).  After expansion, cells take on some of the characteristics 
of germinal centre B cells, expressing the germinal centre-specific marker CD10 and 
an EBV latency II phenotype (Babcock et al, 2000).  Under normal conditions, 
uninfected naïve B cells progress to become germinal centre B cells following 
antigen-mediated activation, whereupon a minority receive the two survival signals 
required for transition into memory B cells (Liu & Arpin, 1997).  These B cell 
survival signals are delivered firstly through the BCR via antigen mediated receptor 
cross-linking, and secondly through the interaction of CD40 on the B cell with CD40 
ligand (CD154) on the surface of T helper cells, which are brought together by MHC 
class II antigen presentation by the B cell.  Cells which fail to receive the second 
survival signal from a helper T cell die by apoptosis.  In the absence of antigen, EBV 
provides infected B cells with these activation and survival signals via LMP1 
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(replacing CD40) and LMP2 (replacing the BCR) (Caldwell et al, 1998; Kilger et al, 
1998).  The infected cells then differentiate into memory B cells, the long term 
reservoir for EBV.  Memory B cells are naturally long-lived, allowing the virus to 
persist for extended periods, with EBNA1 the only viral protein expressed (Hochberg 
et al, 2004).  This latency 0 phenotype prevents detection of infected cells by EBV-
specific T cells.  Antigen-specific differentiation f  EBV infected memory cells into 
plasma cells causes the virus to progress into lytic phase (Crawford & Ando, 1986; 
Laichalk & Thorley-Lawson, 2005), resulting in progeny virus, and subsequent 
infection of naïve B cells to replenish the virus-infected pool (Thorley-Lawson & 
Gross, 2004).  Latently infected memory B cells activ ted by antigen can also re-
circulate back to Waldeyer’s ring.  The infectious progeny virions released there are 
thus in a position not only to infect bystander naïve B cells, but also exit to the saliva 
for transmission.  The resistance of individuals with X-linked agammaglobulinaemia, 
who lack Bruton’s thymidine kinase and consequently functional B cells, to EBV 
infection (Faulkner et al, 1999), lends further support for the hypothesis that B cells 
are both the site of primary as well as persistent infection. 
 
Epithelial cell hypothesis 
EBV enters the host in saliva and infects epithelial cells of the oropharynx.  Lytic 
replication results in the spread of infection to B cells present beneath the epithelium.  
The cycle of infection then continues as outlined in the B cell hypothesis above.  
Later, infection of the epithelial cells by virus released from plasma cells provides an 
exit to the saliva for transmission.  Corroborating evidence for epithelial to B cell and 
B cell to epithelial cell EBV infection is provided by the finding that EBV produced 
in B cells is ‘epithelial cell tropic’ and EBV produced in epithelial cells is ‘B cell 
tropic’, that is they more efficiently infect the opposite cell type (Borza & Hutt-
Fletcher, 2002).  To elaborate, EBV infection of B cells requires the three part 
complex of viral glycoproteins gp85/25/42 to bind to HLA class II, whilst infection 
of epithelial cells requires only gp85/25 two part complex (Li et al, 1995).  Each 
virion carries both three-part and two-part complexes, but virions produced by B 
cells carry relatively more two-part complexes and virions produced by epithelial 
cells carry relatively more three-part complexes, resulting in greater infection 
efficiency for the opposite cell type (Borza & Hutt-Fletcher, 2002).  Ex vivo, cultures 
of resected tonsils have been shown capable of latent infection (Pegtel et al, 2004).  
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Additionally, chronic low level oro/nasopharyngeal virus shedding is seen in healthy 
EBV seropositive individuals (Yao et al, 1985), which may not be produced by B 
cells as they yield relatively little infectious virus, thus supporting a role for 
epithelial infection in amplification of virus to enhance transmission. 
 
A role for other cell types in EBV cycle of infection 
Two recent studies have proposed a role for additional cell types in the EBV cycle of 
infection.  In ex vivo experiments, Tugizov et al (2007) showed that monocytes 
infected with EBV in vitro were able to facilitate the spread of EBV infection t  
epithelial cells in 9 of 14 tongue and buccal explant cultures, compared with 
infection of 1 of 20 explants incubated with cell free virus, with EBV-positive 
langerhans cells (LC) and activated macrophages/LC detected in close proximity to 
the infected epithelial cells (Tugizov et al, 2007).  EBV DNA was also detected in 
CD14+ peripheral blood monocytes of 69% of human immunodeficiency virus 
(HIV) patients and 47% of healthy volunteers.  Furthe more, EBV-infected LCs with 
a latency 0 or reactivation phenotype were observed in vivo, albeit rarely, in oral 
biopsy tissue from HIV patients (Walling et al, 2007).  Therefore, since circulating 
monocyte/macrophage/LCs can migrate to tissue sitesincluding the oral mucosa, 
these cells may serve as a vehicle for virus transfer between the memory B cell 
reservoir in the blood compartment and the oral epith lium from whence virus is 
shed in saliva for transmission. 
 
1.2.5 The immune response to EBV 
As the majority of people are EBV seropositive, yet s roconvert silently and sustain 
an asymptomatic persistent infection, it is clear th t the immune system must play an 
important role in maintaining the balance between virus and host.  This key role for 
the immune system is supported by the presentation of immunocompromised patients 
with severe EBV-associated disease, such as PTLD.  As seroconversion usually goes 
unnoticed, information on primary infection is principally drawn from the study of 
IM, and what is known about primary infection in children tends to suggest a broadly 
similar immune response (Pedneault et al, 1996).  In IM, EBV elicits both a humoral 
and cellular response. 
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1.2.5.1 Humoral response to EBV infection 
The humoral response to primary EBV infection is characterised by detectable IgM 
and IgG to VCA and EA, detectable IgM but relatively weak IgG to MA, and the 
absence of IgG to EBNA (Moss et al, 2001).  The composition of VCA, EA and MA 
is covered in section 1.2.2.3.  Antibodies to gp350/22  within the MA complex are 
neutralising (Thorley-Lawson & Geilinger, 1980).  The pattern of antibody 
expression changes during convalescent IM and for healt y EBV carriers, with stable 
IgG titres to EBNA, VCA and MA, but undetectable or weak IgG to EA (Moss et al, 
2001).  Approximately 85% of IM patients also have transient serum heterophile 
antibodies.  Heterophile antibodies are IgM moleculs reactive with antigens of an 
unrelated species.  In the case of IM, these are antibodies specific for EBV which 
cross react with epitopes found on equine, ovine and bovine erythrocytes.  Detection 
of heterophile antibodies reactive with horse erythrocytes is the basis of the IM 
monospot diagnostic test.  These heterophile antibodies may be the product of EBV 
infected B cells (Garzelli et al, 1984).  EBV specific antibodies could serve to 
prevent virus superinfection or halt further virus transmission (Thorley-Lawson & 
Poodry, 1982; Yao et al, 1991). 
 
1.2.5.2 Cellular response to EBV infection 
NK cells 
Higher NK cell numbers have been correlated with lower viral load in IM patients, 
leading to the suggestion that NK cells may play a role in resolution of primary 
infection with EBV (Williams et al, 2005).  However, of themselves NK cells are not 
sufficient to control initial infection, as shown by outgrowth of EBV-positive lesions 
in primary infection of immunocompromised post transplant patients who retain NK 
function. 
 
CD8+ T cells 
The CD8+ cytotoxic T cell response to EBV infection s characterised by an antigen 
driven proliferation of CD8+ T cells displaying an ctivated phenotype (Callan et al, 
1996).  In IM, these cells are present in both the circulation and the tissues in very 
high numbers.  During acute infection as represented by IM, the CD8+ T cells 
primarily recognise immediate early and early lytic antigens, whilst cells specific for 
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latent antigens are relatively few (Steven et al, 1997; Hislop et al, 2002).  The CD8+ 
T cell response evolves as infection progresses, with numbers of cells specific for 
lytic antigen dropping as primary infection is resolved, while the numbers of cells 
specific for latent antigen increase with the establishment of persistent infection 
(Hislop et al, 2002).  The immune response to latent antigens is dominated by clones 
specific for the EBNA3A, 3B and 3C proteins (Khanna et al, 1992; Murray et al, 
1992).   The long-term memory T cell compartment maintains cells specific for both 
EBV lytic and latent epitopes, with lytic antigen specific cells typically more 
abundant than those specific for latent antigen (Tan et al, 1999).  EBNA3 
immunodominance is preserved amongst those cells specific for latent antigens. 
 
CD4+ T cells 
Although the CD4+ T cell response to EBV infection s less well characterised than 
that of CD8+ T cells, CD4+ cells specific for both lytic and latent antigens have been 
shown in IM patients, secreting interferon (INF)-γ in a T helper (Th)-like manner 
(Precopio et al, 2003).  There is distinct divergence in the capacity of different EBV 
latent proteins to elicit a CD4+ T cell response, with EBNA1 and EBNA3C the most 
immunogenic ahead of LMP1 and LMP2 (Leen et al, 2001).  That is, PBMCs from a 
higher proportion of EBV-seropositive donors secreted INF-γ in response to peptide 
stimulation. This is in contrast to the CD8+ cell response, where EBNA3C is the 
most immunogenic, followed by EBNA1, LMP2 and LMP1 in decreasing order 
(Leen et al, 2001).  In addition to their T-helper role, CD4+ cells may also contribute 
a cytotoxic response, as they have been shown capable of inducing EBV-specific 
lysis via Fas/FasL interaction (Paludan et al, 2002) or granulysin secretion (Sun et al, 
2002).  CD4+ T memory cells are less frequent and of a narrower specific range than 
their CD8+ counterparts (Leen et al, 2001).  
 
1.3 EBV and associated diseases 
Although the majority of EBV-infected individuals exhibit no EBV-related illness, 
primary EBV infection can result in IM and EBV has l o been linked with a number 
of lymphoid and epithelial malignancies.  Despite th ubiquitous nature of the virus, 
EBV-associated malignancies are relatively rare and frequently geographically 
restricted, indicating that infection is not the only ecessary factor in tumourigenesis.  
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With increases in the number of iatrogenically immunosuppressed transplant and 
HIV patients there has been a concomitant rise in EBV-associated disease in this 
setting.  A number of these EBV-associated diseases re discussed in the following 
sections. 
 
1.3.1 Infectious mononucleosis 
IM is a self-limiting lymphoproliferative disease which occurs during primary EBV 
infection of adolescents and young adults.  In Western countries, early studies 
estimated that IM developed in approximately 50% of cases where primary infection 
was delayed until adolescence (Niederman et al, 1970; Sawyer et al, 1971), although 
a more recent study has put this figure closer to 25% (Crawford et al, 2006).  In 
developing nations, IM is relatively rare condition, as virtually all children are 
infected with EBV by the age of two (de-The et al, 1978). 
 
Symptoms of IM can include fever, pharyngitis, lymphadenopathy, general malaise 
and fatigue, and vary in severity from patient to patient.  The illness is usually self-
resolving within two to four weeks, although fatigue may persist during the 
convalescent period for up to six months.  In rare cases, a chronic IM can develop 
(Okano et al, 1991).  Massive lymphocytosis is characteristic of IM, and the 
proliferating cells are predominantly activated CD8+ T cells, although there is also 
an expansion of infected B cells (Klein et al, 1976; Callan et al, 1996).  These 
activated T cells are found in tissues throughout the body, and release 
proinflammatory cytokines including IL-1, IL-6, and TNF-α (Foss et al, 1994), 
which are thought to result in the immunopathological clinical manifestation of IM. 
 
It is not known why primary EBV infection in adolescence can result in IM when 
virtually all childhood infections are asymptomatic.  One possible explanation is that 
the dose of virus received via the oral route is much higher in adolescents.  This 
elevated initial exposure results in the numbers of infected B cells exceeding some 
threshold limit, driving antigen induced T cell proliferation to the point where 
resulting cytokine levels become pathogenic (Rickinson & Kieff, 2007). 
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1.3.2 Burkitt’s lymphoma 
BL typically presents as a tumour of the jaw, although other sites including the 
ovaries, mammary glands, liver, intestine, and kidneys are not uncommon.  Two 
forms of BL have been described, endemic BL (eBL) and sporadic BL (sBL).  eBL is 
found in equatorial Africa and Papua New Guinea, is EBV associated in 96% of 
cases, and is one of the most common childhood cancers in equatorial Africa.  sBL 
occurs worldwide with an incidence that is at least 50-fold less than eBL, and an 
EBV association which falls anywhere between 20 to 70%, depending on the region 
surveyed (Rickinson & Kieff, 2007).   
 
BL tumours consist of rapidly proliferating cells of B cell origin, which 
phenotypically resemble germinal centre B cells, and sporadic infiltrating 
macrophages, resulting in a characteristic ‘starry sk ’ histology (Gregory et al, 
1987).  In EBV-associated BL, the virus is present in all malignant cells in multiple 
episomal copies, and is clonal, suggesting EBV infection is an early event in 
tumourigenesis (Neri et al, 1991).  BL cells display a type I latency, with EBV gene 
expression limited to EBNA1, EBERs and BARTs.  The oncogenic potential of 
EBNA1 remains a topic of contention, but a possible rol  in BL cell survival has 
been suggested (Kennedy et al, 2003).  EBERs may also contribute to the 
pathogenesis of BL, as they have been reported to induce IL-10 (Kitagawa et al, 
2000) and mediate INF-α resistance (Nanbo et al, 2002), potentially supporting 
tumour growth and survival (Ogden t al, 2005). 
 
Three key factors in the tumourigenesis of eBL have be n identified: EBV infection, 
c-myc translocation, and malaria.  All BL tumour cells contain one of three 
chromosomal translocations which result in constitutive expression of c-myc, leading 
to cellular proliferation without differentiation (Rickinson & Kieff, 2007).  BL has 
long been linked with malaria, beginning with Dennis Burkitt himself.  Areas of high 
incidence of holoendemic malaria and eBL in Africa coincide, and where malaria 
prevalence has fallen due to mosquito eradication, s  has the occurrence of eBL 
(Crawford, 2001).  Current theories propose that both malarial stimulation of infected 
B cells and inhibition of EBV-specific CTLs contribute to the pathogenesis of eBL.  
Supporting these hypothesises, children with acute malaria have up to five times 
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more circulating EBV infected cells than those with convalescent malaria (Lam et al, 
1991), and acute malarial infection results in T cell immune suppression (Whittle t 
al, 1984). 
 
BL is highly sensitive to chemotherapy, with disease free survival rates of 80% after 
effective treatment.  Surgery is rarely necessary to remove tumour bulk.  More 
recently, chemotherapy in combination with the chimeric monoclonal antibody 
(mAb) Rituximab, which is specific for the B cell antigen CD20 expressed in BL, 
has been advocated by the Children’s Oncology Group (Giulino et al, 2007). 
 
1.3.3 Hodgkin’s lymphoma 
HL is the most common lymphoma of young people in industrialised countries.  It 
has four subtypes; nodular sclerosing (NS), mixed cellularity (MC), and lymphocyte 
depleted (LD), collectively known as classical HL, and the clinically separate entity 
lymphocyte predominant (LP) HL.  Worldwide, EBV is more likely to be associated 
with classical rather than LP HL, with around 50% of classical HL EBV-associated 
in western countries (Rickinson & Kieff, 2007).  Within classical HL, it is more 
commonly associated with the MC and LD rather than the NS subtype (Rickinson & 
Kieff, 2007).  IM has also been shown to be a risk factor for HL (Glaser & Jarrett, 
1996). 
 
Incidence of classical HL has traditionally been described as bimodal, with peaks in 
children and older adults, although this depiction may be somewhat simplistic and 
subject to regional variations, for example the childhood peak occurs later in affluent 
compared to non-affluent societies (Macfarlane et al, 1995).  To more accurately 
reflect these geographical deviations, a four-disease model of classical HL has been 
proposed (Figure 1.6; Jarrett, 2006).  Based on the age at diagnosis, tumour EBV 
association and history of IM, classical HL is divied into four subgroups, each with 
peak of incidence in a different age group, three of which are EBV-associated (peaks 
a, b, c in Figure 1.6).  Of these three EBV-associated peaks, the first subgroup (a) is 
composed of early childhood disease, which generally occurs before the age of 10 
years, and accounts for the majority of childhood cases in developing countries.  The 
second peak (b) represents disease in young adults, which is associated with previous 
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IM.  The final EBV-associated subgroup (c) represent  disease in older adults, with 
HL generally occurring after 55 years of age.  The largest subgroup is EBV-negative 
HL, and accounts for the young adult peak in developed countries.  The height and 







HL is unusual histologically, as less than 2% of the tumour is made up of the 
malignant mononuclear Hodgkin or multi-nuclear Reed-Sternberg cells (collectively 
referred to as HRS cells), with the remaining tumour b lk consisting of non-
neoplastic infiltrating lymphocytes.  As with BL, EBV in HL is clonal, indicating 
that infection occurs early in tumourigenesis (Anagostopoulos et al, 1989).  When 
present, the virus is carried in HRS cells (Wu et al, 1990), with every malignant cell 
EBV-positive, even in cases with multiple lesions (Rickinson & Kieff, 2007).  
Rearrangement of Ig genes indicates that these HRS cells are derived from germinal 
centre B cells (Kanzler et al, 1996b).  A proportion show obvious ‘crippling’ 
mutations in rearranged Ig genes, which under normal conditions should have 
resulted in apoptosis in the germinal centre, and EBV may play a role in the rescue of 
these cells (Kanzler et al, 1996b).  HRS cells display an EBV latency II phenotype, 
and the expression of LMP1 and LMP2A may promote survival in the pre-apoptotic 
germinal centre cells.  LMP1 likely contributes to the survival and proliferation of 
Figure 1.6: Incidence of 
Hodgkin’s lymphoma. 
Four disease model of 
classical HL, divided on the 
basis of age, EBV-association 
and history of IM.  
Subgroups are childhood (a), 
early adulthood (b), late 
adulthood (c), and EBV-
negative (d).  Adapted from 
Jarrett (2006). 
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HRS cells through activation of NF-κB (Bargou et al, 1997).  Although LMP2A has 
been shown to provide growth and survival signals to B cells (Caldwell et al, 1998), 
its ability to do this in HL is uncertain, as HRS cells have down-regulated many of 
the components involved in the BCR signalling pathway (Schwering et al, 2003). 
 
HL is one of the most treatable adult cancers, with about 80% of patients achieving 
complete remission, although around one third of patients do relapse.  Most 
treatment strategies involve combinations of chemotherapy and radiotherapy, with 
Rituximab an option for refractive or recurrent disea e, as a proportion of HRS cells 
express CD20 (Klimm et al, 2005).   
 
1.3.4 Nasopharyngeal carcinoma 
In contrast to BL and HL, NPC is of epithelial origin and specifically is a tumour of 
the nasopharyngeal squamous epithelium.  Although NPC occurs worldwide, 
incidence is low except amongst the Inuit peoples, in southeast Asia, and most 
especially in southern China, where it occurs in up to 3 in 10000 people (Lopes t al, 
2003).  Incidence remains high in males of Cantonese descent irrespective of 
location, suggesting genetic factors contribute to disease aetiology (Lopes et al, 
2003).  A number of potential environmental cofactors, such as a diet high in salted 
fish, have also been identified (Armstrong et al, 1998). 
 
There are two broadly defined NPC subtypes; differentiated (keratinized), and 
undifferentiated/poorly differentiated (non-keratinized) NPC.  EBV is found in 
virtually all undifferentiated NPC tumours, but the association with differentiated 
NPC remains controversial (Rickinson & Kieff, 2007).  Undifferentiated NPC 
lesions are composed of EBV-positive carcinoma cells with a prominent EBV-
negative non-neoplastic lymphocyte infiltration (Klein et al, 1974).  Interactions 
between these cell types may be important for tumour growth, as tumour cells and 
infiltrating lymphocytes express molecules, for example CD40 on tumour cells and 
CD40 ligand on T cells, allowing them to exchange signals involved in cell 
activation and proliferation (Agathanggelou et al, 1995). 
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As with BL and HL, EBV in NPC is clonal, indicating infection occurs prior to 
expansion of malignant cells (Raab-Traub & Flynn, 1986).  However, pre-malignant 
genetic events in the absence of EBV infection have lso been found, potentially 
predisposing cells to EBV infection (Lo & Huang, 200 ), which is in agreement with 
data showing that epithelial cells unable to differentiate preferentially support stable 
EBV infection (Knox et al, 1996).  To what extent EBV influences the outgrowth of 
malignant cells remains unclear.  At a transcriptional level, NPC displays an EBV 
latency II phenotype, but this is not maintained through to the level of protein 
expression.  The EBNA1 protein is readily detectable in NPC (Young et al, 1988), 
while LMP1 protein expression is variable, being detected only in around 35% cases 
(Young et al, 1988).  Expression of LMP2A has been confirmed by PCR in 94% of 
NPC tumours and 46% of NPC tumours by immunohistochemistry (Brooks et al, 
1992; Heussinger et al, 2004).  NPC patients are also the only group to reproducibly 
show a serum antibody response to the LMP2 (Frech et al, 1990; Lennette et al, 
1995).  
 
NPC is radiosensitive, and radiotherapy controls disease in 80% of early stage cases.  
However, early stage tumours often go undetected and treatment of late stage NPC is 
less reliable and frequently results in refractory  recurrent disease (Wei & Sham, 
2005).  EBV DNA in serum correlates with tumour burden, and can be used to 
monitor for disease relapse (Lo et al, 1999a; Lo et al, 1999b), as can serum 
concentration of IgA specific for VCA (Chien et al, 2001). 
 
1.3.5 Gastric carcinoma 
Approximately 10% of gastric carcinomas worldwide are EBV-associated.  
However, as GC is one of the most common carcinomas the absolute incidence is 
considerable, with estimates exceeding 50000 cases per year.  Both typical 
adenocarcinomas and carcinoma with prominent lymphocyte infiltration, such as 
seen in NPC, have been associated with EBV (Shibata & Weiss, 1992; Nakamura et 
al, 1994). 
 
EBV-associated GC has traditionally been classified as expressing a type I latency.  
However, although EBNA1 is the only latent protein consistently expressed, LMP2 
Chapter 1                                                                                          Introduction 
 29 
transcripts have also been detected in a proportion of cases (Imai et al, 1994; Sugiura 
et al, 1996).  EBV in GC is clonal (Imai et al, 1994), with almost 100% of cells 
containing the EBV episome (Zur Hausen t al, 2004), suggesting EBV infection is 
an early event in tumourigenesis.  However, conflicting reports of the presence of 
EBV in preneoplastic dysplastic mucosa means the role of EBV in tumourigenesis 
has yet to be fully elucidated (Takada, 2000; Zur Hausen et al, 2004). 
 
An interdisciplinary approach is used in the treatment of GC, utilising a combination 
of surgery, chemotherapy and radiotherapy.  However, patient outcome remains 
poor, with frequent disease progression and tumour etastases. 
 
1.3.6 EBV-associated malignancies in the immune com promised  
PTLD 
The lymphoproliferative disorders that arise post transplant, collectively known as 
post transplant lymphoproliferative disease (PTLD), are a heterogeneous collection 
of disorders principally of B cell origin (Hopwood & Crawford, 2000), although T- 
and NK-derived tumours have also been observed (Nalesnik, 2001).  About 90% of 
PTLD tumours are EBV-positive (Crawford, 2001).  The key risk factors for 
development of PTLD are iatrogenic T cell immunosuppression and primary EBV 
infection post transplant, with around 50% PTLD associated with a primary EBV 
infection (Thomas et al, 1990).  PTLD occurs in up to 10% of all transplant patients, 
but rates of incidence vary greatly depending on the organ being transplanted, EBV 
status of the donor and recipient, and choice of immunosuppressive regimen (Burns 
& Crawford, 2004).  PTLD is most likely to occur within one year of transplant, 
when immunosuppressive therapy is highest, with tumours developing after one year 
associated with poorer prognosis (Williams & Crawford, 2006).  PTLD in bone 
marrow transplant (BMT) recipients is generally of donor origin, while PTLD in 
solid organ recipients is of recipient origin. 
 
PTLD tumours usually exhibit a latency III phenotype, although other more 
restricted patterns have been reported (Young et al, 1989a; Cen et al, 1993).  
Decreasing immunosuppressive treatment can lead to an increase in the EBV-
specific immune response and tumour regression, at leas in early stage disease, and 
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this evidence, together with the expression of a full range of latent proteins indicates 
a reliance on EBV to drive the proliferation of malignant cells (Hopwood & 
Crawford, 2000).  EBV in PTLD can be polyclonal, but is generally oligo- or 
monoclonal, with PTLD arising later than one year post transplant more likely to be 
monoclonal (Hanto et al, 1989).  The EBV genome is not necessarily found in all 
cells within the tumour mass, as infiltrating EBV-negative non-neoplastic 
lymphocytes often contribute a substantial proportion (Perera et al, 1998).  Unlike 
other EBV-associated diseases, the malignant cells of PTLD are able to arise from 
various points in the B cell differentiation pathway nd derivation can include naïve 
and memory B cells, as well as post-germinal centre B cells with mutations which 
would normally lead to apoptosis (Timms et al, 2003). 
 
First line treatment for solid organ PTLD is reduction in immunosuppression 
(Gottschalk et al, 2005).  This is particularly effective against polyclonal tumours, 
however it is difficult to sustain given the often grave consequences of graft loss, so 
disease relapse is common.  Response rates to reduction of immunosuppression vary 
from 25 to 63% in adults and 40 to 86% in children (Gottschalk et al, 2005; Taylor et 
al, 2005).  Chemotherapy had been the second line treatment of choice until the 
advent of Rituximab, and combination of the two is now generally used with 
response rates up to 100% (Gottschalk et al, 2005).  Individually, use of 
chemotherapy is complicated by increased severity in side-effects due to immune 
suppression  (Oertel et al, 2003), and Rituximab monotherapy can lead to CD20- 
tumour outgrowth (Verschuuren et al, 2002).  Rituximab alone is the first line 
treatment for BMT PTLD.  Trials of cellular therapy using EBV-specific CTLs for 
refractive disease have shown promising results in both bone marrow and solid organ 
PTLD (Rooney et al, 1995; Haque et al, 2007). 
 
X-linked lymphoproliferative disease 
Individuals with a rare genetic disease, X-linked lymphoproliferative (XLP) disease, 
carry a mutation or deletion in a gene that appears to be important in T and B-cell 
homeostasis after viral infection (Coffey t al, 1998; Sayos et al, 1998).  The gene 
product, SLAM-associated protein (SAP), is expressed in activated T and NK cells, 
and interacts with the signalling lymphocytic activa on molecule (SLAM) protein, a 
member of the Ig superfamily expressed on T, B and dendritic cells (Sayos et al, 
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1998).  In healthy individuals, it is thought that the SAP/SLAM interaction acts to 
maintain equilibrium in Th1/Th2 cytokine production (Williams & Crawford, 2006).  
Similar to the situation in IM, EBV infection in XLP individuals leads to a massive 
proliferation of EBV-infected B cells and a concomitant rise in CTLs.  Unlike IM, 
the CTLs of XLP patients apparently cannot limit this B cell expansion, and the 
resulting cytokine response, primarily of Th1 cytokines such as INF-γ, is thought to 
result in the extensive organ damage seen in such patients (Williams & Crawford, 
2006).  Over 50% of XLP patients die in this acute phase, and the majority of 
survivors go on to develop lymphomas or hypogammaglobulinemia. 
 
AIDS-related lymphomas 
The immune deficiency which results from HIV infection means HIV/acquired 
immune deficiency syndrome (AIDS) patients are at high risk for the development of 
lymphoproliferative diseases.  Like PTLD, AIDS-relat d lymphomas are a 
heterogeneous group of disorders.  AIDS-related central ervous system lymphomas 
derive from post germinal centre B cells and almost always contain EBV, while 30 to 
50% of peripheral lymphomas are EBV-associated (MacMahon et al, 1991).  BL in 
HIV patients is an AIDS-defining illness, but has a less than 50% association with 
EBV (Hamilton-Dutoit et al, 1993).  HL also occurs in HIV-infected individuals, 
with HIV-positive individuals 3 to 7 times more likely to develop HL, and more than 
90% of HIV-HL is EBV-associated (Audouin et al, 1992; Glaser et al, 2003). 
 
1.3.7 Oral hairy leucoplakia 
Oral hairy leucoplakia (OHL) is unique amongst EBV-associated disorders in that it 
alone results from lytic virus replication, confirming that EBV can infect and 
replicate in non-malignant epithelial cells, at least in an immune compromised 
setting (Greenspan et al, 1985).  Benign lesions occur in the superficial layers of the 
tongue epithelium, with EBV DNA, lytic and some laten  proteins found in more 
differentiated but not basal epithelial cells (Thomas et al, 1991).  OHL occurs in the 
immune suppressed, especially late stage AIDS patients, although it has also been 
seen rarely in non-immunosuppressed individuals (Lozada-Nur et al, 1994).  
Treatment is with the antiviral aciclovir, and result  in complete clearance of lesions, 
attesting to the importance of lytic replication in lesion formation (Greenspan et al, 
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1990).  Withdrawal of treatment leads to recurrent disease, although it is not know if 
this derives from reactivation of epithelial infection or reseeding of the epithelium 
from the lymphoid reservoir. 
 
1.4 Animal models of EBV-associated malignancies 
Although the majority of in vivo data collected on EBV have been from latently 
infected healthy virus carriers, or those with abnormal responses to virus as in IM, 
there are also a number of animal models available for the study of EBV infection 
and associated diseases. 
 
1.4.1 Non-human primates 
As mentioned previously, herpesviruses generally have a very narrow host range, and 
initial attempts to study the pathogenesis of EBV by virus inoculation of old world 
primates revealed little evidence of infection (Frank et al, 1976).  This was most 
likely due to presence of cross-reactive immunity to endogenous 
lymphocryptoviruses (LCVs) (the gammaherpesvirinae genus of which EBV is the 
human representative), or species specific restriction for LCV-induced B cell 
transformation (Frank et al, 1976; Moghaddam et al, 1998). 
 
EBV infection of new world primates has proved more successful in providing 
models for human infection.  EBV infection causes an IM-like illness in the common 
marmoset (Callithrix jacchus), with lymphoproliferation and a viral antibody 
response (Wedderburn et al, 1984).  Persistent infection ensues, as shown by 
oropharyngeal virus shedding and EBERs latent transc ipt  detectable in PBMCs 
(Cox et al, 1996; Farrell et al, 1997).  Infection does not result in the development of 
lymphomas, and differs from the human disease in that ere is limited B cell 
involvement (Emini et al, 1986).  Conversely, EBV infection of the cotton-tp 
tamarin (Sagunius oedipus) causes acute B cell lymphoproliferation, with PTLD-like 
tumours displaying a latency III phenotype (Shope et al, 1973; Young et al, 1989b).  
This model has been used for the testing of EBV vaccines (Epstein et al, 1985).  
However, it is not a wholly accurate representation of the human condition, as 
disease has a rapid onset,  lymphoproliferation occurs in 100% of animals infected, 
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and those which survive this initial disease do not become persistently or latently 
infected (Shope t al, 1973). 
 
Primate models using simian gammaherpesvirus have also been explored.  Old world 
primate endogenous LCVs share a number of common features with EBV including  
the ability to transform B cells, and their genomes can be arranged collinearly with 
EBV and show a large degree of homogeneity (Wang et al, 2001).  Also, the 
functional mechanisms of latent genes appear to be largely preserved.  Rhesus 
macaques are naturally immune to EBV, but infection via the oral route with a rhesus 
LCV results in an infection with many similarities to EBV infection in humans, such 
as lymphadenopathy, latent infection in PBMCs, and persistent virus shedding in 
oropharyngeal secretions (Moghaddam et al, 1997).  Co-infection of EBV and simian 
immunodeficiency virus (SIV) in macaque can also result in the development of B 
cell lymphomas containing EBV latent transcripts, analogous to the development of 
EBV-related lymphomas in AIDS patients (Pingel et al, 1997). 
 
The drawbacks to use of non-human primates in the study of EBV infection and 
associated disease are as for any use of such animals.  The high expense, specialist 
facilities, endangered status, and requirement for a high level of security ensure that 
only limited researchers can afford their use, and then usually only in small numbers.  
Additionally, primate biology is not as well understood as that of other species, 
particularly the mouse, and development of transgenic a imals is cumbersome.  
Thus, murine models have been more extensively used, and in particular the SCID 
mouse. 
 
1.4.2 Mouse models 
1.4.2.1 Murine herpesvirus-68 
Originally isolated in 1980 from the bank vole (Blaskovic et al, 1980), murine 
herpesvirus-68 (MHV-68) was later classified a gammaherpesvirus based on 
sequence analysis (Efstathiou et al, 1990).  Its ability to cause both productive and 
latent infection in laboratory mice analogous to EBV infection provided the first 
small animal model for studying immunity and pathogenesis of a gammaherpesvirus 
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in its natural host (Sunil-Chandra et al, 1992a; Sunil-Chandra et al, 1992b).  
However, for the investigation of novel cancer therapies SCID mouse models of 
EBV-associated malignancies are more appropriate, providing as they do human 
cells as targets, and so have been more widely used in this application. 
 
1.4.2.2 Models in immunodeficient mice 
In 1983, a CB17 mouse mutant was described which lacked functional T and B cells 
(Bosma et al, 1983).  The SCID gene was later found to encode the Prkdc protein 
kinase, a component of the recombinase enzyme system ne ded for dsDNA break 
repair, which is also essential for correct joining of the V(D)J sequences in B and T 
cell receptors during lymphocyte maturation (Schuler et al, 1986; Fulop & Phillips, 
1990).  Improper joining leads to non-functional receptors and a block in 
differentiation.  The immunodeficiency is somewhat ‘leaky’, with 2 to 23% of SCID 
mice developing a limited number of functional T and B cells (Bosma et al, 1988).  
CB17 SCID mice do have functional NK cells (Dorshkind et al, 1985), although 
development of new SCID strains has led to animals with reduced NK activity, for 
example non-obese diabetic-SCID mice (Shultz et al, 1995). 
 
The first immunodeficient mouse model of cancer was developed in 1977, when 
athymic nude mice (which lack functional T cells) were shown to support the growth 
of solid human tumours (Fogh et al, 1977).  SCID mice also accept 
xenotransplantation of human cells and tissues, and SCID mice engrafted with cell 
lines derived from a vast array of human malignancies have been used as in vivo 
models for tumour biology, growth, angiogenesis andmetastasis, as well as to test 
novel cancer therapies.  Modelling for EBV-associated disease began when human-
SCID chimeras (hu-PBL-SCID) were developed by grafting SCID mice with human 
PBMCs for studying human immune function (Mosier et al, 1988).  It was noted that 
the chimeras often developed EBV-positive lymphomas of B cell origin if the donors 
were EBV seropositive, (Mosier et al, 1988).  These tumours were subsequently 
shown to be immunoblastic lymphomas phenotypically identical to PTLD tumours 
(Rowe et al, 1991).  Since then additional SCID models of PTLD have been 
developed, using LCLs administered by subcutaneous (sc) or intraperitoneal (ip) 
injection to give rise to tumours (Rowe et al, 1991; Lacerda et al, 1996).   
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With respect to EBV-associated malignancies, several HL cell lines, albeit mostly 
EBV-negative, also form tumours when administered by sc or ip injection in CB17 
SCID mice (von Kalle et al, 1992).  Models of HL with metastasising disease have 
been established using sc or intravenous (iv) inoculation of HL-derived cell lines 
(Winkler et al, 1994).  Xenotransplantation models of EBV-associated NPC and GC 
are also available (Cheung et al, 1999; Oh et al, 2007).  The use of 
xenotransplantation SCID mouse models in the testing of novel cancer therapies is 
well established, and yet some debate remains as to their actual worth, given the 
variable power of such models to accurately predict how humans will respond to the 
treatment in the clinic (Sausville & Burger, 2006).  The major drawback of murine 
xenograft models is that, with regard to genetics and histology, the mouse tumours 
are not always representative of the respective human tumour.  An alternative is 
genetically engineered mouse models, where tumours are histologically and 
genetically accurate models of human cancer and like the human situation are 
heterogeneous with regard to frequency, latency, and growth.  Indeed, there is a 
transgenic model of BL in the mouse (Kovalchuk et al, 2000).  However, BL is 
unique amongst EBV-associated malignancies in having the well defined genetic 
mutations needed for the deliberate establishment of a transgenic model.  Thus, for 
the time being at least, the advantages of xenotranspl tation - synchronized, easily 
observable tumours with a high degree of predictabili y and rapidity of tumour 
formation, which makes them easy to use – means that it is the preclinical model of 
choice for the testing of novel therapies against EBV-associated cancer. 
 
1.5 Cancer immunotherapy 
Most cancer patients are treated by a combination of surgery, radiation and/or 
chemotherapy.  The term cancer encompasses such a broad spectrum of conditions 
that it is difficult to treat with a uniform therapy regimen.  Complications also arise 
with conventional treatment of metastatic disease.  Immunotherapy of cancer has 
developed to overcome the limitations of conventional therapy, such as associated 
toxicities and refractory disease.  The human immune system is exceptionally 
specific once a suitable target is found, and can also provide long term protective 
memory against disease relapse after initial burden is cleared.  The main strategies of 
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cancer immunotherapy aim at exploiting the potential of tumour-specific antibodies 
and cellular immune effector mechanisms. 
 
1.5.1 Antibody therapy 
The first therapeutic mAb, Orthoclone OKT3, was licensed for clinical use in the 
1980s (OrthoGroup, 1985).  It was a mouse antibody specific for human CD3 used to 
treat transplant rejection.  Since then, advances such as humanisation, chimerisation 
and labelling have led to a proliferation in the clini al applications of antibodies.  In 
2007 there were nine antibody based therapies for the treatment of cancer licensed by 
the American Food and Drug Agency (FDA), for such diverse malignancies as breast 
cancer, lymphoma, leukaemia, and colon cancer (FDA Orange Book, 2007), and five 
antibody based therapies for the treatment of cancer li nsed in the UK (British 
National Formulary, 2007). 
 
Monoclonal antibodies can be directed towards a number of cancer-associated 
antigens, including vascular growth factors, tumour-associated stroma, host immune 
checkpoints, and tumour cell surface antigens.  Targeting vascular growth factors, for 
example, can inhibit angiogenesis and prevent tumour growth.  Alone, one vascular 
endothelial growth factor (VEGF)-specific mAb had little direct anti-tumour activity 
but in combination with chemotherapy it prevented neo-vascularisation and 
improved survival in patients with metastatic colon cancer (Hurwitz et al, 2004).  
The tumour stroma may also contain components which differ from those in healthy 
tissue.  The fibroblast activation protein (FAP) found on tumour-associated 
fibroblasts is thought to play a role in tumour formation and metastasis.  Whilst a 
phase I trial of a mAb to FAP in combination with radiotherapy did not result in an 
objective tumour response, encouragingly the mAb did localise to the tumour site 
with no uptake by organs, showing successful tumour targeting (Scott et al, 2003).  
Therapeutic antibodies may also have a role to playin immunomodulation, targeting 
host cells and proteins that act as inhibitory checkpoints in the immune system.  
Cytotoxic T lymphocyte antigen (CTLA)-4 is expressed mainly on CD4+ T cells and 
acts as a CD28 antagonist, regulating activation sig al 2 to CD8+ T cells (Thompson 
& Allison, 1997).  CTLA-4 antibody blockade has been used to enhance anti-tumour 
immunity in patients previously treated with anti-can er vaccines, such as irradiated 
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tumour cells, dendritic cells engineered to express tumour-associated antigens 
(TAA), or TAA peptides alone (Hodi et al, 2003; Phan et al, 2003).  
 
Two of the best known mAbs currently available for the treatment of cancer in the 
UK are Herceptin, for use in breast cancer, and Rituximab, for the treatment of B cell 
lymphomas.  Herceptin is a humanised IgG1 mAb directed against the extracellular 
domain of the HER2/neu protein, a member of the epidermal growth factor receptor 
family.  HER2/neu is overexpressed in around 30% of breast cancers (Slamon et al, 
1987).  In combination with chemotherapy, treatment with Herceptin has shown a 
52% improvement in event-free survival at three years compared with chemotherapy 
alone in breast cancer patients (Romond et al, 2005).  Expression level of HER2/neu 
is critical to the efficacy of Herceptin, with tumours expressing relatively lower 
levels of HER2/neu being generally unresponsive to antibody treatment (Vogel et al, 
2002).  Rituximab is also a humanised IgG1 mAb, which targets the mature B cell 
surface antigen CD20.  The mechanism of Rituximab is complex, and includes 
induction of apoptosis, inhibition of cell growth, complement mediated cell lysis, 
sensitisation of cells to chemotherapy and radiotherapy, and induction of antibody-
dependant cellular cytotoxicity (Smith, 2003).  In clinical trials for low grade 
previously treated B-cell lymphoma, overall response rates of Rituximab alone are 
around 50% (Berinstein et al, 1998; McLaughlin et al, 1998; Piro et al, 1999), and it 
is now regularly used alone or in combination with o er therapies for the treatment 
of non-Hodgkin’s lymphoma (NHL) and other B cell lymphomas including HL and 
PTLD, as well as rheumatoid arthritis. 
 
Antibodies also have the potential to deliver cytotoxic agents to tumour cells (Wu & 
Senter, 2005).  Generally, this requires the antibody t  bind to a target which will 
result in the internalisation of the antibody and conjugate, and is likely to be most 
effective in diffuse malignancies or individual tumours of small volume. The most 
common conjugate, radioisotopes, can be used for tumour imaging, especially occult 
tumour deposits, in addition to treatment.  In a tri l comparing Rituximab with a 
radiolabelled mAb also specific for CD20 in lymphoma patients whose disease had 
worsened after chemotherapy, overall response rates w re 34% and 80% 
respectively, with complete response 20% and 34% respectively (Gordon et al, 
2004).  A variety of small molecule toxins have also been linked to mAb, including 
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the antibiotic calicheamicin, and these conjugated molecules are collectively known 
as immunotoxins.  In a trial for patients with recurrent acute myeloid leukaemia, 
treatment with a CD33-specific calicheamicin conjugated antibody resulted in an 
overall response rate of 26%, with a 13% complete rsponse rate (Larson et al, 
2005).  Agents undergoing clinical development for cancer therapy include 
additional radioisotopes and toxins, as well as drug, cytokine and enzyme 
alternatives (Wu & Senter, 2005; Shaw et al, 2007).   
 
One of the major challenges of antibody drug delivery for cancer therapy is low 
penetration of antibodies into solid tumours (Jain, 2001).  In comparison with whole 
antibodies (Figure 1.7 A), antibody fragments such as Fab (fragment antigen binding 
– that section of an antibody which contains the antige  binding site after proteolysis 
of the molecule; Figure 1.7 B) or scFv (single chain variable fragment – antibody 
variable heavy [VH] and variable light [VL] domains connected by a short DNA 
sequence encoding a flexible peptide linker; Figure 1.7 C) potentially offer better 
tumour penetration whilst retaining full antibody binding specificity (Hudson & 
Souriau, 2003).  Additionally, these smaller molecus are more rapidly cleared from 
the blood, minimising the opportunity for therapeutic side-effects (Holliger & 
Hudson, 2005).  In a phase I trial, an enzyme-linked scFv specific for the oncofetal 
antigen carcino-embryonic antigen (CEA) expressed on a variety of 
adenocarcinomas localised to tumour sites, with the enzyme used converting a 
subsequently administered prodrug to the active form (Mayer et al, 2006).  The 
treatment was well tolerated in patients, and a 10%reduction in tumour diameter was 
seen in one patient by computed tomography imaging.   
 
Fab and scFv fragments are monovalent, which may led to sub-optimal target 
affinity and tumour retention.  However they do have the potential to be engineered 
into dimeric, trimeric or tetrameric molecules in order to increase functional affinity.  
scFv di-, tri-, and tetramers (Figure 1.7 D,E,F, respectively) can be constructed by 
shortening the peptide linker joining the VH and VL domains, facilitating self-
assembly.  The multimers combine the levels of tumor penetration and blood 
clearance seen with the monomers, with the tumour retention as a result of higher 
avidity seen in full antibody molecules (Holliger & Hudson, 2005).  Similarly, Fab 
dimers with improved avidity and stability can also be engineered, usually by 
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chemical conjugation (Figure 1.7, G)  A Fab dimer also specific for CEA has been 
shown to localise to tumours and deliver radioisotopes in a preclinical trial for 
colorectal cancer (Casey et al, 2002).  Alternatively, molecules with multiple 
specificities can be engineered (Figure 1.7 D,G), with the potential to cross-link two 




Figure 1.7: Antibody molecule with Fab and scFv fragments. 
Schematic representation of an intact antibody molecule (IgG; A) together 
with antibody fragments Fab (B) and scFv (C).  The engineered recombinant 
fragments scFv dimer (D), trimer (E), and tetramer (F), and a Fab dimer (G) 
are also shown.  Variable domains are represented by coloured ovals with 
antigen-binding sites indicated by dots.  Constant domains are represented by 
uncoloured ovals.  Colours also represent different specificities in the scFv 
and Fab dimmers (D,G).  Image reprinted by permission from Macmillan 




The engineering of antibodies to produce scFv as outlined above has generally been 
performed in a human or murine setting.  From a therap utic standpoint, human 
derivatives are currently superior as they have a lower immunogenicity, although as 
research continues it may eventually be possible to identify and remove 
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immunogenic epitopes on molecules.  Nevertheless, in recent years much interest has 
focused on the immunoglobulin-like molecules of thecamelids (camels and llamas) 
and cartilaginous fish (wobbegong and nurse sharks) species, which have evolved 
naturally single-domain variable regions.  The requirement for relatively short 
complementarity determining regions (CDR) (short amino acid sequences within the 
variable domains of an antibody which come into contact with antigen during 
antibody-antigen interactions) in human and murine antibodies limits target antigens 
to predominantly flat or concave topologies (Hudson & Souriau, 2003).  Camelid and 
shark variable domains can stably incorporate longer CDR loops, and are thus also 
able to access convex surfaces or cavities (Dooley & Flajnik, 2005).  Examples of 
these include the binding sites of enzymes and narrow cavities in surface antigens of 
viruses which have evolved to bind their cognate receptor while remaining generally 
inaccessible to intact antibodies and thus immunosilent (Holliger & Hudson, 2005).  
This makes antibody fragments derived from camelid an shark variable domains 
potentially very useful as targeting agents, especially against pathogenic organisms.   
Their inherent stability and solubility currently suit them to in vitro diagnostic use 
until methods for reducing their immunogenicity in humans can adapt them for 
therapeutic use. 
 
Although mAb therapy has many promising applications in cancer therapy, cancer is 
a diverse range of illnesses, and what is applicable in one setting may not be 
appropriate in another.  Harnessing the cellular immune system may provide 
effective therapies where antibodies alone cannot.  The role of the cellular immune 
response in cancer immunotherapy, with particular emphasis given to CD8+ CTLs, is 
outlined in the next section. 
 
1.5.2 Cellular therapy 
To date, the majority of clinical cellular immunotherapy has been directed against 
viruses, specifically CMV and EBV.  In pioneering work, Riddell et al (1992) 
prophylactically administered CMV-specific CTL clones derived from donor 
peripheral blood mononuclear cells (PBMCs) to a small number of at risk BMT 
patients, who were protected from CMV-related disease.  The first treatment of 
virus-associated cancer occurred soon after, when donor PBMCs were used to treat 
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EBV-associated PTLD in BMT patients (Papadopoulos et al, 1994).  Three of five 
patients responded well to therapy, however all three also developed graft versus host 
disease (GVHD).  The following year, 10 BMT patients were infused with donor 
derived polyclonal EBV-specific CTLs (Rooney et al, 1995).  Three patients with 
EBV-related lymphoproliferation responded to treatment, and EBV DNA in PBMCs 
fell to normal levels.  None of the remaining seven patients developed PTLD.   
Preparation of virus-specific cells ex vivo appeared to deplete the alloreactive T cells 
seen in the earlier trial, and GVHD was not observed in any patient (Papadopoulos et 
al, 1994; Rooney et al, 1995).  In an extended trial by the same group, EBV-specific 
CTLs prevented development of PTLD in all of 39 trea ed patients compared with 
seven of 61 (11.5%) controls, and five of six (83.3%) patients treated for overt 
lymphoma achieved complete remission  (Rooney et al, 1998).  In a trial of 33 solid 
organ transplant patients, EBV-specific CTLs have also been used to successfully 
treat PTLD, with an overall response rate of 52% (Haque et al, 2007).  Donor 
PBMCs are not usually available in this setting, so allogeneic or autologous 
strategies for EBV-specific CTL manufacture have ben stablished for the treatment 
of PTLD (Haque et al, 1998; Khanna et al, 1999).  Cellular therapy has also been 
tested against other EBV-associated cancers including HL and NPC.  However, as 
these tumours arise in immunocompetent hosts and express a more restricted pattern 
of viral antigens, they are less responsive to EBV-specific therapy.  In small-scale 
trials, three of six patients with refractory NPC and three of 11 relapsed HL patients 
achieved a measurable response to treatment with EBV-specific CTLs (Bollard et al, 
2004; Straathof et al, 2005a). 
 
With respect to cancers not associated with viral infection, early therapies using 
donor PBMCs re-induced remission in BMT patients with relapsed chronic myeloid 
leukaemia (CML) (Kolb et al, 1990).  This is a graft versus leukaemia (GVL) effect 
and not transferable for general cancer therapy, although it showed proof of principle 
that the immune system could combat tumours.  However, the majority of TAA are 
weakly immunogenic self-antigens and natural T cells against these antigens are low 
in frequency, have low T cell receptor (TCR) avidity or are anergic, and thus a more 
robust cellular therapy is needed (Tey t al, 2006).  To this end, leukaemia-specific 
CTLs have been generated from PBMCs by loading dendritic cells with antigen 
derived from whole leukaemic blasts, capable of lysing tumour cells in vitro 
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(Montagna et al, 2001).  Anti-leukaemic CTLs have also been shown to mediate 
tumour regression of CML in vivo (Falkenburg et al, 1999).  In the autologous 
setting, CTLs specific for melan-A peptide could be generated from the PBMCs of 
melanoma patients using dendritic cells pulsed with tumour peptide epitopes as 
antigen presenting cells (APCs), and clinical respon es were seen in some patients 
(Meidenbauer et al, 2003).  However, this approach is limited to patients carrying the 
HLA haplotype required to bind the previously defind immunogenic epitope.  
Alternatively, lines of tumour infiltrating lymphocytes (TILs) can be cultured from 
individual patients and screened for specific clones reactive with autologous tumours 
cells, which can then be re-infused into the patient.  In one trial of metastatic 
melanoma refractory to standard therapies, objectiv responses to TIL therapy were 
seen in six of 13 patients, and mixed responses in four others (Dudley et al, 2002).  
 
The strategies mentioned above are highly labour intensive and clinical trials of 
cancer cellular immunotherapy have, virus-associated malignancies aside, shown 
modest and variable response rates.  Effective therapies require T cells to persist, 
expand, traffic and home to tumours and mediate effctor function.  One approach to 
target weakly immunogenic TAA is to engineer T cell specificity by gene 
modification, which will be covered in the next section. 
 
1.5.3 Engineered T cells 
There are two strategies by which T cells can be genetically engineered with a 
defined tumour specificity, or ‘re-targeted’.  The α and β chains of a TCR define a T 
cells antigen specificity, and thus the first approach is simply to transfer native α and 
β TCR chains with the required specificity into T cells HLA matched with the target.  
This has been accomplished with TCRs specific for TAA, and engineered cells 
(those containing the transferred genes) against TAAs such as the melan-A protein 
expressed in melanoma are capable of in vitro antigen-specific anti-tumour activity 
(Clay et al, 1999).  The strategy by which engineered T cells are employed in the 
treatment of patients is outlined in Figure 1.8.  The first clinical trial using transferred 
native TCRs resulted in tumour regression in two of 15 patients with progressive 
metastatic melanoma (Morgan et al, 2006).  Issues associated with this method 
include mispairing of the introduced and endogenous α and β TCR chains and low 
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surface expression of the introduced TCR (Morgan et al, 2006).  Steps to overcome 
these limitations are being undertaken, including modification of the introduced TCR 
chains to prevent mispairing and potentially also increase surface expression (Cohen 
et al, 2007).   However, as each TCR is specific for a peptide-MHC complex, this 




Figure 1.8: Treatment using engineered T cells. 
An outline of the process by which T cells are taken from a suitable cancer 
patient, engineered to express tumour-specific cTCRs, expanded and re-
infused into the patient as treatment.  Adapted with permission from the 
ATTACK Project website (www.attack-cancer.org). 
 
 
The second strategy by which T cells can be re-targe ed is by transfer of a chimeric 
TCR (cTCR), also known as a chimeric antigen receptor (CAR) or ‘t-body’ (Eshhar 
et al, 1993).  These molecules generally contain an antibody based external domain 
such as a scFv (see Figure 1.7), and the internal domain of a TCR for signal 
transduction and T cell activation (Eshhar et al, 2001).  They are expressed on the 
surface of the T cell as a single gene-encoded homodimer, enabling MHC-
independent recognition of native TAA.  Cells engineered with cTCRs specific for a 
range of TAA, including CD19, CD30, HER2/neu and prostate-specific membrane 
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antigen (PSMA), have been shown capable of specific tumour cell lysis in vitro 
(Gong et al, 1999; Haynes et al, 2002; Cheadle t al, 2005; Savoldo et al, 2007), and 
are listed with other TAAs targeted by cTCRs in Table 1.4.   
 
 
Table 1.4: Tumour associated antigens targeted by cTCR engineered T cells. 
[FBP; folate-binding protein: CEA; carcino-embryonic antigen: NCAM; neural 
cell adhesion molecule: PSMA; prostate-specific membrane antigen] 
targeted antigen target cells reference 
CD19 B cell lymphoma Brentjens et al (2003) 
CD20 B cell lymphoma Jensen et al (2003b) 
CD30 Hodgkin's lymphoma Hombach et al (2001) 
CD171 neuroblastoma Park et al (2007) 
CEA gastrointestinal tumours Gilham et al (2002) 
FBP ovarian carcinoma Kershaw et al (2002) 
ErbB-2 breast, ovarian carcinoma Haynes et al (2002) 
carboxy anhydrase IX renal cell carcinoma Weijtens et al (2000) 
MAGE-A1 melanoma Willemsen et al (2000) 
NCAM neuroblastoma Gilham et al (2002) 
PSMA prostate cancer Gong et al (1999) 
 
 
Engineering chimeric receptors for T cells is still an evolving field, and technical 
challenges remain to be resolved.  One problem involves the binding of engineered 
cells to targets.  The scFv-TAA association must be specific yet permit 
disengagement for efficient killing of multiple target cells (Kalergis et al, 2001).  
Thus, to allow serial killing as well as to limit potential cross-reactivity with healthy 
tissue, scFv and target antigens must be chosen with care.  Another challenge is the 
optimal transduction of signals through the cTCR.  Early cTCR constructs contained 
the intracellular CD3ζ moiety, which delivered a potent signal 1 to the engineered 
cell upon antigen binding, but the downregulation of T cell costimulation molecules 
on most tumours result in a lack of signal 2, leading to apoptosis or anergy of the 
engineered cell (Maher & Davies, 2004).  The two signal model of T cell activation 
is illustrated in Figure 1.9.  Initial research focused on incorporating CD28 into the 
cTCR, fusing the signalling domain of this costimulatory protein in series with the 
CD3ζ domain, to create receptors capable of delivering both signal 1 and signal 2 for 
T cell activation (Finney et al, 1998; Eshhar et al, 2001; Maher et al, 2002).  
Additional activation signal domains including lck tyrosine kinase and OX40 are 
now also being investigated (Geiger et al, 2001; Pule et al, 2005). 






Binding of a native TCR to its cognate peptide/MHC complex results in the 
phosphorylation of ITAMs within the intracellular CD3 molecules, and transduction 
of an activation signal via Lyk and Fyn kinases recruited primarily to CD3-ζ (Pitcher 
& van Oers, 2003).  How precisely peptide/MHC binding nduces this transduction 
remains unclear, although several factors are thougt to play a role, including 
conformational changes in the TCR and receptor aggregation.  The TCR/CD3-ε 
complex undergoes a conformational change that uncovers a proline-rich sequence in 
the CD3-ε cytoplasmic tail, allowing it to bind the ubiquitously expressed adapter 
protein Nck, which may recruit further effector molecules to the CD3 ITAMs 
(Buday, 1999; Gil et al, 2002).  Aggregation of TCR complexes following 
multimeric peptide/MHC binding brings individual CD3 cytoplasmic domains into 
close proximity, facilitating transphosphorylation of the ITAMs (Minguet et al, 
2007).  Aggregation of receptors also draws the membranes of target and effector 
cells together, excluding large molecules such as CD45 with its intracellular 
phosphotases, allowing CD3 ITAMs to remain phosphorylated (Rudolph et al, 2006).  
Correspondingly, the BCR (which incorporates surface-bound antibody) also 
transduces signals using a combination of conformation l changes and aggregation.  
It is likely signal transduction by cTCRs is accomplished in a similar way to native 
Figure 1.9: Two signal model of T 
cell activation. 
T cells require two signals to become 
fully activated.  Signal 1 [activation] is 
initiated by the binding of the TCR 
complex (including CD3) to the 
antigenic peptide presented by MHC.  
Signal 2 [co-stimulation] is antigen 
independent and is also delivered by 
the antigen presenting cell (APC) via a 
B7-CD28 interaction. The second 
signal promotes T cell activation and 
proliferation, increasing expression of 
IL-2. 
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TCRs, utilising the aggregation of receptors, although if conformational change plays 
a role it has yet to be elucidated, as cTCRs do not inc rporate CD3-ε. 
 
With the inclusion of a second signal, engineered T cells can be repeatedly activated 
by antigen in vitro, with each round of stimulation resulting in specific lysis of target 
cells and IL-2 driven proliferation (Maher t al, 2002).  Engineered T cells have also 
been shown capable of controlling tumour growth in animal models (Haynes et al, 
2002; Brentjens et al, 2003).  Recent phase I clinical studies have proved the therapy 
well tolerated for the treatment of metastatic ovarian cancer and neuroblastoma 
(Kershaw et al, 2006; Park et al, 2007).  Although tumour regression was not 
observed, bearing in mind the heavy and refractory disease burden of patients in such 
trials, these were overall positive results.  Persistence of therapeutic cells in vivo 
remains an issue; both trials saw rapid clearing of cells carrying cTCRs, as measured 
by vector specific PCR of PBMCs.  It should be noted that neither of the cTCRs used 
carried a domain for signal 2 transduction within the TCR.  However, the cells used 
to treat ovarian cancer patients were alloreactive via their native TCR, due to 
engineered PBMCs being co-cultured with irradiated allogenic PMBCs prior to 
cTCR transduction, as it had been shown that this strategy provided proliferation 
signals in response to subsequent immunisation with allogeneic PBMCs (Kershaw et 
al, 2002). 
 
One issue likely to affect further development of cTCR engineered T cell is the 
vector used to transport the receptor into cells.  Currently, the majority of research is 
carried out using retroviral vectors.  However, as seen in a gene therapy trial for X-
linked severe combined immune deficiency (SCID), this carries the risk of viral 
insertional mutagenesis and subsequent cellular transformation (Hacein-Bey-Abina 
et al, 2003).  Experimental results indicate that lentiviral vectors are less prone to 
insertional mutagenesis than retroviral vectors, at le st in mouse models (Montini et 
al, 2006), and as such are an alternative option, although a large amount of in vivo 
data needs to be collected to more accurately determin  their overall safety.  A 
further option is the inclusion of conditional suicide genes in the vector.  An example 
is herpes simplex virus thymidine kinase (HSV-TK), which has been used in phase II 
trials for BMT patients with relapsed haematological malignancies receiving 
infusions of donor lymphocyte transduced with HSV-TK (Ciceri et al, 2007).  
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Tumour regression was concurrent with GVHD, which abated after ganciclovir 
administration tripped the suicide switch.  This approach would guard against 
potential inappropriate responses to therapy.   
 
Research into cTCR engineered T cells is still in its infancy, but it is a field with vast 
potential for application in the therapy of cancer.  Although there are many issues 
still to address, it holds great promise for treatments applicable to refractory or 
recurrent malignancies. 
 
1.6 Antibody phage display 
1.6.1 Background 
Antibodies have such a wide range of applications, medically and scientifically, that 
their use has become near ubiquitous in biotechnology.  Beyond the treatment of 
cancer, antibody technology has been exploited for diagnostic testing, in vivo 
radioimaging, labelling of cells for experimental pur oses, and treatment of non-
malignant illnesses, to name but a few examples.  In the early period of their use, 
serum containing polyclonal antibodies was collected from immunised animals.  
With the advent of hybridoma technology it was possible to reliably produce mAbs 
(Kohler & Milstein, 1975).  However, there remained a number of limitations to 
hybridoma technology.  As animals still needed to be immunised in the initial stage, 
it was not possible to produce antibodies against toxic, pathogenic, non-
immunogenic or some self antigens (Winter & Milstein, 1991).  Importantly for 
clinical uses, the antibody molecule was murine, leading to the generation of human 
anti-mouse antibodies in patients, especially with repeated dosing.  Generation of 
hybridomas was also costly and time consuming.  In groundbreaking work, Dr 
George Smith established a method by which polypeptid s could be presented on the 
surface of filamentous phage, a virus able to infect the common laboratory bacteria 
E.coli and capable of replication and assembly without host cell lysis (Smith, 1985).  
This method was subsequently adapted for antibody presentation (McCafferty et al, 
1990). 
 
The filamentous phage particle has a thread-like shape approximately 6.5 nm in 
diameter and 1 µm in length (Paschke, 2006). Its circular single-stranded DNA 
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genome is encased in a cylindrical protein coat, predominantly composed of the 
major coat protein, pVIII. At one end, the phage particle incorporates about five 
copies of the minor coat proteins pVII and pIX.  Atthe other end, three to five 
molecules of the remaining minor coat proteins pIII and pVI are displayed.  A 
schematic diagram of a filamentous phage is shown in Figure 1.10.  Antibodies 
displayed on filamentous phage are not entire IgG molecules, but rather scFv or Fab 
antibody fragments (see Figure 1.7).  A comparison of Fab and scFv formats for 




Figure 1.10: Filamentous phage particle. 
Schematic of a filamentous phage particle, showing the major coat protein pVIII 
encasing the single-stranded DNA genome, with minor pr teins pIII, pVI, pVII and pIX 
incorporated into the coat at either tip.  Image adapted from Paschke M. Applied 
Microbiology and Biotechnology 70:2-11, copyright (2006), with kind permission from 




Table 1.5: Comparison of scFv and Fab formats in antibody phage display. 
scFv Fab 
Better tolerated by bacteria More difficult to synthesise 
Less likely to be degraded More likely to be degraded 
Can form dimers No dimerisation 
Single protein molecule Two protein molecules 
Peptide linker can shorten No such problems 
Less stable More stable 
A fraction of expressed scFv  
can be non-functional 
Tends to be more functional 
 
DNA insert 700 bp DNA insert >1500 bp 
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1.6.2 Phage and phagemids 
The principle underlying all phage display systems is the physical linkage of a 
polypeptide's phenotype to its corresponding genotype.  For antibody phage display, 
antibody fragments are fused to a minor coat protein, usually pIII.  The C terminus of 
the pIII protein inserts into the coat, and is essential for the structural integrity of the 
phage, whilst the antibody fragment is presented on the surface of the phage particle.  
As the genetic information encoding the fusion protein is contained in the phage 
genome packaged inside the phage particle, identification of a desirable clone by 
fragment binding allows simultaneous recovery of the gene encoding the selected 
antibody fragment.  These fragments can then be cloned into vectors encoding intact 
Ig molecules, or alternative targeted immunotherapy frameworks, such as chimeric 
receptors (Willemsen et al, 2001; Nagy et al, 2002). 
 
There are two genetic systems used in antibody phage display, the first being phage 
vectors and the second phagemid vectors.  The properties of each system are outlined 
in Table 1.6.  In phage vectors, the antibody-pIII fusion gene is inserted directly into 
the phage genome (McCafferty et al, 1990).  The major advantage of this is that all 
copies of the pIII protein contain the antibody fragment.  However, the disadvantages 
are consequent low transduction efficiency and a negative selection pressure on 
phage carrying the fusion product, as replication and pIII expression is linked to the 
genome.  In the second method, the antibody-pIII fusion gene is contained in a 
phagemid vector (Hoogenboom et al, 1991).  A phagemid is a plasmid that bears a 
phage-derived origin of replication in addition to i s plasmid origin of replication.  
The additional proteins necessary for replication and packaging of the phagemid 
vector into a phage particle are encoded in a second ‘helper’ phage, with which the 
bacteria are superinfected, a process know as ‘phage rescue’.  The helper phage is 
also able to replicate itself, and thus two types of phage particles are produced 
carrying either phagemid or helper phage DNA.  The fraction of phage containing 
the helper phage genome can be reduced significantly by using a helper phage with a 
defective origin of replication or packaging signal, leading to preferential packaging 
of the phagemid DNA over the helper phage genome (Russel et al, 1986).  Wildtype 
pIII expressed by the helper phage is also preferentially incorporated into the phage 
particle.  This can lead to the production of ‘bald phage’ which display no antibody 
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fragments.  The frequency of bald phage can be reduced sing helper phage with 
mutated, trypsin-sensitive pIII protein (Kristensen & Winter, 1998).  The cleaved 
pIII molecule is non-infectious, preventing bald phage being amplified during rescue. 
 
 
Table 1.6: Comparison of phage and phagemid systems for antibody display libraries. 
phage  phagemid 
Three to five copies of antibody per phage 
 
Only 1 –10% of phagemids have one  
copy of the displayed antibody 
Difficult to transfect and make DNA Easy to handle 
Faster to select and easier to use Slower to select (helper phage needed) 
Must subclone to make soluble Ab Soluble Ab made directly 
Phenotypic and genotypic homogeneity Phenotypic and genotypic heterogeneity 
Genetically less stable (deletions) More stable genetically 
Greater diversity of antibodies selected Lower diversity of antibodies selected 
Lower affinity antibodies also selected due 
 to avidity effects 
Higher affinity antibodies selected due to  
monomeric display 
Not suitable for affinity maturation due to  
avidity effects 





1.6.3 Antibody libraries 
Antibody phage libraries are divided into four categories depending on the type and 
source of the antibody fragment: immune, naïve, semi- and fully-synthetic.  Immune 
libraries are constructed using B cells from an immunised animal or immune patient, 
and are thus pre-enriched for antigen-specific clones, making it possible to isolate 
high affinity antibodies from relatively small libraries.  The disadvantage of immune 
libraries is that they require immunogenicity of the target antigen in either humans or 
animals, and immunisation and library construction is required for each antigen.   
 
Naïve libraries, as the name suggests, are constructed sing PBMCs or splenocytes 
from unimmunised animals or human donors.  The librar es are constructed using 
antibody VH and VL domains, which are amplified from cytoplasmic RNA (as B cells 
are highly enriched in Ig mRNA) or synthesised de novo.  The two variable domains 
Chapter 1                                                                                          Introduction 
 51 
are combinatorially assembled to create a large and diverse array of antibodies.  
Semi-synthetic libraries are derived from unrearranged V-genes from germline B 
cells, or from a single antibody framework, with at least one CDR genetically 
randomised, while fully synthetic libraries use a single framework with randomly 
integrated CDR cassettes.  The greatest advantage of synthetic libraries is the ability 
to isolate antibodies specific for self antigens, which is not always possible with 
immune or naïve libraries. 
 
Naïve, semi-synthetic and fully synthetic libraries are collectively know as ‘single 
pot’ libraries, as they are not be biased towards any particular antigen, and 
theoretically contain antibody fragments which will bind to virtually every antigen.  
Thus one library can be used for the isolation of high affinity clones against multiple 
targets.  Libraries with a theoretical diversity of up to 1010 independent clones have 
been generated (Paschke, 2006). 
 
1.6.4 The process of selection 
Selection from phage display libraries is a cyclic process of discriminating 
enrichment and amplification.  The phage library is exposed to antigen, allowing 
specific phage to bind to their targets.  Antigen-bound phage are then recovered and 
subsequently amplified by infection in E.coli.  This process is known as ‘panning’, in 
the same sense that historically prospectors panned for gold.  The amplified phage 
population is then subjected to the next round of panning.  Generally, two to four 
rounds of panning are completed before the selected phage are individually analyzed 
to identify specific binders.  If affinity for the antigen is sufficiently high for the 
intended purpose, the selected antibody fragment can be used directly in 
immunotherapy applications.  Otherwise, affinity matur tion techniques, for example 
site-specific or combinatorial mutagenesis of the CDRs, can be used to enhance the 
binding properties of the fragment (Wu et al, 1998; Boder et al, 2000). 
 
An extensive range of methodologies exists for the isolating of specific clones from 
phage libraries (Bradbury & Marks, 2004).  At its most basic, selection involves 
immobilisation of the protein antigen on a solid base such as an immunotube or 
ELISA plate.  More complex variations on this theme include the fixing of whole 
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cells to solid supports or enrichment on tissue sections (de Kruif et al, 1995).  
Another alternative is biotinylation of the antigen, allowing retrieval of 
phage/antigen using streptavidin coated magnetic beads for example.  Phage can also 
be selected on whole cells grown in monolayers or in solution, with cells lysed to 
release internalised specific binders (Griffiths et al, 1993).  Alternatively, phage 
selection on whole cells can be performed by fluorescence associated cell sorting 
(FACS), using labelled monoclonal antibodies specific for the phage particle and a 
selectable marker co-expressed on target cells within a eterogeneous population (de 
Kruif  et al, 1995). 
 
Over the course of successive rounds of panning, several assays can be employed to 
monitor selection.  These include polyclonal enzyme-linked immunosorbant assays 
(ELISA), which measure the increases in specific binders, PCR screening, which 
monitors selection pressure by examining the presence of antibody fragment inserts, 
and restriction mapping of the antibody fragments, which assesses diversity within 
the phage population. The analysis of target specificity in individual clones at the end 
of selection can also be assayed in several ways.  Monoclonal phage ELISA is often 
used in the first instance as it is a rapid and relatively sensitive test.  Following this 
initial screen, other assays can be employed, including sequencing of antibody 
fragments, and expression of soluble antibody fragments from the phage vector.  The 
majority of phage libraries are engineered so that soluble expression of antibody 
fragments includes a peptide tag such as myc or Flag, to facilitate the use of soluble 
fragments in screening ELISAs, FACs, Western blots or immunohistochemistry.   
 
1.7 Project aims 
EBV-associated malignancies have been successfully treated using virus-targeted 
immunotherapy.  However, the majority of EBV-associated malignancies display a 
restricted set of viral latent antigens, and there r main a proportion of patients who 
respond to neither conventional nor experimental therapies.   
 
Chapter 1                                                                                          Introduction 
 53 
 
The aim of this project was to investigate the following hypothesis: 
 
‘Engineering with a chimeric T cell receptor directd against the 
Epstein-Barr virus latent membrane 2 will confer upon T cells the 
ability to target and kill the malignant cells of cancers associated with 
Epstein-Barr virus.’ 
 
In order to test this hypothesis, three main projects were undertaken: (1) SCID mouse 
models for EBV-associated HL, NPC and GC were set up to provide a framework in 
which to test engineered cells; (2) PBMCs were engineered with a cTCR specific for 
the B cell antigen CD19, and their effect against HL derived cell lines examined, and 
(3) a novel scFv specific for the extracellular sections of EBV LMP2 was sought 
from phage display libraries, for incorporation in a cTCR and eventual use as an 






2 Materials and Methods 
 
2.1 Materials  
2.1.1 Equipment  
Automatic pipettor   ‘Pipetboy acu’, Integra Biosciences 
     ‘Powerpette plus’, Jencons 
 
Balances    fine: ‘AE163’, Mettler 
medium: ‘BP310P’, Sartorius 
gross: ‘EK-200G’, AND 
 
Centrifuges    ‘1-15K’, Scientific Laboratory Supplies 
‘3K18C’, Sigma Laboratory Centrifuges 
‘Falcon 6/300’, MSE 
‘J2-21’, Beckman Coulter 
‘Micro Centaur’, MSE 
‘Mistral 3000E’, MSE 
‘Mistral 3000i’, MSE 
 
Flow cytometers   ‘FACScan’, Becton Dickinson  
‘FACSCalibur’, Becton Dickinson 
 
Fume hood    Lynwood Installations 
 
Gamma counter   ‘1480 Wizard’, Perkin Elmer 
 
Gel Documentation System UVP transilluminator and camera with a ‘UP-
D895’ Synoptics printer and UVP ‘Labworks 
Image Acquisition and Analysis’ software 
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Gel electrophoresis system Scotlab tank with Stratagene ‘Feather Volt 500’ 
power pack 
 
Haemocytometer   Scientific Laboratory Supplies 
 
Heating block    ‘DB.3’, Techne 
 
Histology Image Capture ‘BX51’ Olympus microscope with Polaroid 
‘PDMC-2’ camera and ‘DMC le’ software 
 
Humidity chamber   Sandrest 
 
Incubators    30°C: Hearson 
     37°C: Gallenkamp, Sandrest 
     37°C humidified: Leec, Forma Scientific  
37°C shaking: ‘4536’, Forma Scientific 
55°C: Hybaid 
 
Microbiological safety cabinets Medical Air Technology 
(Class II)    Envair 
     Arrowmight Biosciences 
 
Microscopes    ‘Laborlux K’, Leitz 
     ‘TMS’, Nikon 
 
Microwave    ‘SM18’, Proline 
 
PCR machine    ‘T3 Thermocycler’, Biometra 
 
pH meter    ‘HI 8521’, Hanna Instruments 
 
Pipettes    ‘Pipetman’, Gilson 
     ‘Nichipet’, Nichiryo 
Plate reader    ‘MRX’, Dynex Technologies 
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Real time PCR machine  ‘R-3000’, Rotor-Gene 
 
Refrigeration    4°C: Electrolux 
     -20°C: Labcold 
     -70°C: ‘Ultra 85’, Assab 
 
Roller Mixer    ‘SRT1’, Stuart Scientific  
 
Shakers    ‘Orbital shaker’, Denly 
‘R/100/TW’, Luckham 
 
Spectrophotometer   ‘GeneQuant II’, Pharmacia Biotech 
‘CE 272’, Cecil Instruments 
 
Stirrer     ‘Magnetic Stirrer Hotplate’, Stuart Scientific 
 
Vortex     ‘MS2 Minishaker’, IKA 
 
Waterbaths    Clifton 
     Grant Instruments 
 
2.1.2 Suppliers  
AbD Serotec   Endeavour House, Kidlington, Oxford, OX5 1GE, UK. 
    www.ab-direct.com 
 
Barloworld Scientific  Beacon Road, Stone, ST15 0SA, UK.  
www.barloworld-scientific.com 
 
Becton Dickinson   21 Between Towns Road, Cowley, Oxford,  
OX4 3LY, UK. 
www.bdeurope.com 
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Clonetec   2 Avenue du President Kennedy, 78100  
Saint-Germain-en-Laye, France.  
www.clontech-europe.com 
 
Dako    Denmark House, Angel Drive, Ely, CB7 4ET, UK. 
www.dako.co.uk 
 
Fisher Scientific Bishop Meadow Rd, Loughborough, LE11 5RG, UK. 
www.fisher.co.uk 
 
GE Healthcare Amersham Place, Little Chalfont, HP7 9NA, UK. 
www.amershambiosciences.com 
 
Geneservice Ltd  Cambridge Science Park, Milton Road, Cambridge,  
CB4 0FE, UK.  
www.geneservice.co.uk 
 
Greiner Bio-One  Brunel Way, Stroudwater Business Park, Stonehouse,  
GL10 3SX, UK.  
www.greinerbioone.com 
 
Invitrogen   Inchinnan Business Park, 3 Fountain Drive, Paisley,  
PA4 9RF, UK.  
www.invitrogen.com 
 
Marligen Biosciences Stirling Road, High Wycombe, HP12 3ST, UK. 
www.marligen.com 
 
Miltenyi Biotec  Almac House GU24 9DR Surrey, UK. 
    www.miltenyibiotec.com 
 
New England Biolabs  75-77 Knowl Piece, Wilbury Way, Hitchen,  
SG4 0TY, UK. 
www.neb.uk.com 
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Nunc Brand   Supplied by Fisher Scientific.  
 
Perbio Unit 9, Atley Way, North Nelson Industrial Estate, 
Cramlington, NE23 1WA, UK.  
www.perbio.com 
 
Promega Delta House, Southampton Science Park, 
Southampton, SO16 7NS, UK.  
www.promega.com/uk 
 
Qiagen    Qiagen House, Fleming Way, Crawley,  
RH10 9NQ, UK. 
www1.qiagen.com 
 
Sigma Aldrich   The Old Brickyard, New Road, Gillingham,  
SP8 4XT, UK.  
www.sigmaaldrich.com 
 
StemCell Technologies 60 rue des Berges, Miniparc Polytec,  
batiment Tramontane Grenoble 38000, France. 
www.stemcell.com 
 
Thistle Scientific  DFDS House, Goldie Road, Uddingston,  
G71 6NZ, UK. 
    www.thistlescientific.co.uk 
 
UDP    Amber Park, Berristow Lane, South Normanton,  
DE55 2FH, UK.  
www.udg.co.uk 
 
Vector Laboratories  3 Accent Park, Bakewell Road, Peterborough  
PE2 6XS, UK.  
www.vectorlabs.com 
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Vision BioSystems  Balliol Business Park, West Benton Lane,  
Newcastle Upon Tyne, NE12 8EW, UK.  
www.vision-bio.com 
 
VWR    Hunter Boulevard, Magna Park, Lutterworth,  
LE17 4XN, UK.   
uk.vwr.com 
 
2.1.3 Solutions  
CBS    PBS with: 
    2% FBS 
    1mM EDTA 
 
H-top agar   1% (w/v) tryptone 
    0.8% (w/v) NaCl 
    0.6% (w/v) bacto-agar 
 
Minimal agar   7.6mM (NH4)2SO4 
    0.1% (w/v) dextrose 
    1.7mM Na3C6H5O7.2H2O 
    1.5% (w/v) bacto-agar 
    1mM MgSO4 
    0.0005% (w/v) Thiamine-HCl 
    33.1mM KH2PO4 
    60.1mM K2HPO4 
 
PBS pH 7.4   137mM NaCl 
    2.7mM KCl 
    4.3mM Na2HPO4 
    1.4mM KH2PO4 
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PBSA     PBS with: 
1% w/v BSA 
0.1% w/v sodium azide 
0.2% w/v EDTA 
 
TBE buffer pH 8.3  0.44M Tris 
    0.44M Boric acid 
    12mM EDTA 
 
TBS    25mM Tris 
    137mM NaCl 
    27.7µM KCl 
 
2xTY medium   1.6% (w/v) tryptone 
    1% (w/v) yeast extract 
    0.5% (w/v) NaCl 
 
2xTY AG   2xTY medium with: 
    100µg/ml ampicillin 
1% (w/v) glucose 
 
2xTY AKG   2xTY medium with: 
    100µg/ml ampicillin 
50µg/ml kanamycin 
0.1% (w/v) glucose 
 
TYE agar   1% (w/v) tryptone 
    0.5% (w/v) yeast extract 
    0.8% (w/v) NaCl 
    1.5% (w/v) bacto-agar 
 
TYE AG   TYE agar with: 
    100µg/ml ampicillin 
1% (w/v) glucose 
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2.2 Tissue culture techniques 
2.2.1 Maintenance of cell lines 
Cell lines were cultured in sterile plastic-ware and maintained at 37°C in 5% 
humidified CO2 in the appropriate medium as listed in Table 2.1. 
 
Table 2.1: Media and cell lines used for tissue cult re. 
[RPMI; Roswell Park Memorial Institute, FBS; foetal bovine serum, DMEM; 
Dulbecco’s Modified Eagles Medium] 
culture medium media supplements cell lines reference 
complete medium-20 RPMI FBS to 20% (v/v) CTLs  
  2mM L-glutamine  HDLM2 (Drexler et al, 1986) 
  100U/ml penicillin L540 (Diehl et al, 1981) 
  100U/ml streptomycin  L591 (Diehl et al, 1982) 
   PG13 (Miller et al, 1991) 
complete medium-10 RPMI FBS to 10% (v/v) AGS (Barranco et al, 1983) 
  2mM L-glutamine  B95-8 (Miller et al, 1972) 
  100U/ml penicillin K562 (Lozzio & Lozzio, 1975) 
  100U/ml streptomycin  L1236 (Wolf et al, 1996) 
   LCLs  
   NUGC3 (Akiyama et al, 1988) 
    Raji (Pulvertaft, 1964) 
complete medium-8 RPMI FBS to 8% (v/v) C666.1 (Cheung et al, 1999) 
  2mM L-glutamine    
  100U/ml penicillin   
  100U/ml streptomycin    
DMEM DMEM FBS to 10% (v/v) HT1080 (Rasheed et al, 1974) 
  2mM L-glutamine    
  100U/ml penicillin   




Cell lines HDLM2, L1236, L540 and L591 were a gift from Professor Ruth Jarrett, 
LRF Virus Centre, University of Glasgow; AGS and NUGC3 a gift from Professor 
Kenzo Takada, Institute for Genetic Medicine, Hokkaido University, Japan; and 
C666.1 a gift from Professor Paul Farrell, School of Medicine, Imperial College, 
London, UK.  RPMI, DME, L-glutamine, penicillin, and streptomycin were supplied 
by Invitrogen.  FBS was supplied by Perbio.  Plastics for cell culture were supplied 
by Barloworld Scientific, Becton Dickinson, Fisher Scientific and Greiner Bio-One. 
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2.2.2 Passaging adherent cell lines 
Culture medium was removed from the cell monolayer and cells were washed with 
0.02% versene (0.5mM EDTA, 0.001% phenol red in PBS) then incubated with a 1:1 
solution of versene and 0.25% (w/v) trypsin (Invitrogen) at 37°C until the cells 
detached from the plastic.  The cells were either se ded directly into a new culture 
flask, or centrifuged at 180g for 7 minutes and the resulting pellet resuspended in 
fresh medium and seeded into a new flask. 
 
2.2.3 Freezing and thawing cells 
For long term storage of cell lines, viable cells were centrifuged at 180g for 7 
minutes and resuspended in freeze medium (70% RPMI, 20% FBS and 10% DMSO) 
at cell concentrations between 5x106 and 2x107 cells/ml.  Volumes of 1ml were 
aliquoted into cryovials and placed in a cryo 1°C freezing container (VWR) for 
overnight slow freezing at -70°C before being transferred to liquid nitrogen. 
 
Frozen cell lines were thawed quickly in a 37°C incubator and washed twice by 
centrifugation in Hank's buffered salt solution (HBSS) (Invitrogen), or in RPMI with 
20% FBS for CTLs and transduced cells, at 180g for 7 min.  Pelleted cells were 
resuspended at the appropriate concentration and media for the line 
 
2.2.4 Cell separation by centrifugation 
Ficoll-hypaque density centrifugation was used to separate PBMCs from whole 
blood and to remove dead cells from cultures.  Cellsuspensions were layered into an 
equal volume of Histopaque-1077 (Sigma) and centrifuged at 600g and 4°C for 20 
minutes.  Viable cells were removed from the Histopaque/medium interface and 
resuspended in HBSS (Invitrogen) and centrifuged at 180g for 7 minutes.  Cell 
pellets were resuspended in an appropriate volume of media or buffer, as required. 
 
2.2.5 Cell separation by antibody-coated magnetic b eads 
EasySep systems (StemCell Technologies) were used to separate cell populations on 
the basis of cell surface antigen expression, following the manufacturer’s 
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instructions.  Briefly, cells were washed in cell sparation buffer (CSB) at 180g for 7 
minutes and resuspended at 1x108 cells/ml in CSB.  The appropriate EasySep 
positive selection cocktail (bi-specific tetrameric antibody complexes directed 
against the selection antigen and dextran) was added  at a concentration of 100µL/ml 
cells for CD56 selection and 200µL/ml cells for CD34 selection, and the mixture 
incubated for 15 minutes at room temperature.  Nanop rticles (magnetic dextran iron 
particles in water) were added at a concentration of 50µL/ml, and the mixture 
incubated for 10 minutes at room temperature.  Total volume was brought to 2.5ml 
with CBS and the tube placed in an EasySep magnetic for 5 minutes.  The 
supernatant was poured off, the tube removed from the magnet, 2.5ml CSB added to 
the remaining cells, and the tube placed back in the magnet.  The separations were 
repeated a total of 4 times for CD34 selection and 3 times for CD56 selection.  Both 
the positively selected fraction and the depleted fraction were retained, counted, and 
resuspended at 1x106 cells/ml in complete medium-20 for further culture. 
 
2.2.6 Counting cells 
An aliquot of cells was diluted 1:1 with 0.4% (w/v) trypan blue (Sigma) and applied 
to a haemocytometer.  Stained and unstained cells wre counted to determine the 
percentage of viable cells and total cell number. 
 
2.3 DNA Extraction 
2.3.1 Extraction of phagemid DNA from bacteria 
Single colonies of bacteria infected with phage growing on agar plates or clones 
stored in 15% glycerol at -70°C were inoculated into 5ml 2xTY AG and incubated 
overnight, shaking at 37°C.  An aliquot of 1ml was pelleted by centrifugation at 
11600g for 5 minutes and the DNA extracted using the Rapid Plasmid Miniprep 
System (Marligen Bioscience Inc) according to the manufacturer’s instructions.  
Briefly, the cells were resuspended in 250µl buffer G1, to which 250µl Buffer G2 
was added to lyse the bacteria and the mixture incubated for 5 minutes at room 
temperature.  Following lysis, 350µl Buffer M3 was added, the tube inverted several 
times and centrifuged at 12000g for 10 minutes.  The supernatant was applied to a 
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spin cartridge which was subsequently centrifuged at 12000g for 1 minute.  The 
cartridge was washed with 700µl Buffer G4 at 12000g for 1 minute and the DNA 
eluted by addition of 50µl H2O, incubation at room temperature for 1 minute and 
centrifugation at 12000g for 2 minutes.  DNA was stored at -20°C. 
 
2.3.2 Extraction of viral and genomic DNA from cell  lines 
DNA from cultured cells was extracted using a QIAamp DNA Mini Kit (Qiagen) 
according to the manufacturer’s instructions.  Briefly, 2-5x106 cells were pelleted by 
centrifugation at 180g for 7 minutes and resuspended in 200µl PBS.  To this was 
added 20µl Proteinase K (600mAU/ml) and 200µl Buffer AL.  The solution was 
vortexed for 15 seconds then incubated at 56°C for 10 minutes.  200µl ethanol was 
added and the mixture vortexed again for 15 seconds. The mixture was applied to a 
spin column which was subsequently centrifuged at 6000g for 1 minute.  The column 
was washed with 500µl Buffer AW1 at 6000g for 1 minute, followed by 500µl 
Buffer AW2 at 20000g for 3 minutes, and the DNA elut d by addition of 50µl H2O, 
incubation at room temperature for 1 minute and centrifugation at 6000g for 1 
minute.  DNA was stored at -20°C. 
 
2.3.3 Ethanol precipitation 
0.1 volume 3M NaOAc (Sigma) pH 4.6 and 2.5 volumes 95% (v/v) ethanol at -20°C 
(Sigma) were added to 1 volume DNA.  The mixture was vortexed, incubated on ice 
for 20 minutes then centrifuged for 30 minutes at 13000g and 4°C.  The pellet was 
rinsed in 70% (v/v) ethanol then centrifuged for 15 minutes at 13000g and 4°C.  The 
supernatant was aspirated and the DNA pellet air dried for 1 hour before 
resuspension in H2O and storage at -20°C. 
 
2.3.4 Determination of DNA concentration 
DNA concentration was measured using a spectrophotometer, with water used to 
reset the machine.  The OD260 of the DNA was measured and the concentration 
calculated using the following formula: 
 DNA concentration (µg/ml) = OD260 x dilution factor x 50 
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2.4 Molecular Techniques 
2.4.1 Restriction digests 
PCR amplified phagemid DNA was digested with the restriction enzyme BstNI (New 
England Biolabs), at approximately 1 unit per µg DNA, in the supplied reaction 
buffer with 100µg/ml BSA, in a total volume of 24µl.  Reactions were incubated at 
60°C for 2 hours and visualised on a 2% (w/v) agarose gel. 
 
2.4.2 Standard PCR  
Standard PCR was used to screen phage clones for the p esence of 935 bp full length 
inserts, as per the supplier’s instructions (Geneservice).  The reaction mix contained 
1.5mM Mg2+ (Promega), 200µM dNTPs (GE Healthcare), 10pmoles of each primer, 
10µl 5x Green GoTaq Flexi Buffer (Promega), 1.5U GoTaq Flexi DNA Polymerase 
(Promega) and DNA in a final volume of 50µl.  DNA was added either to a total 
amount of approximately 50ng, or as bacteria picked directly from an agar plate.  A 
negative reaction with dH2O in place of template DNA was included in all runs.   
 
Primers (synthesised by Sigma) were; 
LMB3:  5’ - CAGGAAACAGCTATGAC - 3’ and  
pHEN seq:  5’ - CTATGCGGCCCCATTCA - 3’. 
 
PCR were carried out on a T2 Thermocycler (Biometra).  The reaction consisted of 
an initial denaturation step (95°C, 2 minutes), followed by 30 cycles of denaturation 
(95°C, 30 seconds), annealing (55°C, 30 seconds) and elongation (72°C, 2 minutes).  
A final elongation step (72°C, 5 minutes) was followed by cooling to 4°C before 
visualisation on a 2% (w/v) agarose gel. 
 
2.4.3 Real time PCR 
Real time PCR was used to assay EBV viral load (Leung et al, 2002).  After DNA 
extraction a section of the viral polymerase was amplified and the levels of product 
determined using a 6-carboxyfluorescein (FAM) and 6-carboxy-
tetramethylrhodamine (TAMRA) dual-labelled fluorogenic hybridisation probe.  A 
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section of the housekeeping gene β-globin was also amplified from each sample in 
order to normalise DNA calculations.  The reaction mix contained 3mM Mg2+ 
(Promega), 200µM dNTPs (GE Healthcare), 100pmoles each primer, 200pmol 
probe, PCR reaction buffer (10mM Tris-HCl pH 9.0, 5mM KCl, 0.1% TritonX), 
1.25U Taq DNA polymerase (Promega), 275ng TaqStart antibody (Clonetec) and 
1µg DNA in a volume of 25µl.  A negative reaction with dH2O in place of template 
DNA was included in all runs.   
 
Oligonucleotides for the EBV polymerase amplification were;  
forward: 5’ - AGTCCTTCTTGGCTACTCTGTTGAC - 3’,  
reverse:   5’ - CTTTGGCGCGGATCCTC - 3’, and  
probe:   5’ - FAM-CATCAAGAAGCTGCTGGCGGCC-TAMRA - 3’. 
 
Primers for β-globin amplification were;  
forward:   5’ - GGCACCCCTAAGGTGAAGGC - 3’,  
reverse:   5’ - GGTGAGCCAGGCCATCACTA - 3’ and  
probe:      5’ - FAM-CATGGCAAGAAAGTGCTCGGTGCCT-TAMRA - 3’. 
 
All oligonucleotides for real time PCR were synthesis d by Sigma.  PCRs were 
carried out on an R-3000 Real Time Thermal Cycler (Rotor-Gene).  The reaction 
consisted of  an initial denaturation step (95°C, 10 minutes), followed by 60 cycles of 
denaturation (95°C, 20 seconds) and annealing and elongation (58ºC  60 sec).  An 
initial standard curve was generated from serially di uted DNA extracted from Raji 
cells, which contain approximately 50 copies of the EBV genome per cell (Glaser & 
Nonoyama, 1974), and imported during analysis for calculation of DNA copy 
number.  Several standards of known copy number were amplified during each run 
for comparison with the imported curve. 
 
2.4.4 Agarose gel electrophoresis 
Agarose was dissolved in the appropriate volume of TBE buffer by heating in a 
microwave.  Ethidium bromide to a final concentration of 100µg/l was added to the 
molten gel to allow visualisation of the DNA.  Samples were loaded into the set gel, 
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and run at 100V in TBE for 1 hour.  The nucleic acid bands were visualised on a UV 
transilluminator. 
 
2.4.5 DNA sequencing 
Between 300-500ng of DNA was resuspended in nuclease-free water to a total 
volume of 5µl.  Samples were sent to Jill Lovell at the School of Biological Sciences 
Sequencing Service, University of Edinburgh, for sequencing using the BigDye 
Terminator Cycle Sequencing System and an ABI Sequencer (Applied Biosystems). 
 
2.4.6 HLA typing 
DNA was resuspended in nuclease-free water to a finl concentration of 100-
300µg/ml.  Samples were sent to Professor Anthony Dodi, the Anthony Nolan Bone 
Marrow Trust, Royal Free Hospital, London, UK, for HLA typing at the A, B or C 
loci, and Karen Stewart at the Scottish National Blood Transfusion Service Tissue 
Typing Laboratory, Royal Infirmary, Edinburgh, UK, for typing at the A, B, C, DR 
and DQ loci. 
 
2.5 Virus Techniques 
2.5.1 Production and titration of EBV 
B95-8 cultures in complete medium-10 were grown to appropriate volumes, and then 
culture vessels sealed and incubated at 37°C to drive virus into the lytic phase.  After 
7-10 days, supernatant was centrifuged at 490g for 10 minutes then passed through a 
0.8µ filter.  The virus stock was used immediately or stored at -70°C.  For titration, 
10-fold dilutions of the virus stock was added to 2x106 EBV negative PBMCs in 
complete medium-10, which were then transferred to 10 replicate wells per dilution 
in a 96-well flat bottomed culture plate at 2x105cells per well.  Cells were incubated 
at 37°C in 5% humidified CO2 for four weeks, with additional media added to the
plates as necessary.  After four weeks, each dilution was scored for outgrowth of 
transformed cells, with the lowest dilution having ≥50% positive wells taken as the 
virus titre. 
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2.5.2 In vitro infection with EBV 
For infection of the EBV-negative HL cell lines HDLM2, KMH2, L1236, and L540, 
a pellet of 107 cells was resuspended in 100µL virus preparation and the volume 
made up to 1ml in culture medium, before incubation at 37ºC in 5% humidified CO2 
for 1 hour.  Cells were washed with HBSS then plated at a density of 2x106 cells per 
well in a 24-well plate for continuing culture.  Samples were collected at 3, 14, and 
where necessary 49 days post infection for DNA extraction. 
 
2.5.3 Production and titration of retrovirus 
PG13 producer cell lines (Miller et al, 1991) for a retrovirus encoding either a 
chimeric TCR specific for CD19 with a truncated CD34 molecule as a marker of 
transduction, or the empty vector with green fluorescent protein (GFP) as a marker of 
transduction, were provided by Dr Eleanor Cheadle, Paterson Institute for Cancer 
Research, University of Manchester (Cheadle et al, 2005).  As a cell monolayer 
approached 70% confluence the supernatant was aspirated and fresh media added.  
After overnight incubation at 37°C the supernatant was passed through a 0.45µ filter 
and used immediately or stored at -70°C.  For titration, 10-fold dilutions of the virus 
stock and approximately 4µg/ml polybrene (Sigma) was added to HT1080 cells 
which had been seeded 24 hours previously in a 24-well culture plate at a density of 
1x104 cells per well.  Cells and virus were incubated overnight at 37°C, then the 
virus was removed and fresh media added.  Following a further 5 days incubation the 
cells were harvested and stained with anti-CD34-fluorescein isothiocyanate (FITC) 
for FACS analysis.  The titre was calculated as follows; 
 
     titre (tu/ml) = frequency positive cells (%) x initial cell number x dilution factor 
           100 
 
2.6 Phage library techniques 
2.6.1 Phage libraries used 
Tomlinson I+J 
The Tomlinson phage library is in phagemid/scFv format, with a diversity of 2.8x108 
(Goletz et al, 2002).  It is a synthetic library based on a single human framework for 
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VH (V3-23/DP-47 and JH4b) and Vκ (O12/O2/DPK9 and Jκ1).  The canonical 
structure encoded by this structure is the most comm n in the human antibody 
repertoire. pIT2 was used as the phagemid vector.  The CDR3 of the heavy chain was 
designed to be as short as possible while still forming an antigen binding surface. 
Side-chain diversity was incorporated in CDR3 and CDR2 regions in both VH and Vκ 
at positions which make contacts to the antigens. CDR1 regions were kept constant.  
Additional diversity was generated by PCR using partially degenerate primers 
designed to introduce random sequences into the VH and Vκ CDR3 loops.  The 
library was preselected on Protein A and Protein L, favouring the retention of 
functional scFv.  HIS6 and myc tags were included for the identification of soluble 
scFv.  The Tomlinson I+J human single fold scFv phage libraries were supplied by 
Geneservice Ltd.  Included with the libraries were control clones specific for 
ubiquitin and BSA, T-phage resistant E.coli strain TG1 for phage propagation and 
KM13 helper phage (Kristensen & Winter, 1998) for lib ary rescue 
 
ETH2Gold 
The ETH2Gold phage library is in phagemid/scFv format, with a diversity of 3x109 
(Silacci et al, 2005).  It is a synthetic library, and uses one VH and two Vκ regions for 
the scFv framework (DP47/DPL16 and DP47/DPK22).  pHEN1 was used as the 
phagemid vector.  Diversity was generated by PCR using partially degenerate 
primers designed to introduce random sequences into the VH and Vκ or Vλ CDR3 
loops.  The library was preselected on Protein A and Protein L, favouring the 




The RotMar library was constructed using an identical method as the de Haard 
library (de Haard et al, 1999).  It is in phagemid/Fab format, with a diversity of 
5.36x109.  The RotMar is a naïve library, with PBL from two d nors and spleen from 
two donors used as a source of RNA for amplification of VH and VL regions.  
Primers were designed as to allow amplification of all commonly used V-gene 
segments.  VH and VL regions were combined by cloning VH regions into a vector 
already containing VL.  70% of clones contain a κ light chain and 30% a λ light 
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chain.  pCES1 was used as the phagemid vector.  A single CH1 domain was used.  
HIS6 and myc tags were included for the identification of soluble Fab. 
 
2.6.2 Growing E.coli TG1 
Frozen TG1 stock in 15% glycerol was streaked onto minimal agar plates and 
incubated 24-48 hours at 37°C.  Single colonies were picked into 5ml 2xTY medium 
and grown shaking overnight at 37°C.  The overnight cul ure was diluted 1:100 in 
fresh 2xTY medium and grown shaking at 37°C until the OD at 600nm (OD600) 
reached 0.4-0.5, and the bacteria were in an exponential growth phase. 
 
2.6.3 Preparing helper phage KM13 
TG1 at an OD600 of 0.4-0.5 was added to 100-fold dilutions of the KM13 helper 
phage.  After incubation at 37°C in a waterbath for 30 minutes, cultures were added 
to molten H-top agar at 42°C and the mixture immediately poured onto pre-warmed 
TYE plates, then incubated overnight at 37°C.  A small plaque was picked into 5ml 
fresh TG1 at an OD600 of 0.4-0.5 and the culture grown shaking at 37°C for 2 hours.  
The culture was then diluted 1:100 in fresh 2xTY medium and grown shaking at 
37°C.  After 1 hour, kanamycin was added to a final concentration of 50µg/ml to 
select for bacteria infected with helper phage, as KM13 carries a kanamycin 
resistance gene, and the culture grown shaking overnight at 30°C.  The overnight 
culture was centrifuged at 10800g for 15 minutes and o e part polyethylene glycol 
(PEG)/NaCl (20% (w/v) PEG 6000 in 2.5M NaCl) added to four parts of the 
supernatant to precipitate the helper phage.  The mixture was incubated on ice for 1 
hour, then the helper phage pelleted by centrifugation at 10800g for 30 minutes.  The 
phage was resuspended in PBS and the precipitation repeated.  The resuspended 
helper phage was then centrifuged at 11600g for 10 minutes to remove any bacterial 
debris, and stored at 4°C for the short term or -70°C in 15% glycerol for the long 
term.  To titre the helper phage stock, TG1 at an OD600 of 0.4-0.5 was added to 100-
fold dilutions of phage, as well as 100-fold dilutions of phage which had been treated 
with 1mg/ml trypsin (Sigma) for 30 minutes at 37°C.  Following incubation at 37°C 
in a waterbath for 30 minutes, cultures were plated in H-top agar as above, and then 
incubated overnight at 37°C.  If the titre of the trypsin-treated phage was 105-108 
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lower than the titre of the non-trypsin treated phage, the preparation was deemed 
acceptable. 
 
2.6.4 Rescuing phage libraries 
Phage libraries in TG1 were grown in 2xTY with 100µg/ml ampicillin to select for 
bacteria infected with phage clones, which carry an ampicillin resistance gene, and 
1% (w/v) glucose as the scFv gene is under the control of a lacZ promoter and the 
glucose inhibits expression of soluble scFv fragments.  For library rescue, phage 
stock in TG1 was grown shaking at 37°C until the OD600 reached 0.4-0.5.  A 10-fold 
excess of KM13 was added to an aliquot of the library l rge enough to ensure library 
diversity was not compromised and incubated without shaking in a 37°C waterbath 
for 30 minutes.  The bacteria were pelleted by centrifugation at 3000g for 10 
minutes, resuspended in 2xTY AKG, and grown shaking overnight at 30°C.  The 
overnight culture was centrifuged at 3300g for 30 minutes and one part PEG/NaCl 
added to four parts of the supernatant to precipitate he phage.  The mixture was 
incubated on ice for 1 hour, then the phage pelleted by centrifugation at 3300g for 30 
minutes.  The phage was resuspended in PBS, centrifuged at 11600g for 10 minutes 
to remove any bacterial debris, and then stored at 4°C for the short term or at -70°C 
in 15% glycerol for the long term.  To titre library stock, TG1 at an OD600 of 0.4-0.5 
was added to 100-fold dilutions of phage.  After incubation at 37°C in a waterbath 
for 30 minutes, cultures were spotted onto TYE AG plates and incubated overnight at 
37°C. 
 
2.6.5 Selection on immunotubes 
In early selection experiments, immunotubes (Nunc) were coated directly with the 
peptide being used as capture antigen.  In later experiments, immunotubes were 
coated with either streptavidin or avidin and biotinylated peptides added 
subsequently.  Finally, a negative selection step was incorporated into the protocol in 
which the phage were passed through two immunotubes coated with streptavidin or 
avidin, added to the biotinylated peptide in solutin and then the mixture applied to a 
third immunotube coated with streptavidin or avidin.  All peptides were 
manufactured by Thistle Scientific.  Protocols for selection were as follows: 
Chapter 2                                                                              Materials nd Methods 
 72 
1. Unmodified peptides 
Immunotubes were coated overnight at 4°C with 100µg/ml peptide in PBS.  The 
following day the tubes were washed three times with PBS and blocked for 2 hours 
at room temperature with 2% marvel skim milk powder in PBS (MPBS).  The tubes 
were washed three times with PBS, phage in MPBS was added and the tubes 
incubated at room temperature for 1 hour rolling and 1 hour standing.  The tubes 
were washed 10 (round 1) or 20 (rounds 2 and 3) times with PBS containing 0.1% 
Tween 20 (PBS-Tween) and the phage eluted using 1mg/ml trypsin and a rolling 
incubation for 10 minutes at room temperature. 
 
2. Biotinylated peptides 
Immunotubes were coated overnight at 4°C with 500ng/ml streptavidin or avidin in 
0.1M NaHCO3 pH 8.2.  Streptavidin was used in rounds 1 and 3, avidin in round 2.  
The following day the tubes were washed twice with PBS and twice with PBS-
Tween and blocked for 2 hours at room temperature with MPBS.  The tubes were 
washed twice with PBS and twice with PBS-Tween, 100µg/ml biotinylated peptide 
in MPBS was added and the tubes incubated for 1 hour at room temperature.  Tubes 
were washed twice with PBS and twice with PBS-Tween, phage in MPBS was added 
and the tubes incubated at room temperature for 1 hour rolling and 1 hour standing.  
The tubes were washed 5 and 5 (round 1) or 10 and 10 (rounds 2 and 3) times with 
PBS-Tween 20 and PBS and the phage eluted using 1mg/ml trypsin and a rolling 
incubation for 10 minutes at room temperature. 
 
3. Biotinylated peptides with negative selection 
Immunotubes were coated overnight at 4°C with 500ng/ml streptavidin or avidin in 
0.1M NaHCO3 pH 8.2.  Streptavidin was used in round 1, avidin n round 2.  The 
following day the tubes were washed twice with PBS and twice with PBS-Tween and 
blocked for 2 hours at room temperature with MPBS.  The tubes were washed twice 
with PBS and twice with PBS-Tween, phage in MPBS added and the tube incubated 
rolling for 15 minutes.  The phage mixture was then d canted into a fresh coated tube 
and incubated standing for 15 minutes.  The phage mixture was next added to 
100µg/ml biotinylated peptide in MPBS and incubated 1 hour shaking and 1 hour 
standing at room temperature.  The phage-peptide mixture was decanted in to a final 
fresh coated tube and incubated 15 minutes rolling a d 15 minutes standing.  The 
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tubes were washed 5 and 5 (round 1) or 10 and 10 (round 2) times with PBS and 
PBS-Tween and the phage eluted using 1mg/ml trypsin and a rolling incubation for 
10 minutes at room temperature. 
 
In the above protocols, eluted phage was rescued by addition of TG1 at an OD600 of 
0.4-0.5.  After incubation in a 37°C waterbath for 30 minutes, 10-fold dilutions of the 
culture were spotted onto TYE AG plates to titre th selection output and the 
remaining bacteria pelleted by centrifugation at 11600g, resuspended in a small 
volume of 2xTY and spread on a BioAssay dish (Nunc) containing TYE AG (round 
1 only) or TYE AG plate.  Titre plates were incubated overnight at 37°C, pellet 
plates incubated overnight at 30°C. 
 
2.6.6 Amplifying selected phage 
After overnight growth of pellet plates, 2xTY with 15 % glycerol was added to plates 
and the cells loosened with a disposable spreader then collected into a tube. Aliquots 
of the harvested bacteria were added to 2xTY AG until the OD600 reached 
approximately 0.1, then the culture grown shaking at 37°C until an OD600 of 0.4-0.5 
was reached.  A 10-fold excess of KM13 was added to an aliquot of the culture and 
incubated without shaking in a 37°C waterbath for 30 minutes.  The bacteria were 
pelleted by centrifugation at 3000g for 10 minutes, r suspended in 2xTY AKG and 
grown shaking overnight at 30°C.  The overnight culture was centrifuged at 3300g 
for 30 minutes and one part PEG/NaCl added to four parts of the supernatant to 
precipitate the phage.  The mixture was incubated on ice for 1 hour and then the 
phage pelleted by centrifugation at 3300g for 30 minutes.  The pellet was 
resuspended in PBS, centrifuged at 11600g for 10 minutes to remove any bacterial 
debris, and then stored at 4°C for the short term o -70°C in 15% glycerol for the 
long term. 
 
2.6.7 Rescuing monoclonal phage 
Phage eluted from selection tubes was rescued by addition of TG1 at an OD600 of 
0.4-0.5.  After incubation at 37°C in a waterbath for 30 minutes, 10-fold dilutions of 
the culture were spread onto TYE AG plates to titrehe selection output and ensure 
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well separated colonies, then incubated overnight at 37°C.  Individual colonies were 
inoculated into 2xTY AG in 96-well flat bottomed plates (Nunc) and grown shaking 
overnight at 37°C.  The next day 5µl of the culture was transferred to fresh 2xTY AG 
in 96-well plates and grown shaking at 37°C.  After 2 hours, 109 KM13 per well 
were added and the cultures shaken at 37°C for a further hour.  The plates were then 
centrifuged at 1800g for 10 minutes, the supernatant aspirated, and the bacterial 
pellet resuspended in 2xTY AKG before being incubated shaking overnight at 30°C.  
The next day, the plate was centrifuged at 770g for 10 minutes and the supernatant 
reserved for analysis by ELISA. 
 
2.6.8 Phage ELISA 
Coating and blocking of the 96-well assay plate (Nunc) was carried out using the 
same concentration of target antigen and identical conditions to those used for 
coating and blocking the immunotubes during the selection of the phage to be 
assayed.  Once this was complete, phage in 2% MPBS was added and the plate 
incubated for 1 hour at room temperature.  Generally, 10µl PEG precipitated 
polyclonal phage (see 2.6.6) or 50µl monoclonal phage supernatant (see 2.6.7) was 
used.  The phage solution was then discarded and the plate washed twice with PBS-
Tween and twice with PBS.  A 1:5000 dilution of HRP-anti-M13 (GE Healthcare) in 
2% MPBS was then added and the plate incubated for 1 hour at room temperature, 
then washed twice with PBS-Tween and twice with PBS.  A substrate solution of 
100µg/ml 3,3’,5,5’-tetramethylbenzidine (Sigma) in 100mM sodium acetate pH 6.0 
with 0.006% (v/v) hydrogen peroxide was added to each well and the plate incubated 
for 10 minutes at room temperature before the reaction was stopped with 1M 
sulphuric acid and the OD(450-650) for each well read. 
 
2.7 Preparation of therapeutic cells 
2.7.1 PBMC activation 
Fresh or frozen PBMCs were washed twice by centrifugation in RPMI, first at 800g 
for 8 min, then 400g for 7 min.  Pelleted cells were resuspended at 1x106 cells/ml in 
complete medium-20 supplemented with 1µg/ml anti-CD3 (Becton Dickinson) and 
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1µg/ml anti-CD28 (Becton, Dickinson), and incubated at 37°C in 5% humidified 
CO2 for 72 hours. 
 
2.7.2 Retrovirus transduction 
Activated PBMCs were resuspended in undiluted supernatant from a PG13 retrovirus 
producer cell line (see 2.5.3).  6ug/ml polybrene (Sigma) was added to the 
suspension, which was then centrifuged at 1200g and 4°C for 3 hours.  Transduced 
cells were resuspended at approximately 5x105 cells/ml in complete medium-20 
supplemented with 100IU/ml IL-2 (UDG) and incubated overnight at 37°C in 5% 
humidified CO2.  Transduction was repeated the following day.  Transduced cells 
were cultured for up to 2 weeks in complete medium-20, with IL-2 to a concentration 
of 100IU/ml added to the culture three times a week. 
 
2.7.3 Establishing an LCL 
PBMCs were resuspended in undiluted EBV preparation (see 2.5.1) and incubated at 
37°C with occasional agitation.  After 1 hour the suspension was centrifuged at 180g 
for 7 minutes, the pellet resuspended at 2x106 cells/ml in complete medium-10 
supplemented with 1µg/ml cyclosporin A (Sigma), and the cells seeded into a 48-
well plate.  Culture plates were incubated at 37°C in 5% humidified CO2 until 
outgrowth of immortalised clones signalled establishment of a cell line. 
 
2.7.4 Reviving CTLs 
All CTLs and HLA matched LCLs were sourced from a cell bank created in our 
laboratory (Wilkie et al, 2004).  Frozen CTLs were thawed and washed twice by 
centrifugation in complete medium-20 at 180g for 7 min.  Pelleted cells were 
resuspended at 2x106 cells/ml in complete medium-20 supplemented with 20U/ml 
IL-2 and incubated at 37°C in 5% humidified CO2 overnight before use. 
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2.7.5 Flow cytometric analysis 
Cells to be analysed were added to polystyrene round bottom tubes (Becton 
Dickinson) and washed twice in PBSA (1% w/v BSA, 0.1% w/v sodium azide, 0.2% 
w/v EDTA) by centrifugation at 120g for 5 minutes.  The supernatant was decanted 
and cells resuspended in residual liquid.  10µL of the appropriate antibody (see Table 
2.2) was added and the tubes incubated for 20 minutes at 4°C in the dark.  Cells were 
washed twice in PBSA then resuspended in 1x CellFix (Becton Dickinson) and 
stored at 4°C in the dark for up to one week until FACS evaluation on either a 
FACScan (Becton Dickinson) or FACSCalibur (Becton Dickinson) flow cytometer.  
At least 10000 events were acquired for each sample.  Data was subsequently 
analysed using the CellQuest software. 
 
Table 2.2: Antibodies used in flow cytometric analysis. 
[FITC: fluorescein isothiocyanate; PE: phycoerythrin] 
antibody clone isotype conjugate supplier 
CD4 RPA-T4 IgG1, κ PE Becton Dickinson  
CD8 RPA-T8 IgG1, κ PE Becton Dickinson  
CD19 HIB19 IgG1, κ PE Becton Dickinson  
CD34 581 IgG1, κ FITC Becton Dickinson  
CD56 B159 IgG1, κ PE Becton Dickinson  
 
 
2.7.6 Chromium release assay 
Cytotoxic activity in vitro was measured using a standard chromium (Cr) release 
assay (Haque t al, 1998).  Cells from each target cell line were labe led with 51Cr for 
1 hour at 37°C before plating with effector cells at an effector:target ratio of 20:1, 
10:1 and 5:1.  After incubation at 37°C for 4 hours the release of 51Cr from lysed 
cells was measured on a gamma counter.  Spontaneous r lease was calculated by 
incubating target cells without effector cells, and maximum release calculated by 
incubating target cells with 1% Triton-X (Sigma).  Percent specific lysis was 
calculated as follows; 
 
 % specific lysis   =  (test release – spontaneous release)  x  100  
          (maximum release – spontaneous release) 
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2.8 Animal Models  
CB17 SCID mice (Bosma et al, 1983) were maintained in a specific pathogen free
unit and housed in microinsulator caging.  Procedurs were carried out under Project 
Licences 60/2766 and 60/3530, and Personal Licence 60/10062.  
 
2.8.1 Tumour induction in SCID mice 
Cells for injection were washed once in HBSS then rsuspended in complete 
medium-10.  A volume of 100µl was administered for each injection.  Mice injected 
by the subcutaneous (sc) route received injections n one or both flanks.  Mice 
injected by the intraperitoneal (ip) route received one injection in the abdomen.  For 
tumour prophylaxis or treatment, intravenous (iv) injections of cells were given into 
a tail vein.   
 
2.8.2 Monitoring tumour growth and collection of sa mples 
Mice were observed three times a week for illness or tumour formation.  Upon 
showing signs of illness, appearance of skin necrosis at the tumour site, tumour 
growth exceeding 18mm in any plane, or at a predetermin d time point, mice were 
culled by cervical dislocation and examined post mortem.  Any macroscopic tumour 




2.9.1 Preparation of slides 
To create slides of cultured cells, approximately 1x108 cells were washed in HBSS at 
180g for 7 minutes and then fixed in 5ml NBF for 2 hours at room temperature.  
Fixed cells were pelleted at 180g for 7 minutes and resuspended in cooled 2% (w/v) 
agarose in PBS. 
 
Cell pellets and mouse tissue fixed in NBF were embdded in paraffin wax blocks.  
Sections of 6µm were cut from the blocks and mounted on polysine coated 
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microscope slides (VWR).  This work was carried out by Mrs Grace Grant, School of 
Biomedical Sciences, University of Edinburgh. 
 
2.9.2 Rehydration of sections 
Paraffin wax-embedded sections were dewaxed by immersion in xylene for 5 
minutes, and then rehydrated by sequential immersion in 100%, 90%, 70%, and 30% 
(v/v) ethanol for 5 minutes each.  The slides were washed in distilled water for 5 
minutes and left to air dry. 
 
2.9.3 Antibody retrieval 
Dewaxed slides were immersed in Target Retrieval Solution (Dako) in a coplin jar 
which had been preheated to approximately 95°C for 20 minutes.  The entire jar was 
removed to the bench and allowed to cool for a further 20 minutes.  The slides were 
then washed twice with distilled water and left to air dry. 
 
2.9.4 Antibody staining using AP 
Visualisation of antibody staining using alkaline phosphotase (AP) was performed 
using the EnVision Detection System (Dako) according to the manufacturer’s 
instructions.  Briefly, after dewaxing and antibody retrieval, sections were incubated 
with primary mouse anti-human mAb (see Table 2.3) at the appropriate dilution for 
30 minutes at room temperature.  Antibodies were diluted in block buffer (0.05mol/l 
Tris-HCl pH7.2-7.6, 1% w/v BSA).  Slides were washed twice in TBS, and then 
incubated with an AP-labelled polymer specific for mouse immunoglobulin for 30 
minutes at room temperature.  The slides were washed again with TBS, and then the 
AP label developed using a Fast Red solution (naphtol AS-Mx phosphate in Tris 
buffer) with levamisole to inhibit endogenous AP.  The slides were then washed 
twice in distilled water and counterstained with Gill’s formula haematoxylin (Vector 
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Table 2.3: Antibodies used in immunohistochemistry. 
antibody clone isotype dilution supplier 
BZLF1 BZ.1 IgG1, κ 1:20 Dako 
CD4 4B12 IgG1, κ 1:20 Vision BioSystems 
CD8 1A5 IgG1 1:20 Vision BioSystems 
CD15 HI98 IgM, κ 1:150 Becton Dickinson 
CD19 LE-CD19 IgG1 1:200 AbD Serotec 
CD20 L26 IgG2A, κ 1:400 Dako 
CD30 BerH8 IgG1, κ 1:150 Becton Dickinson 
cytokeratin AE1/AE3 IgG1, κ 1:100 Dako 
EBNA2 PE2 IgG1, κ 1:25 Dako 
LMP1 CS.1-4 IgG1, κ 1:100 Dako 
 
 
2.9.5 Antibody staining using HRP 
Visualisation of antibody staining using horse radish peroxidase (HRP) was 
performed using the Novolink Polymer Detection System (Vision BioSystems) 
according to the manufacturer’s instructions.  Briefly, after dewaxing and antibody 
retrieval, sections were incubated with a peroxidase block for 5 minutes to neutralise 
endogenous peroxidases, washed twice with TBS, incubated with a protein block for 
5 minutes, washed twice with TBS and then incubated with primary mouse anti-
human mAb (see Table 2.3) at the appropriate dilution for 30 minutes at room 
temperature.  Antibodies were diluted in Antibody Dilutant (Dako).  Slides were 
washed twice in TBS, then incubated with a post prima y block for 30 minutes, 
washed twice again in TBS, then incubated with a HRP-labelled polymer specific for 
mouse immunoglobulin for 30 minutes at room temperature.  The slides were washed 
twice with TBS, and then the HRP label developed using a 1.74% 3,3-
diaminobenzidine (DAB) solution.  The slides were th n washed twice in distilled 
water and counterstained with haematoxylin for five minutes before mounting with 
Faramount. 
 
2.9.6 EBER in situ hybridisation 
EBER ISH was carried out using a PNA ISH Detection Kit (Dako).  Dewaxed slides 
were rehydrated by sequential immersion in 100%, and 95% ethanol and double 
processed water (Sigma) for 5 minutes each.  Sections were then incubated with 
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15µg/ml Proteinase K (Sigma) in 50mM Tris-HCl pH 7.6 for 30 minutes at 37°C in a 
humidity chamber, then washed twice in double processed water and dehydrated by 
immersion in 95% ethanol for 10 seconds.  An EBV (EBER) PNA Probe (Dako) 
labelled with FITC was added to each section, covered with a coverslip, and 
incubated at 55°C for 3 hours in a humidity chamber.  Coverslips were removed 
during immersion in the supplied stringent wash soluti n for 25 minutes at 55°C.  
Slides were washed once in TBS, and then incubated for 30 minutes at room 
temperature with the supplied AP-labelled anti-FITC detection antibody, before 
being washed twice with TBS and twice with distilled water.  AP was developed 
using a 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium (BCP/NBT) 
Alkaline Phosphotase Substrate Kit (Vector Laboratories), with slides being 
incubated with substrate solution for 45 minutes at room temperature in a humidity 
chamber, and then washed in 100mM Tris-HCl pH 9.5 and running tap water.  
Sections were counterstained with haematoxylin for five minutes before mounting 
with Faramount. 
 
2.9.7 Haematoxylin and eosin staining 
Dewaxed and rehydrated slides were immersed in haematoxylin for 10 minutes, 
washed with running tap water for 5 minutes, immersed in 1% w/v eosin Y (Sigma) 
for 15 minutes then washed again in running tap water for 5 minutes.  Sections were 
mounted with Vectamount permanent mounting medium (Vector).  Histological 
examination was assisted by Dr Christopher Bellamy, Department of Pathology, 
Royal Infirmary, Edinburgh. 
 
2.10  Statistical analysis 
Data is presented as mean ± standard deviation (SD).  The non-parametric Mann 
Whitney t test was used to compare levels of specific lysis in chromium release 
assays.  Fisher’s exact test for comparison of proportions, and Wilcoxon rank sum 
test for comparison of two groups, was used to analyse immunotherapy data.  In all 
cases, P<0.05 was accepted as indicating a significa t difference.  Tests were carried 




3 Animal Models for EBV-Associated 
Malignancies 
 
The modelling of human diseases in animals provides researchers with essential tools 
for studying disease pathogenesis and offers valuable insight into the mechanism and 
effect of new treatments.  Small animal models, especially murine, are routinely used 
to test novel cellular therapies (Brentjens et al, 2003; Zeng et al, 2005; Savoldo et al, 
2007).  In vitro techniques such as the chromium release assay are able to test the 
effector mechanism of therapeutic cells, as will be se n in Chapter 4.  In vivo models 
are able to investigate other characteristics, such as the ability of cells to traffic to 
tumour sites and exert an effect over an extended period of time.  These abilities are 
essential if therapeutic cells are to be effective in a patient setting.  Thus, in order to 
test our hypothesis that engineered T cells could targe  and kill the malignant cells of 
cancers associated with EBV, an in vivo model was desirable.  To provide in vivo 
models for HL, NPC and GC, SCID mice were inoculated sc with cell lines derived 
from these EBV-associated malignancies.  The cell lines and resulting SCID tumours 
were evaluated for histology, immunophenotype, viral gene expression and growth 
characteristic for comparison with parent tumours. 
 
3.1 Histology of cell lines 
In order to characterise the HL (HDLM2, L1236, L540, L591), NPC (C666.1) and 
GC (AGS, NUGC3, NUGC3-EBV) cell lines (see Table 2.1) prior to use in vivo, cells 
from in vitro culture were pelleted, fixed in NBF, and embedded in 2% w/v agarose.  
Sections were mounted on slides and stained with haematoxylin and eosin to 
examine cell morphology.  Photomicrographs of HL cell lines are shown in Figure 3.1 












Figure 3.1: Haematoxylin and eosin staining of HL cell lines. 
HL cell lines HDLM2 (A) and L1236 (B) at x200 magnification, and L540 





Histologically, the four HL cell lines (HDLM2, L1236, L540, L591) displayed a 
pleiomorphic phenotype in culture (Figure 3.1).  The majority of cells were small and 
lymphoid in appearance, with occasional, large, bi- and multi-nuclear blastoid cells, 
which is consistent with a HRS cell phenotype.  The carcinoma cell lines (AGS, 
NUGC3, NUGC3-EBV, C666.1) were also pleiomorphic in culture, with an 











Figure 3.2: Haematoxylin and eosin staining of carcinoma cell lines. 
GC lines AGS (A), NUGC3 (B) and NUGC3-EBV (C) at x400 
magnification, and NPC line C666.1 (D) at x200 magnification, with blue 




3.2 In vitro infection of EBV-negative HL cell lines 
As L591 is the only naturally EBV-positive HL cell line (Diehl et al, 1982), an 
attempt was made to infect the remaining HL cell lines (HDLM2, L1236, L540) with 
EBV in vitro, with the aim of expanding the available range of EBV-positive targets 
for later use in SCID mice.  Cells were incubated with EBV for one hour at 37°C in 
5% humidified CO2 and then maintained in culture (see 2.2.1), with samples taken at 
3, 14, and 49 days post infection for DNA extraction.  Real time PCR was used to 
assay viral load (see 2.4.3; Leung et al, 2002).  An EBV-positive L591 sample and a 
no template control (NTC) were included. 
 
DNA from L591 cells was amplified by PCR, and no product was present in the 
NTC sample.  The three cell lines (HDLM2, L1236, L540) were infected with EBV, 
showing DNA amplification on at least one time point.  However, the infection was 
transient in all three cell lines, with no EBV DNA detected at 14 (L540) or 49 
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(HDLM2, L1236) days post infection (Table 3.1).  Therefore, L591 remained the only 
EBV-positive HL in the following experiments. 
 
Table 3.1: Viral load of HL cells after infection in vitro with EBV. 
cell line time point (days) EBV copies/106 cells 
L591  -  3.5x106 
HDLM-2 3 2.3x105 
 14 1.5x104 
 49 0 
L1236 3 5.6x105 
 14 5.4x104 
 49 0 
L540 3 1x102 




3.3 Tumour outgrowth 
To set up animal models for EBV-associated malignancies, a panel of four HL cell 
lines (HDLM2, L1236, L540, L591), one NPC cell line (C666.1) and four GC cell 
lines (AGS, AGS-EBV, NUGC3, NUGC3-EBV) were used (see Table 2.1).  SCID 
mice were injected sc into the flank with 1x107 cells and monitored for tumour 
formation and subsequent growth (see 2.8.1 and 2.8.2).  Additional cell doses of 
5x106, 2x106 and 1x106 were used for the L591, NUGC3-EBV and C666.1 cell lines 
to determine optimum cell dose for tumour formation. 
 
3.3.1 Time to tumour onset 
Time to onset following sc injection was defined as the day at which tumours 
became macroscopically apparent.  Experiments were terminated at a predetermined 
time limit of 100 days (Johannessen t al, 2000). 
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All four HL cell lines tested formed tumours in SCID mice (Table 3.2).  At a dose of 
1x107 cells, at least 80% of mice injected with HDLM2, L1236, L540, or L591 
developed tumours, with median time to tumour onset ranging between 14 days for 
L1236 and 44 days for HDLM2.  As the only EBV-positive HL cell line, L591 was 
selected for further titration experiments to determine the minimum dose required for 
reliable engraftment. 
 
Table 3.2: Tumour incidence following sc inoculation of SCID mice with HL cell lines. 
cell cell  number of tumours/ time to tumour onset 
line dose site injected (%) median range 
HDLM2 1x107 8 / 10    (80) 44 41-53 
L1236 1x107 9 / 10    (90) 14 14-20 
L540 1x107 11 / 12    (92) 22 19-44 
L591 1x107 11 / 12    (92) 28 14-37 
 5x106 17 / 22   (77) 20 16-28 
  2x106 9  / 16    (56) 32 32-54 
 
 
In the L591 titration experiment, a cell dose of 2x106 did not result in reliable tumour 
formation, as tumour outgrowth was seen in only 9 of 16 cases (56%).  Although 
engraftment rates dropped from 11 of 12 (92%) to 17 of 22 (77%) between doses of 
1x107 and 5x106 respectively, there was a narrower range in time to tumour onset, 
14-37 days compared with 16-28 days.  This allowed for more accurate estimations 
of time to tumour formation and hence facilitating the planning of immunotherapy 
experiments.  Thus it was decided that a dose 5x106 cells per injection would be used 
in immunotherapy experiments. 
 
Next, the ability of carcinoma cell lines (AGS, AGS-EBV, NUGC3, NUGC3-EBV, 
C666.1) to cause tumour outgrowth in SCID mice was assessed.  All carcinoma cell 
lines formed tumours in SCID mice, with the exception of AGS-EBV (Table 3.3).  At 
least 70% of mice injected with AGS, NUGC3, NUGC3-EBV, or C666.1 at a dose of 
1x107 cells developed tumours, with median time to tumour onset ranging between 8 
days for C666.1 and 71 days for AGS.  As the sole EBV-positive representatives for 
their respective tumours, NUGC3-EBV for GC and C666.1 for NPC were selected 
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for further titration experiments to determine the minimum dose required for reliable 
engraftment. 
 
In titration experiments with NUGC3-EBV and C666.1, cell doses of 1x106 cells and 
2x106 respectively resulted in tumour formation in 100% of mice.  The range in time 
to tumour onset remained relatively narrow at 23-26 days for NUGC3-EBV and 17-
24 days for C666.1.  Thus it was decided that a dose 1x106 cells per injection for 
NUGC3-EBV, and 2x106 cells per injection for C666.1, would be used in 
immunotherapy experiments.   
 
Table 3.3: Tumour incidence following sc inoculation of SCID mice with CG 
and NPC cell lines. 
cell  cell number of tumours/ time to tumour onset 
line dose sites injected (%) median  range 
AGS 1x107 7 / 10    (70) 71 60-95 
AGS-EBV 1x107 0 / 10    (0)  -   -  
NUGC3 1x107 10 / 10    (100) 21 18-21 
NUGC3-EBV 1x107 12 / 12    (100) 18 11-18 
 5x106 4 / 4    (100) 13 13 
 2x106 4 / 4    (100) 13 13 
 1x106 4 / 4    (100) 25 23-26 
C666.1 1x107 10 / 10    (100) 8 8 
 5x106 4 / 4    (100) 17 17-21 
  2x106 4 / 4    (100) 23 17-24 
 
 
In order to assess the suitability of ip tumours to model EBV-associated 
malignancies in SCID mice, a study of tumour engraftment via ip administration was 
undertaken.  All cell lines (HDLM2, L1236, L540, L591, AGS, AGS-EBV, NUGC3, 
NUGC3-EBV, C666.1) were injected at a dose of 1x107 cells per mouse.  Time to 
onset was defined as time from injection of cells to termination of mice showing 
signs of distress (hunched back, poor grooming, lethargy, panting). 
 
Although each group contained only three mice, engraftment rates were generally 
poor compared with sc injection, with L1236 alone engrafting in 100% of mice 
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(Table 3.4).  L540 and NUGC3 engrafted in 2 of 3 mice (67%), L591, AGS, NUGC3-
EBV, and C666.1 engrafted in 1 of 3 mice (33%), and HDLM2 and AGS-EBV 
injected mice did not develop tumours.  In light of these results, and due to difficulty 
in determining tumour onset before mortality (as death rapidly followed initial 
clinical symptoms of illness, usually within 8 hours), it was decided not to pursue 
this model any further. 
 
Table 3.4: Tumour incidence following ip inoculation of SCID 
mice with HL, GC and NPC cell lines. 
cell derivation number of tumours/ 
line   number of mice (%) 
HDLM2 HL 0 / 3    (0) 
L1236  3 / 3   (100) 
L540  2 / 3   (67) 
L591  1 / 3    (33) 
AGS GC 1 / 3    (33) 
AGS-EBV  0 / 3    (0) 
NUGC3  2 / 3    (67) 
NUGC3-EBV  1 / 3    (33) 




3.3.2 Growth rate 
Following sc tumour onset, SCID mice from the experim nts in 3.3.1 were followed 
over time to monitor tumour growth and assess suitability for use as EBV-associated 
malignancy models for testing immunotherapies.  Tumo rs were measured in the 
cranial/caudal and ventral/dorsal planes, with tumor size taken as the product of 
these two measurements (Haynes et al, 2002).  Experiments were terminated upon 
tumours exceeding 18mm in any plane, in order to sample tumour tissue, or when the 
pre-set time limit of 100 days was reached. 
 
Once established, all HL tumours (HDLM2, L1236, L540, L591) continued to 
increase in size over time. Growth curves from mice inj cted sc with 1x107 cells are 
shown in Figure 3.3.  There were no cases of complete spontaneous tumour 
regression.  After a delayed onset compared to other cell lines, HDLM2 tumours 
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grew very slowly, with only one tumour exceeding 10mm in length prior to the 100 
day time point.  In light of this it was decided tha  HDLM2 was not a suitable in vivo 
model, as differences in growth rate between treated nd untreated groups could be 
difficult to discern.  In comparison, L1236 and L540 tumours engrafted earlier and 
displayed much faster growth, capable of doubling tumour size in an average of 2 or 
5 days respectively.  This rapid growth rate, especially in L1236 tumours, 
contributed to the decision not to pursue these cell lines for further modelling, as 
therapeutic cells might not be capable of an effectiv  response in such a short time 
frame.  L591 tumours displayed slow but constant growth, and as such were deemed 
most suitable for future use, as therapeutic cells would be given sufficient time to 
mount an effective response against tumour cells, and differences in tumour growth 





Figure 3.3: Tumour growth curves of HL cell lines in SCID mice. 
Cell lines HDLM2 (A), L1236 (B), L540 (C) and L591 (D) were injected sc at a dose 
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Once engrafted, all tumours from carcinoma cell lines (AGS, NUGC3, NUGC3-
EBV, C666.1) continued to increase in size over time.  Growth curves from mice 
injected with 1x107 cells are shown in Figure 3.4.  There were no cases of complete 
spontaneous tumour regression.  Tumours in mice injected with AGS cells developed 
tumours after a long period of time, with a wide range of onset, 60-95 days post 
injection.  This model was subsequently deemed not suitable for further modelling 
due to the consequent difficulty in planning immunotherapy experiments.  NUGC3, 
NUGC3-EBV, and C666.1 all engrafted early after inoculation, at a median of 21, 18 
and 8 days post inoculation, respectively.  Growth as also rapid, with tumours from 
all three cell lines capable of doubling in size in an average of 4 days, leading to the 





Figure 3.4: Tumour growth curves of carcinoma cell ines in SCID mice. 
GC cell lines AGS (A), NUGC3 (B), and NUGC3-EBV (D), and NPC cell line C666.1 (C) 
were injected sc at a dose of 1x107.  Each line represents an individual tumour. 
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3.4 Characterisation of HL, NPC and CG SCID tumours  
To characterise HL, NPC and GC SCID malignancies, samples of tumours were 
fixed in NBF and embedded in paraffin wax.  Sections were stained with 
haematoxylin and eosin for histological analysis.  HL tumours were immunostained 
with a panel of mAbs for cell surface markers to differentiate between tumour types 
and confirm parent cell line identity.  NPC and GC tumours were immunostained for 
cytokeratin to demonstrate epithelial derivation.  Finally, tumours were 
immunostained for a range of EBV latent and lytic antigens to verify EBV infection 
and latency state. 
 
3.4.1 Histology 
Sections of tumours derived from EBV-positive tumour cell lines were stained with 
haematoxylin and eosin to determine the histology of the tumours.  




Figure 3.5: Haematoxylin and eosin staining of HL SCID tumours. 
HL cell lines HDLM2 (A), L1236 (B), L540 (C) and L591 (D) at x200 magnification, 
with blue nuclear and pink cytoplasmic staining. 




Figure 3.6: Haematoxylin and eosin staining of GC and NPC SCID tumours. 
GC lines AGS (A), NUGC3 (B) and NUGC3-EBV (C), and NPC line C666.1 (D), at 
x200 magnification, with blue nuclear and pink cytoplasmic staining.  White arrows 
indicate areas of necrosis. 
 
 
Three of the HL cell lines (HDLM2, L1236, L540) gave rise to relatively 
homogeneous tumours, despite cells in culture displaying a more heterogeneous 
phenotype, with haematoxylin and eosin staining of sections showing sheets of blast 
cells (Figure 3.5 panels A,B,C).  Tumours derived from L591 cells retained their 
culture heterogeneity, with sections showing a polym rphic population of large bi- 
and multi-nuclear blast cells, again consistent with a HRS cell phenotype (Figure 3.5 
panel D).  Tumours derived from carcinoma cell lines (AGS, NUGC3, NUGC3-EBV, 
C666.1) showed sheets of undifferentiated malignant cells (Figure 3.6). 
 
3.4.2 Immunophenotype 
In order to characterise the cell surface phenotype of SCID tumours derived from HL 
cell lines (HDLM2, L1236, L540, L591), immunostaining for a panel of human CD 
antigens was performed.  Panel mAb were directed against: CD4 (T-lineage antigen), 
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CD15 (myeloid/HL-associated antigen), CD20 (B-cell marker), and CD30 
(activation/HL-associated antigen).  Antibodies were selected for their combined 
ability to differentiate between tumour types and confirm parent cell line identity.  At 
least five tumours derived from each cell line were valuated.  Expression was 




Figure 3.7: CD4 expression on HL SCID tumours. 
HL tumours derived from HDLM2 (C), L1236 (D), L540 (E) and L591 (F) at x200 
magnification, stained for CD4 expression.  AP detection system shows positive red 
membrane staining (B,D).  HRP detection system shows positive brown membrane 
staining (C).  Negative control was GC SCID tumour (A), positive control was a CTL 
line (B).  Black arrows indicate areas of positive staining (C,D), or single positive cells 
(B).  Sections were counterstained with haematoxylin. 
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Expression of CD4 was seen in sections of HDLM2 andL1236 tumours, but not 
L540 or L591 tumours (Figure 3.7).  Expression of CD15 was seen in sections of 
HDLM2 and L540 tumours, but not L1236 or L591 tumours (Figure 3.8).  L591 alone 
expressed CD20 (Figure 3.9), while all tumours expressed CD30 (Figure 3.10).  A 
summary of these results is shown in Table 3.5.  The immunophenotype of tumours 




Figure 3.8: CD15 expression on HL SCID tumours. 
HL tumours derived from HDLM2 (C), L1236 (D), L540 (E) and L591 (F) at x200 
magnification, stained for CD15 expression.  AP detection system shows positive red 
membrane staining (B,E).  HRP detection system shows positive brown membrane 
staining (C).  Negative control was GC SCID tumour (A), positive control was human 
tonsil (B).  Black arrows indicate individual positive cells.  Sections were 
counterstained with haematoxylin. 





Figure 3.9: CD20 expression on HL SCID tumours. 
HL tumours derived from HDLM2 (C), L1236 (D), L540 (E) and L591 (F) at x200 
magnification, stained for CD20 expression.  AP detection system shows positive red 
membrane staining (B,F).  Negative control was GC SCID tumour (A), positive control 
















Figure 3.10: CD30 expression on HL SCID tumours. 
HL tumours derived from HDLM2 (C), L1236 (D), L540 (E) and L591 (F) at x200 
magnification, stained for CD30 expression.  AP detection system shows positive red 
membrane staining (B,D,E,F).  HRP detection system shows positive brown membrane 
staining (C).  Negative control was GC SCID tumour (A), positive control was a CTL 




Table 3.5: Cell surface phenotype of HL SCID tumours. 
SCID antigen expression 
tumour CD4 CD15 CD20 CD30 
HDLM2  +   +   -   +  
L1236  +   -   -   +  
L540  -   +   -   +  
L591  -   -   +   +  
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In order to confirm epithelial origin, SCID tumours derived from GC cell lines AGS, 
NUGC3 and NUGC3-EBV, and NPC cell line C666.1 were stained for human 
cytokeratin of both Type I and II (Woodcock-Mitchell t al, 1982).  As shown in 




Figure 3.11: Cytokeratin expression in GC and NPC SCID tumours. 
GC tumours derived from AGS (C), NUGC3 (D), and NUGC3-EBV (E), and NPC 
tumour derived from C666.1 (F) at x200 magnification, stained for cytokeratin 
expression.  AP detection system shows positive red cytoplasmic staining (B,C,D,E,F).  
Negative control was a T cell lymphoma SCID tumour (A), positive control was 
NUGC3 cell line (B).  Sections were counterstained with haematoxylin. 
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3.4.3 EBV infection 
To confirm the EBV status of cell lines (L1236, L540, L591, NUGC3-EBV, 
C666.1), tumour sections were probed for EBERs expression using in situ 
hybridisation.  At least five tumours derived from each cell line were evaluated.  
Results are shown in Figure 3.12. 
 
The EBV-positive cell lines L591, NUGC3-EBV and C666.1 expressed EBERs, with 
characteristic nuclear staining evident in 100% of tumour cells (Figure 3.12).  The 
EBV-negative cell lines L1236 and L540 showed no EBERs expression. 
 
In order to assess the level of latent and lytic replication in the infected cells, tumours 
derived from the EBV-positive cell lines (L591, NUGC3-EBV, C666.1) were 
subsequently immunostained for three EBV latent and lytic antigens.  Antigens were 
EBNA2, expressed in latency III, LMP1, expressed in latency II and III, and the 
immediate early lytic protein BZLF1.  At least three tumours derived from each cell 
line were evaluated.  Expression was assessed on a qualitative basis, and positively 
stained cells were not quantitated. 
 
EBNA2 protein was expressed in L591 and C666.1 tumours, but not NUGC3-EBV 
tumours (Figure 3.13).  All three tumour types expressed the latent protein LMP1 
(Figure 3.14), although this was only seen in 1 of 3 (33%) NUGC3-EBV tumours.  
BZLF1 was not expressed at all in NUGC3-EBV or C666.1 tumours, but the 
occasional BZLF1-positive cell was observed in L591 tumours (Figure 3.15).  A 
summary of these results is shown in Table 3.6. 
 
 
Chapter 3                                        Animal Models for EBV-Associated Malignancies 
 98 
 
Figure 3.12: EBERs expression in HL, GC and NPC SCID tumours. 
HL tumours derived from L1236 (C), L540 (D), and L591 (E), and GC derived NUGC3-
EBV (F), and NPC derived C666.1 (G), all at x200 magnification, probed by in situ 
hybridisation for EBERs expression.  AP and BCP/NBT detection system shows positive 
black nuclear staining (B,E,F,G).  Negative control is human bowel lymphoma with 
negative control probe (A), positive control is human bowel lymphoma with EBERs 
probe (B).  Sections were counterstained with haematoxylin. 





Figure 3.13: EBNA2 expression in EBV-positive SCID tumours. 
HL cell line L591 (C), GC cell line NUGC3-EBV (D), and NPC cell line C666.1 (E), 
at magnification x200, stained for EBNA2 expression. HRP detection system shows 
positive brown nuclear staining (B,C,E).  Negative control was EBV-negative HL 
SCID tumour (A), positive control was LCL (B).  Black arrows indicate areas of 
positive staining.  Sections were counterstained with haematoxylin. 
 





Figure 3.14: LMP1 expression in EBV-positive SCID tumours. 
HL cell line L591 (C), GC cell line NUGC3-EBV (D), and NPC cell line C666.1 (E), 
at magnification x200, stained for LMP1 expression. HRP detection system shows 
positive brown membrane staining (B,C,D,E).  Negative control was EBV-negative HL 
SCID tumour (A), positive control was LCL (B).  Black arrows indicate individual 
positive cells.  Sections were counterstained with haematoxylin. 




Figure 3.15: BZLF1 expression in EBV-positive SCID tumours. 
HL cell line L591 (C), GC cell line NUGC3-EBV (D), and NPC cell line C666.1 (E), 
at magnification x200, stained for BZLF1 expression. HRP detection system shows 
positive brown cytoplasmic staining (B,C).  Negative control was EBV-negative HL 
SCID tumour (A), positive control was LCL (B).  Black arrows indicate individual 
positive cells.  Sections were counterstained with haematoxylin. 
 
 
Table 3.6: Viral antigen expression in EBV-positive SCID tumours. 
(+): rare positive cells    -/+: expression in 1 of 3 samples 
SCID human antigen expression 
tumour derivation EBNA2 LMP1 BZLF1 
L591 HL  +   +  (+) 
NUGC3-EBV GC  -   -/+   -  
C666.1 NPC  +   +   -  
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3.5 Summary of results 
Hodgkin’s lymphoma cell lines 
In vitro: 
• Cell lines (HDLM2, L1236, L540, L591) displayed a heterogeneous phenotype 
in culture.  The majority of cells were small and lymphoid in appearance.  
Occasional large bi- and multi-nuclear blastoid cells, consistent with a HRS 
cell phenotype, were also present. 
• Three EBV-negative cell lines (HDLM2, L1236, L540) were infected with 
EBV in vitro.  However, infection was not sustained. 
In vivo: 
• HL cell lines (HDLM2, L1236, L540, L591) injected sc in SCID mice formed 
tumours which displayed sustained growth over time. 
• Titration of the L591 cell line determined that 5x106 cells was the minimum 
cell number for consistent sc tumour formation, and this dose was used in 
subsequent immunotherapy experiments. 
• Injection of cell lines ip in SCID mice resulted in poor outgrowth of tumours.  
Furthermore, it was difficult to determine tumour onset in vivo.  This model 
was not utilized in further experiments. 
• Histology of sc SCID tumours derived from three HL cell lines (HDLM2, 
L1236, L540) showed homogeneous sheets of blast cells.  SCID tumours 
derived from L591 consisted of a heterogeneous population of large bi- and 
multi-nuclear blast cells, consistent with a HRS cell phenotype. 
• The immunophenotype of sc SCID tumours derived from HL cell lines 
(HDLM2, L1236, L540, L591) was consistent with that of parental cell lines. 
• EBER ISH of L591 sc SCID tumours confirmed EBV infection, with 
immunostaining showing a viral latency III gene expression pattern. 
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Carcinoma cell lines 
In vitro: 
• Cell lines (AGS, NUGC3, NUGC3-EBV, C666.1) were a pleiomorphic 
population in culture, displaying an undifferentiated malignant phenotype. 
In vivo: 
• Cell lines (AGS, NUGC3, NUGC3-EBV, C666.1) injected sc in SCID mice 
formed tumours which displayed sustained growth over time, with the 
exception of one cell line (AGS-EBV) which did not f rm tumours in vivo. 
• Titration of the NUGC3-EBV and C666.1 cell lines determined that 1x106 and 
2x106 cells, respectively, were the minimum cell dose for consistent sc tumour 
formation, and these doses were used in subsequent immunotherapy 
experiments. 
• Histology of sc SCID tumours derived from carcinoma cell lines (AGS, 
NUGC3, NUGC3-EBV, C666.1) showed sheets of undifferentiated malignant 
cells. 
• Immunostaining for cytokeratin in SCID tumours deriv d from carcinoma cell 
lines (AGS, NUGC3, NUGC3-EBV, C666.1) confirmed their epithelial origin. 
• EBER ISH of NUGC3-EBV and C666.1 sc SCID tumours confirmed EBV 
infection, with immunostaining showing a viral latency II/I expression pattern 
for NUGC3-EBV and latency III for C666.1. 
 
3.6 Discussion 
Although much information can be gathered from in vitro experiments, 
investigations into the safety and efficacy of new therapeutic agents are best carried 
out using relevant in vivo models.  Interactions between agent and subject are 
complex and not always predictable, therefore testing in a situation akin to that of the 
clinic is likely to provide a more accurate view oftherapeutic effect and limit 
unforeseen events.  Thus, the initial aim of the project was to establish mouse models 
of the EBV-associated malignancies HL, NPC and GC in which to test novel 
immunotherapies. 
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The malignant cells of HL, the HRS cells, have a heterogeneous phenotype both 
morphologically and immunophenotypically (Gruss & Kadin, 1996).  Reed-
Sternberg cells are multi-nucleated, while Hodgkin cells are mono-nucleated.  The 
antigenic profile of HRS cells varies between tumours, although a panel of antigens 
common to most primary HRS cells has been identified.  This panel includes the 
surface antigens CD15, CD25, CD30, CD40, CD54, CD70, CD71, MHC class II and 
the nuclear proliferation antigen Ki-67 (Gruss & Kadin, 1996).  No individual cell 
line is able to model all possible manifestations of a HRS cell, and thus a panel of 
HL cell lines was assembled in order to represent more accurately the clinical 
situation.  As the bulk of a HL tumour consists of infiltrating lymphocytes with only 
a small proportion of HRS cells, attempts to propagate HRS cell lines in vitro have 
often resulted in the outgrowth of EBV-positive LCLs rather than true HRS cell 
lines.  This situation can also occur in vivo, as SCID mice implanted with HL lymph 
node biopsy samples can develop EBV-positive tumours de ived from virus infected 
B cells rather than HRS cells (Meggetto et al, 1996).  Equally, it is possible that 
during initial attempts to propagate HL samples in vitro, EBV-positive HRS cell 
lines may have been discarded, as EBV infection of a cell line was considered a 
contamination in the past.  Given the difficulties ncountered in establishment of 
these early HL cell lines, it is now virtually impossible to prove that three lines used 
in the current project (HDLM2, L540, L591) are deriv d from HRS cells.  
Nevertheless, they display characteristics not inconsistent with HRS cells, including 
expression of cell surface markers from the panel common to primary HRS listed 
above, polynuclearity and morphological heterogeneity (Drexler, 1993), and continue 
to be used widely as cell lines representative of HL (Baumforth et al, 2005; Savoldo 
et al, 2007).  Furthermore, the L1236 cell line has been identified definitively as 
being derived from HRS cells, as identical Ig gene rearrangement sequences were 
demonstrated in L1236 cells and HRS cells in the bone marrow of the patient from 
whom the cell line was established originally (Kanzler et al, 1996a). 
 
To test EBV-targeted immunotherapies, EBV-positive cell lines are required.  Three 
EBV-negative HL cell lines (HDLM2, L1236, L540) were initially infected with the 
B95-8 laboratory strain of the virus.  Although none of these cell lines express the 
EBV receptor CD21 (Diehl et al, 1981; Drexler et al, 1989; Kis et al, 2005), it has 
been shown that CD21 is not absolutely required for EBV infection of either B 
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lymphocytes or epithelial cells (Janz et al, 2000).  The cell lines harboured EBV 
DNA as demonstrated by PCR three days after in vitro infection (Table 3.1).  
However, EBV copy number declined over time until EBV DNA could no longer be 
amplified from the infected cells.  This is in line with other reports of transient EBV 
infection in susceptible cell lines, including the HL-derived KMH2 cell line (Kis et 
al, 2005).  As these cells are already transformed, there is not likely to be any 
survival advantage accorded by EBV infection in vitro and so negative selection 
pressure may cause EBV-positive cells to be lost frm culture.   
 
For lasting EBV infection of cell lines in vitro, recombinant EBV carrying a 
selectable marker is generally used until stably infected sublines are established 
(Shimizu et al, 1996; Imai et al, 1998; Baumforth et al, 2005; Kis et al, 2005).  One 
such HL cell line (KMH2-EBV), and two GC cell lines (AGS-EBV, NUGC3-EBV), 
were acquired together with their parent lines (Shimizu et al, 1996; Imai et al, 1998; 
Kis et al, 2005).  At a dose of 1x107 cells, sc injection of KMH2 or KMH2-EBV in 
SCID mice resulted in tumour formation on 4 of 10 (4 %) and 0 of 5 (0%) occasions, 
respectively.  In light of this poor rate of tumour outgrowth no further experiments 
were performed with the KMH2 cell lines.  As stated in the project aims, the original 
intention was to model EBV-associated malignancies so as to have a framework 
within which to test novel LMP2-targeted therapies.  The generation of target cell 
lines expressing a range of EBV latent antigens more reflective of the restricted virus 
gene expression characteristic of HL is an ongoing issue for researchers developing 
EBV-targeted therapies for HL.  Cell lines currently used are LCLs expressing the 
full set of latent antigens, or EBV-negative cell lines transduced with recombinant 
vaccinia constructs encoding individual EBV genes (Murray et al, 1990; Murray et 
al, 1992).  Interestingly, the in vitro infected subline of the AGS GC cell line also 
failed to form tumours in SCID mice, while 70% AGS injections gave rise to 
tumours (Table 3.3).  In the NUGC3 GC setting, the EBV infected subline and the 
EBV-negative parent were equally as efficient in forming tumours.  The SCID model 
is known to be ‘leaky’, that is 2 to 23% of mice develop some functional T and B 
cells in addition to their native NK cell activity (Bosma et al, 1988).  It is possible 
that infection with recombinant EBV caused the KMH2 and AGS cell lines to 
become more ‘visible’ to the residual SCID immune system, although why this 
should occur in only two of three cell lines is not clear.  However, the low level 
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immune function, if present, is unlikely to affect the SCID models in which tumour 
formation was observed, as no spontaneous tumour regression was seen in any case. 
 
EBER ISH confirmed EBV infection in three cell lines; L591 derived from HL, 
NUGC3-EBV from GC and C666.1 from NPC (Figure 3.12).  EBV-associated HL 
expresses a latency II phenotype, which is not seen in L591.  In contrast, the 
observed EBV expression pattern for L591 is type III (Vockerodt et al, 2002), with 
positive immunostaining seen for EBNA2 (Table 3.6).  As such, it more closely 
resembles an LCL, and the presence of occasional lytical  infected cells as detected 
by BZLF1 immunostaining supported this. 
 
 
Figure 3.16: EBNA2 expression in the C666.1 NPC cell line. 
NPC cell line C666.1, at magnification x400, without primary antibody (C) and stained 
for EBNA2 expression (D). HRP detection system shows positive brown nuclear 
staining (B,D).  Negative control was EBV-negative HL SCID tumour (A), positive 
control was LCL (B).  Sections were counterstained with haematoxylin. 
 
 
Tumours derived from C666.1 were also positive for EBNA2 expression by 
immunohistochemistry, which is also not consistent with the expected latency II 
EBV expression pattern of NPC, and contradicts the findings of the laboratory in 
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which the cell line was established (Cheung et al, 1999).  A drift from latency I to 
latency III expression has been seen in some BL cell lin s after prolonged in vitro 
culture, and a similar event may have occurred here.  Immunostaining of C666.1 
cells embedded in agarose confirmed EBNA2 expression in the NPC cell line (Figure 
3.16). 
 
In some respects, the discrepancy between EBV latency phenotypes in HL and NPC 
models compared with the in vivo human situation does not affect the use of these 
models for testing targeted cellular therapies.  That is, provided expression levels of 
the target protein remain largely unaffected by changes in latency state.  As will be 
discussed in Chapter 4, cells engineered with a CD19-specific cTCR were tested 
using EBV-positive HL cells as targets.  Expression f CD19 was the only 
requirement of these targets, and the presence of EBV antigens extraneous.  If the 
therapeutic cells target EBV proteins, the issue may become more complicated.  
However, expression of the full range of EBV latent a igens does not prevent lysis 
of LCLs by CTLs specific for the subdominant viral protein LMP2 (Lalonde et al, 
2007).  Again, as expression of the target protein is the only requirement, until in 
vitro and in vivo model systems with restricted viral gene expression analogous to 
EBV latency II are developed, models with full EBV latent antigen expression will 
remain useful for testing novel targeted therapies. 
 
In conclusion, the SCID models of HL, NPC and GC characterised here will be 
useful in the future for pre-clinical testing of novel immunotherapies, in particular 
those targeting EBV within the cancerous cell.  Within the scope of this project, the 
HL SCID model provided a framework within which to gauge the ability of CD19-






4  Immunotherapy Using      
Engineered T Cells 
 
In recent years, immunotherapy with infusions of allogeneic, EBV-specific CTLs has 
been used to successfully treat PTLD tumours (Haque et al, 2002).  However, the 
EBV infected cells of HL, NPC and GC lack expression of immunodominant viral 
antigens, and similar therapies in these malignancies have resulted in a less potent 
CTL anti-tumour response (Bollard et al, 2004; Straathof et al, 2005a).  To increase 
CTL effectiveness, T cells can be genetically engineered to express cTCR directed 
against tumour antigens. 
 
The overall aim of this project was to engineer a cTCR specific for the EBV LMP2 
protein.  As cTCRs are modular, generally the scFv extracellular portion from an 
existing cTCR is exchanged for a new scFv as a starting point for the engineering of 
cTCRs with novel specificity.  To this end, whilst a suitable scFv specific for LMP2 
was being sought (see Chapter 5), the cytotoxic potential of a cTCR specific for the 
B cell signalling molecule CD19 was assessed.  Additionally, HRS cells can express 
CD19, so T cells engineered with a CD19-specific cTCR could in the future be used 
for treatment of HL. 
 
CD19-specific cTCR (CD19-cTCR) engineered T cells have been shown to 
specifically lyse the CD19+ve Raji BL cell line, as well as non-Hodgkin’s lymphoma 
(NHL) lymph node tumour biopsy cells in vitro (Cheadle et al, 2005), but have not 
been tested on HL cells.  The aim of these experiments was to engineer T cells to 
express this CD19-cTCR, kindly supplied by Dr Eleanor Cheadle, and to test their 
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4.1 Engineering therapeutic T cells 
To engineer T cells, a retroviral vector encoding the CD19-cTCR was centrifuged 
with PBMCs previously activated with anti-CD3 and -CD28, for three hours at 4°C 
on two sequential days, then cultured in media supplemented with IL-2 for up to 14 
days (see 2.7.1 and 2.7.2).  As the vector expression cassette contained a truncated 
CD34 gene (a haematopoietic stem cell marker not expressed on any other cell types 
utilized in these experiments), CD34 expression wasused as a surrogate marker of 
transduction and hence also cTCR expression.  PBMCs were also transduced with 
mock virus containing the vector backbone with GFP substituted for the CD19-cTCR 
expression cassette as a negative control.  
 
4.1.1 PBMC donors 
All frozen PBMCs used to generate CD19-cTCR T cells were sourced from a cell 
bank created in our laboratory, as were unmodified EBV-specific CTLs and matched 
LCLs (Wilkie et al, 2004).  It was planned that therapy with unmodifie  CTLs would 
be used as a comparison standard for treatment with engineered T cells.  In order to 
select the best match donor from the bank, HLA typing of cell lines was carried out 
at the Anthony Nolan Bone Marrow Trust, London, UK, or the Scottish National 
Blood Transfusion Service Tissue Typing Laboratory, Edinburgh, UK (see 2.4.6). 
 
Tissue typing results are shown in Table 4.1.  After typing, donor A was selected for 
L591, with matching loci A1 and B35; donor B was selected for NUGC3, with 
matching loci A24 and B52; and donor C was selected for C666.1, with matching 
locus B57.  However, in addition to the HLA Class I, CTL-C and C666.1 also had a 
HLA Class II locus in common, DR1.  Donor D was selected as a complete 










Table 4.1: HLA typing of target cell lines for immunotherapy, and best match donors. 
    HLA type 
cell line L591    A1 A33 B8 B35   
 NUGC3   A24 B52   
 C666.1     - * B57 B58 DR1 DR3 
donor A  A1 A3 B35 B57   
 B  A21 A24 B7 B52   
 C  A1 A2 B8 B57 DR1 DR7 
  D   A11 A24 B18 B44     





4.1.2 Virus titration 
The first CD19-cTCR virus preparation collected from the PG13 producer cell line 
was titred on HT1080 cells in duplicate wells of a 24-well tissue culture plate.  Cells 
were incubated overnight with neat, 1:10, 1:100, and 1:1000 dilutions of virus and 
transduction was assessed by FACS using an anti-CD34 antibody after five days 
culture (Figure 4.1).   
 
At a 1:10 dilution, 38% of cells expressed CD34 (Figure 4.1), which equated to a titre 
of 1.9x105 tu/ml.  This figure was in line with previous virus preparations both in our 
laboratory and that of Dr Cheadle.  For transduction of PBMCs, 15ml of undiluted 
PG13 supernatant was used per 2x106 PBMCs, and thus the multiplicity of infection 












Figure 4.1: CD19-cTCR virus titration. 
FACS plots of CD19-cTCR titration on HT1080 cells, showing CD34 
expression as a marker of transduction, with undiluted (B), 1:10 (C), 1:100 
(D), and 1:1000 (E) dilutions of virus, and a virus free negative contr l (A). 
 
 
4.1.3 Transduction of fresh and frozen PBMCs 
In order to assess if frozen stocks of PBMCs could be used to generate engineered T 
cells, the transduction rates between fresh and frozen PBMCs were compared.  A 
total of 6x106 cells from each source were transduced with virus o  media in place of 
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virus (subsequently designated untransduced), then cultured for 13 days (see 2.7.2).  
Cell viability and absolute live cell number in the total culture volume were assessed 
at 4, 8, 11 and 13 days post transduction (Figure 4.2). 
 
At all time points in the four cultures cell viability remained above 75%.  There was 
no apparent difference in cell expansion between any of the cultures, with final 
absolute live cell number on day 13 slightly higher for fresh cells (untransduced - 
5.1x108; CD19cTCR - 5.7x108) compared with frozen cells (untransduced - 2.8x108; 
CD19cTCR - 3x108) (Figure 4.2). 
 
 
Figure 4.2: Growth of PBMCs post transduction.  
Absolute live cell numbers of PBMCs after transduction with a 
retrovirus encoding a CD19-specific cTCR, or untransduced 
PBMCs subjected to the transduction protocol with culture medium 
in place of virus. 
 
 
After 11 days in culture, the level of transduction in fresh and frozen cultures was 
assessed by anti-CD34 FACS analysis.  Fresh and frozen PBMCs gave very similar 
transduction rates, with 18% of fresh PBMCs expressing CD34, compared with 19% 
frozen PBMCs (Figure 4.3).  In light of these results, frozen PBMCs were usd in 
subsequent transductions as the bank provided a more convenient and uncomplicated 
source of PBMCs than colleagues. 
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Figure 4.3: Transduction of fresh and frozen PBMCs with a CD19-cTCR. 
FACS plots of CD19-cTCR transduced PBMCs, showing CD34 expression as 
a marker of transduction in 18% of fresh (C) and 19% of frozen (D) cells, 
with unstained fresh (A) and frozen (B) cells as negative controls. 
 
4.1.4 Transduction rates of CD19-cTCR and GFP virus  
In total, transduction experiments with two viruses (GFP and CD19-cTCR) and three 
donors (donors A and D, and fresh PBMCs from a colleague) were completed, with 
mean transduction rates of 5%±3% for the GFP virus and 13%±6% for the CD19-
cTCR virus.  Results are shown in Figure 4.4.  Transduction rates for individual 
experiments ranged from 2-8% for the GFP virus and 6-20% for the CD19-cTCR 
virus.  Cells from some of these experiments were subsequently used for in vivo 
studies (see 4.3.1 and 4.3.2).  
 
virus   GFP CD19-cTCR 
transduced  2.3 6.4 
cells  3.3 7.6 
(%)  4.3 8.6 
  8.1 17.9 
   18.9 
   20.3 
mean   4.7 13.27 
SD   2.5 6.39 
Figure 4.4: Transduction rates of PBMCs with retroviral vectors. 
The transduction rates of retroviral vectors containing GFP or a CD19-cTCR in 
PBMCs, assayed by FACS analysis of GFP or CD34 expression.  A table of results 
from all experiments (A) and a graphical summary with mean±SD (B) is shown. 
A B 
Chapter 4                                               Immunotherapy Using Engineered T Cells 
 114 
 
4.1.5 Transgene expression over time 
Extended culture of transduced T cells may result in loss of transgene expression and 
hence reduced efficacy of T cell therapy (Eshhar et al, 2001; Morgan et al, 2006).  In 
order to assess the optimum time frame for use of PBMCs transduced with CD19-
cTCR, expression of the GFP and CD19-cTCR transgenes was assayed at days 2, 4, 
6, 9, 10 and 11 post transduction using FACS analysis. 
 
Expression of GFP continued to increase over the entire measurement period, from 
1.4% to 3.4% of total cells (Figure 4.5).  In contrast, expression of CD34 as a marker 
for CD19-cTCR expression peaked on day nine at 9.0% then fell slightly over the 
following two days to 8.6% of total cells on day 11.  In light of these results, 
transduced cells were cultured for between 10 and 14 post transduction before use in 





Figure 4.5: Transgene expression over time. 
Level of transgene expression over an 11 day culture period in 
PBMCs transduced with a retroviral vector containing GFP or 
CD19-cTCR, as assessed by FACS analysis. 
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4.1.6 Immunophenotype of transduced PBMCs 
In order to define cell subpopulations within the CD19-cTCR transduced cell culture, 
expression of cell surface antigens was assayed by FACS.  CD4 and CD8 
immunostaining was used to determine T cell subsets, CD19 immunostaining was 
used to detect B cells, and CD56 immunostaining was used to identify NK cells. The 
results of four transduction experiments using PBMCs from donors A and D are 
shown in Figure 4.6.   
 
CD8+ T cells made up 57%±6% of the total population, a d CD4+ T cells 39%±4% 
(Figure 4.6).  Less than 1% of cultured cells expressed CD19.  CD56+ NK cells 
comprised 14%±4% of the total population. 
 
 
antigen CD4 CD8 CD19 CD56 
positive 34.0 61.0 0.37 16.6 
cells 36.4 61.0 0.00 18.1 
(%) 44.2 58.1 0.02 10.4 
 40.0 48.1 0.00 11.4 
mean 38.7 57.1 0.10 14.1 
SD 4.4 6.2 0.18 3.8 
 
Figure 4.6: Immunophenotype of PBMCs transduced with CD19-cTCR. 
Expression of cell surface antigens CD4, CD8, CD19 and CD56 on PBMCs transduced 
with CD19-cTCR, assayed by FACS analysis.  A table of results from all experiments 
(A) and a graphical summary (B) is shown. 
 
4.2 In vitro killing by engineered T cells 
To gauge the cytotoxic potential of T cells engineered with CD19-cTCR, standard 4 
hour 51Cr release assays were performed (Haque et al, 1998).  The targets used in 
these assays were L591, donor A derived LCL, L1236, and NK cell sensitive K562.  
CD19 expression on target cells was assessed using flow cytometry.  Briefly, target 
cells were labelled with 51Cr then incubated with effector cells (PBMCs from donor 
A or D transduced with GFP [mock] or CD19-cTCR virus) at effector to target ratios 
of 20:1, 10:1 and 5:1.  After 4 hours, the amount of 51Cr released from lysed cells 
was measured on a gamma counter, and the level of specific lysis calculated, as 
described in 2.7.6. 
A B 
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4.2.1 CD19 expression on target cell lines 
In order to confirm the expression of CD19 on the target cell lines (L591, donor A 
derived LCL, L1236, K562), FACS analysis was carried out prior to performing 51Cr 
release assays (Figure 4.7).  Immunostaining of SCID tumours resulting from sc 
injection of L591 and LCLs was used to verify maintenance of expression patterns i  
vivo (Figure 4.8). 
 
Both the HL cell line L591 and donor A LCLs expressd CD19, as analysed by 
FACS, with 100% and 80% of cells respectively staining positive (Figure 4.7).  SCID 
tumours derived from L591 and LCLs also expressed CD19 (Figure 4.8).  Neither the 
K562 nor the L1236 cell line expressed CD19.  Consequently, in 51Cr release assays 
the K562 cell line was used as a control for levels of NK cell killing, and L1236 was 
used as a negative control. 
 
 
Figure 4.7: CD19 expression on 51Cr  release assay target cell lines. 
FACS analysis shows expression of CD19 on the HL cell lin  L591 (A) and an 
LCL (B), but no expression on the NK sensitive K562 (C) or HL L1236 (D) cell 
lines. 




Figure 4.8: CD19 expression on SCID tumours. 
Tumours derived from HL L591 (C) and an LCL (D) at x200 magnification, stained for 
CD19 expression.  HRP detection system shows positive brown membrane staining 
(B,C,D).  Negative control was GC derived SCID tumour (A).  Positive control was 
human tonsil (B).  Sections were counterstained with haematoxylin. 
 
 
4.2.2 Chromium release assays using engineered T ce lls 
For each transduction experiment the cytotoxicity of CD19-cTCR transduced 
PBMCs, and mock GFP transduced PBMCs was assessed uing a 51Cr release assay.  
L591 and donor A LCLs were used as target cell lines, with K562 and L1236 as 
control targets.  The effector to target ratios used w re 20:1, 10:1 and 5:1.  Results 
shown are from five (L591, LCL, K562) and three (L1236) experiments (Figure 4.9). 
 
Specific lysis was seen at all effector to target ratios against L591 and LCLs.  At an 
effector to target ratio of 20:1, PBMCs expressing CD19-cTCR lysed the target cells 
at a significantly higher rate than mock transduced PBMCs (Figure 4.9).  Specific 
lysis for L591 target cells was 24%±11% (range 12-35%) for CD19-cTCR 
transduced cells compared with 5%±3% (range 2-9%) for mock-transduced cells 
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(Mann Whitney, p=0.0079), and for LCLs was 29%±13% (range 12-44%)for CD19-
cTCR transduced cells compared with 3%±2% (range 1-6%) for mock-transduced 
cells (Mann Whitney, p=0.0079).  This significant difference between CD19-cTCR 
and mock transduced cells continued at effector to target ratios of 10:1 and 5:1 for 
both L591 and LCL target cell lines.  Mean % specific lysis and Mann Whitney p 
values are shown in Table 4.2. 
 
 
Figure 4.9: Specific lysis of target cells by engineered T cells. 
Cytotoxicity of CD19-cTCR transduced PBMCs and mock GFP transduced 
PBMCs in an in vitro 51Cr release assay, against target cell lines L591 (A), donor 
A derived LCLs (B), K562 (C) and L1236 (D).  Specific lysis was seen against 
L591 and LCLs (A,B), but not K562 and L1236 (C,D).  Bars show mean±SD for 
five (A,B,C) and three (D) experiments. 
 
 
There was no significant difference in the ability of mock or CD19-cTCR transduced 
cells to lyse the K562 or L1236 target cell lines, with both effector lines capable of 
high levels of cytotoxicity (Figure 4.9).  Specific lysis at an effector to target ratio of 
20:1 for K562 target cells was 39%±15% (range 25-57%) for CD19-cTCR 
transduced cells, compared with 35%±16% (range 18-53%) for mock-transduced 
cells (Mann Whitney, p=0.8413); and for L1236 was 52%±11% (range 40-50%) for 
CD19-cTCR transduced cells, compared with 44%±10% (range 32-51%) for mock-
transduced cells (Mann Whitney, p=0.4000).  This non-significance between CD19-
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cTCR and mock transduced cells continued at effector to target ratios of 10:1 and 5:1 
for both K562 and L1236 target cell lines.  Mean % specific lysis and Mann Whitney 
p values are shown in Table 4.2.  Given the similarities in the patterns of specific lysis 
of L12356 and K562, which is an NK sensitive target, and the presence of NK cells 
in transduced cultures (mean 14.1% of total population CD56+, Figure 4.6), the effect 
of NK activity on in vitro cytotoxicity was examined. 
 
 
Table 4.2: Mean specific lysis (%) of target cells by engineered T cells. 
Comparison of specific lysis between CD19-cTCR and mock transduced 
PBMCs on effector cell lines L591, LCL, K652 and L1235, with Mann Whitney 
P values. [* indicates significant difference] 
effector:target 
ratio 20:1 10:1 5:1 
effector cells mock CD19-cTCR mock CD19-cTCR mock CD19-cTCR 
L591 5 24 3 15 1 9 
 p=0.0079* p=0.0079* p=0.0079* 
LCL 3 29 1 21 1 13 
 p=0.0079* p=0.0079* p=0.0079* 
K562 35 39 21 26 12 15 
 p=0.8413 p=0.6905 p=0.6905 
L1236 44 52 30 36 2 28 




4.2.3 Effect of NK cells on in vitro cytotoxicity 
To assess the role of CD56+ NK cells in the 51Cr release assays, a depletion 
experiment was performed.  CD56+ cells were separated from a population of donor 
A PBMCs transduced with CD19-cTCR three days previously using anti-CD56 
coated magnetic beads.  Enriched and depleted fractions were maintained in culture 
for a further seven days and the number of CD56+ cells r maining in each fraction 
was then analysed by FACS (Figure 4.10).  The cytotoxic potential of each fraction, 
as well as unfractionated CD19-cTCR transduced cells and GFP mock transduced 
cells, was then assessed by 51Cr release assay. 
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Before separation, CD56+ cells made up 18% of the total population (Figure 4.10).  
After separation, the NK-depleted fraction contained 11% CD56+ cells, and the NK-




Figure 4.10: Percentage of NK cells in a population of CD19-cTCR 
transduced cells before and after CD56 separation. 
FACS analysis in PBMCs transduced with CD19-cTCR (B) and following 
CD56-depletion (C) or CD56-enrichment (D).  Unstained cells are shown in (A). 
 
 
The number of transduced cells before separation was 8%.  This number remained 
the same in the NK-depleted fraction, but was reduc in the NK-enriched fractions 
to 3% (Figure 4.11). 




Figure 4.11: Percentage of transduced cells before and after CD56 separation. 
FACS analysis of CD34 expression as a marker of transduction in PBMCs transduced 
with CD19-cTCR (B) and following CD56-depletion (C) or CD56-enrichment (D).  




In a 51Cr release assay, specific lysis of K562 and L1236 was dramatically reduced 
when CD56+ cells were depleted from the effector cell population, and increased 
when CD56+ cells were enriched at all effector to target ratios (Figure 4.12).  Specific 
lysis at an effector to target ratio of 20:1 for K562 target cells was 52% for CD19-
cTCR transduced cells, compared with 53% for mock-transduced cells; and for 
L1236 was 40% for CD19-cTCR transduced cells, compared with 47% for mock-
transduced cells; whilst for CD56-depleted and CD56-enriched populations it was 
9% and 78% for K562 and 20% and 82% for L1236, respectively.  Killing of L591 
and LCL targets was minimally affected.  This suggests that NK cells are principally 
responsible for the high levels of L1236 killing observed previously (see 4.2.2). 
 




Figure 4.12: Effect of NK cells on in vitro cytotoxicity. 
51Cr release assays using mock, transduced, transduced CD56-depleted and transduced 
CD56-enriched effector cells at effector to target ratios of 20:1 (A), 10:1 (B) and 5:1 (C) 
show lysis of the K562 and L1236, but not L591 and LCL target cell lines is dependent 
on NK cells. 
 
4.2.4 Selection of CD34+ transduced cells 
The final fraction of cells expressing the CD34 transgene after transduction with the 
CD19-cTCR vector ranged from 6-20% (see 4.1.4).  With such low transduction 
efficiencies in some experiments, it was decided to enrich a population of CD19-
cTCR transduced cells using the truncated CD34 molecule as a selection marker.  
This would increase the fraction of cells expressing CD19-cTCR and potentially also 
enhance specific lysis of L591 cells.  CD34+ cells were selected from a population of 
PBMCs which had been transduced with the CD19-cTCR vector nine days earlier, 
using anti-CD34 coated magnetic beads.  CD34-enriched and CD34-depleted 
fractions were cultured overnight, then the number of CD34+ cells remaining in each 
fraction as well as in unfractionated CD19-cTCR transduced cells was analysed by 
FACS (Figure 4.13).  The cytotoxic potential of each fraction, unfractionated CD19-
cTCR transduced cells, and GFP mock transduced cells was then assessed by 51Cr 
release assay (Figure 4.14). 
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Before separation, CD34+ cells made up 8% of the total population (Figure 4.13).  
After separation, the transduced CD34-depleted fraction contained 1% CD34+ cells, 
and the transduced CD34-enriched population contained 82% CD34+ cells. 
 
 
Figure 4.13: Percentage of transduced cells before and after CD34 separation. 
FACS analysis of CD34 expression as a marker of transduction in PBMCs 
transduced with CD19-cTCR (B) and following CD34-depletion (C) or CD34-
enrichment (D).  Unstained cells are shown in (A). 
 
 
In a 51Cr release assay, specific lysis of L591 and LCL cell lines was increased when 
number of transduced cells increased (Figure 4.14).  When the percentage of CD34+ 
cells in CD19-cTCR transduced cells, the CD34-deplet d fraction, and the CD34-
enriched fraction was 8%, 1% and 82%, respectively, specific lysis at an effector to 
target ratio of 20:1 of L591 cells was 12%, 10%, and 21%, respectively, while 
specific lysis of LCLs was 12%, 7%, and 41%, respectiv ly.  In contrast, specific 
lysis of the NK target K562 cell line decreased when the number of transduced 
effector cells increased. With CD19-cTCR transduced lls, the CD34-depleted 
fraction, and the CD34-enriched fraction as effectors, specific lysis at an effector to 
target ratio of 20:1 was 57%, 47% and 10% respectivly (Figure 4.14).  Thus, 
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increasing the fraction of cells specific for CD19 enhanced specific lysis of L591 and 
LCL target cells. 
 
 
Figure 4.14: Effect of transduced cell numbers on in vitro cytotoxicity. 
51Cr release assays using mock, transduced, transduced CD34-depleted and transduced 
CD34-enriched effector cells at effector to target ratios of 20:1 (A), 10:1 (B) and 5:1 
(C) show lysis of L591 and LCL but not NK target K562 is dependent on cells 
transduced with CD19-cTCR. 
 
 
4.2.5 Freezing and thawing of transduced cells 
In order to assess whether frozen stocks of CD19-cTCR transduced PBMCs could be 
utilised, an experiment was conducted to test if specific lysis was affected by the 
freeze/thawing process.  Cells were frozen and stored at -70°C for nine days, then 
thawed and cultured overnight in complete medium-20 supplemented with IL-2.  A 
test sample where IL-2 in the overnight culture medium was replaced with the 
activation antibodies anti-CD3 and -CD28 was also included.  Results of a 51Cr 
release assay are shown in F gure 4.15.   
Although specific lysis of L591 cells fell slightly after freezing from 16% to 13%, in 
LCLs specific lysis remained steady at 21% and 20%; suggesting that storage of 
transduced cells is a viable option (Figure 4.15).  Freeze/thawing seemed to inhibit the 
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ability of NK cells to lyse their K562 targets with specific lysis falling from 52% 
before freezing to 19% after thawing.  Reactivation with anti-CD3 and -CD28 
increased the specific lysis of all three targets to 31%, 39% and 78% for L591, LCL 
and K562 respectively.  These results were consistent for an effector to target ratio of 
10:1 (Figure 4.15 panel B). At an effector to target ratio of 5:1 (Figure 4.15 panel C), 
specific lysis was below 8% for targets L591 and LCL and all effectors except 
restimulated frozen cells, where it was 17% and 18% respectively.  For K562, target 
lysis at an effector to target ratio of 5:1 was as for higher effector to target ratios, 
with similar levels seen with mock transduced and freshly transduced effector cells, 
and a reduction or increase in lysis for frozen andrestimulated cells, respectively.  
Restimulation with anti-CD3 and -CD28 appears therefore, to enhance NK as well as 
T cell activity, and thus is not suitable for improving specific activity of T cells in ex 




Figure 4.15: Effect of freezing and thawing of CD19-cTCR transduced PBMCs on in 
vitro cytotoxicity. 
51Cr release assays using mock, fresh CD19-cTCR transduced, frozen and thawed CD19-
cTCR transduced, and frozen, thawed restimulated CD19-cTCR transduced PBMCs at 
effector to target ratios of 20:1 (A), 10:1 (B) and 5:1 (C) show freeze/thawing had no effect 
on  the L591, LCL or K562 target cell lines. Reactiva on increased lysis in a non-specific 
manner. 
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4.2.6 EBV-specific CTLs 
51Cr release assays were performed in order to gauge the ability of EBV-specific 
CTLs generated from PBMCs of donors A, B and C (CTL-A, -B, -C) to lyse their 
respective matched targets, (HL - L591, GC - NUGC3-EBV and NPC - C666.1 [see 
4.1.1]).  Effector to target ratios of 20:1, 10:1 and 5:1 were used, and autologous 
LCLs and K562 were also employed as targets. 
 
 
Figure 4.16: In vitro cytotoxicity of EBV-specific CTLs against HLA best match 
target cell lines. 
51Cr release assays with effector/target matches of donor A CTLs and L591 (A), 
donor B CTLs and NUGC3-EBV (B), and donor C CTLs and C666.1 (C) show 
specific lysis against autologous LCL for all combinations, with comparatively less 
(A,C) or no (B) lysis against best match EBV-associated malignancy targets. 
 
 
All three CTL lines showed cytotoxicity against autologous LCLs, with specific lysis 
at all effector to target ratios above 40%, 16%, and 39% for CTL-A, CTL-B and 
CTL-C, respectively (Figure 4.16).  Matched CTLs showed little or no cytotoxicity 
against carcinoma cell lines NUGC3-EBV and C666.1, with specific lysis not 
exceeding 2% at any effector to target ratio.  In comparison, L591 cells were lysed 
by matched CTLs, with specific lysis of 14%, 12%, and 11% at effector to target 
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ratios of 20:1, 10:1 and 5:1, respectively.  As mentioned previously (see 1.2.2.2), the 
restricted viral antigen expression seen in GC, HL and NPC (Table 1.3) protects 
tumour cells from targeting by T cells when compared with autologous EBV-infected 
cells expressing the full range of latent antigens, and this data supports that 
observation. 
 
4.3 Immunotherapy of tumours  in vivo 
In parallel experiments, prevention of tumour formation by EBV-specific CTLs and 
engineered T cells was evaluated in the SCID mouse model described in Chapter 3.  
Two strategies were tested: a prophylactic strategy where EBV-specific CTLs were 
injected simultaneously with tumour cells lines, eith r with both tumour and 
therapeutic cells sc, or with tumour cells sc and therapeutic cells iv; and a treatment 
strategy with administration of therapeutic cells iv after sc tumour onset. 
 
4.3.1 Prophylactic immunotherapy of SCID HL 
To assess the ability of therapeutic cells to prevent tumour formation in the L591 HL 
in vivo model, three strategies were tested.  Firstly, 5x106 L591 cells were injected sc 
into three SCID mice simultaneously with 3.5x107 CTL-A.  Secondly, 5x106 L591 
cells were injected sc into six SCID mice simultaneously with 5x107 PBMCs 
transduced with CD19-cTCR.  Finally, 5x107 PBMCs transduced with CD19-cTCR 
were injected iv into five SCID mice coincident with sc injection of 5x106 L591.  
Time to onset and subsequent tumour growth was monitored. 
 
Results of prophylactic therapy of SCID HL are shown in Table 4.3. Administration 
of CTL-A sc or CD19-cTCR transduced cells iv made no significant difference to 
tumour formation, with 2 of 3 (67%) CTL-A treated mice (Fisher’s exact, p=1.0) and 
4 of 6 (67%) iv administered CD19-cTCR treated mice (Fisher’s exact, p=0.6219) 
developing tumours.  None of 6 (0%) mice administered CD19-cTCR sc developed 
tumours, which was a significant effect (Fisher’s exact, p=0.001).  Median time to 
tumour in untreated mice was 20 days, compared with29 days in iv administered 
CD19-cTCR treated mice, which was not a significant difference (Wilcoxon rank 
sum test, p=0.0625). 
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Table 4.3: Tumour incidence in HL SCID mice given prophylactic immunotherapy. 
Tumour formation following sc injection of HL L591 cells and coincident treatment with 
CTL-A administered sc, or CD19-cTCR transduced PBMCs administered sc or iv.          
[* indicates significant effect p=0.001] 
treatment cells number of tumours/ time to tumour onset (days) 
cell line cell number route  number of mice (%) median  range 
untreated  -   -   17 / 22  (77)  20 16-28 
CTL-A 3.5x107 sc  2 / 3 (67)  27 26-28 
CD19-cTCR 5x107 sc  0 / 6* (0)   -   -  
CD19-cTCR 5x107 iv   4 / 6 (67)   29 21-33 
 
 
Tumour growth in untreated, sc administered CTL-A trea ed mice and iv 
administered CD19-cTCR transduced PBMC treated mice is shown in Figure 4.17.  
Tumours in sc administered CTL-A treated mice showed sustained growth from time 
of onset until termination of the experiment at day 70.  Of the four iv administered 
CD19-cTCR transduced PBMC treated mice which developed tumours, three 
showed sustained tumour growth, and one had completely cleared tumour burden by 
day 64 post L591 injection.  
 
Figure 4.17:  HL SCID tumour growth following prophylactic immunotherapy. 
Prophylactic immunotherapy with either EBV-specific CTLs or CD19-cTCR 
transduced PBMCs did not prevent formation of sc HL tumours in SCID mice.  
Each line represents an individual mouse. 
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4.3.2 Immunotherapy of established HL SCID tumours 
The ability of PBMCs transduced with CD19-cTCR to treat established sc L591 
tumours was also tested.  Six tumour-bearing SCID mice were injected iv with 5x107 
PBMCs transduced with CD19-cTCR between three and ni e days after tumour 
formation, and subsequent tumour growth observed (Figure 4.18). 
 
Three mice were culled prior to the conclusion of the experiment due to tumour 
necrosis.  These lesions displayed sustained tumour growth up to time of culling.  
The remaining three mice had completely cleared their umour burden by 65, 69 and 
83 days post L591 injection (Figure 4.18).  This was a significant effect when 
compared with 17 untreated mice with established tumours from doses of 5x106 and 
2x106 L591 cells who showed no tumour regression (Fisher’  exact, p=0.011).  In a 
time course experiment to confirm trafficking of transduced cells to tumours, five 
tumour-bearing SCID mice were injected iv with 5x107 PBMCs transduced with a 
CD19-cTCR.  At each of 1, 4, 7, 11, and 18 days post treatment a single mouse was 
culled and immunohistochemistry performed on tumour sections.  An anti-CD8 
antibody was used as an indirect marker to detect CD19-cTCR cells infiltrating the 
tumours.  Infiltrating cell presence was assessed on a qualitative basis, and positively 
stained cells were not quantitated.  CD8+ cells were seen in tumours on day 11 and 
18 post treatment, but not days 1, 4 or 7 (Figure 4.19). 
Figure 4.18: HL SCID tumour growth following immunotherapy. 
Tumour growth curves of SCID mice bearing sc tumours derived from HL L591 cells 
treated with CD19-cTCR transduced PBMCs, showing complete regression in three of six 
mice.  Each line represents an individual mouse. 
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Figure 4.19: Infiltration of CD8+ T cells in HL SCID tumours. 
Immunostaining showing CD8+ cells in L591 tumours tea ed with CD19-cTCR 
transduced PBMCs at days 11 (F) and 18 (G), but not days 1 (C), 4 (D) or 7 (E) post 
treatment.  HRP detection system shows positive brown membrane staining (B,F,G).  
Negative control was GC derived SCID tumour (A).  Positive control was a CTL line 
(B).  Black arrows indicate individual positive cells.  Sections were counterstained with 
haematoxylin. 
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4.3.3 Prophylactic immunotherapy of SCID NPC 
To assess the ability of donor C CTLs to prevent tumo r formation in vivo, 2x106 
C666.1 cells were mixed with 4.5x107 CTL-C and injected sc into five SCID mice.  
Time to tumour formation and subsequent tumour growth was observed. 
 
Treatment with CTLs did not prevent C666.1 tumour formation as 5 of 5 (100%) 
mice injected developed tumours (Table 4.4).  Median time to tumour in untreated 
mice was 19 days, compared with 13 days in treated mice, which was not a 
significant difference (Wilcoxon rank sum test, p=0.25).  All tumours showed 
sustained growth from time of onset until termination of the experiment (Figure 4.20). 
 
 
Table 4.4: Tumour incidence following sc inoculation of SCID mice with the NPC 
cell line C666.1 alone, or mixed with partially HLA matched, EBV-specific CTLs. 
cell cell CTL number of tumours/ time to tumour onset (days) 
line dose dose number of mice (%) median  range 
C666.1 2x106  -  7 / 7    (100) 19 12-24 





Figure 4.20: Tumour growth after prophylactic therapy of NPC 
SCID tumours with EBV-specific CTLs. 
Tumour growth curves of sc injected C666.1 cells in SCID mice, with 
and without partially matched, EBV-specific CTLs.  Each line 
represents an individual mouse. 
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Mice were culled at day 34 post injection and immunohistochemistry performed on 
tumour sections.  An anti-CD8 antibody was used as a direct marker of tumour 
infiltrating CTLs.  Infiltrating cell presence was ssessed on a qualitative basis, and 
positively stained cells were not quantitated.  In 5 of 5 treated mice (100%), but 0 of 
3 untreated mice (0%), CD8+ cells were present in the tumour (Figure 4.21). 
 
 
Figure 4.21: Infiltration of CD8+ cells in NPC SCID tumours. 
Immunostaining showing CD8+ cells in C666.1 tumours treated with partially HLA 
matched, EBV-specific CTLs (D), which are not present in untreated tumours (C).  HRP 
detection system shows positive brown membrane staining (B,D).  Negative control is 
GC derived SCID tumour (A).  Positive control is a CTL line (B).  Sections were 
counterstained with haematoxylin. 
 
 
4.4 Summary of results 
• Activated PBMCs were transduced with a retroviral vector encoding a cTCR 
specific for CD19.  Mean transduction rate was 13%±6 , with a range of 6-
20%. 
• Optimum transgene expression levels were achieved between 9 and 11 days 
post transduction. 
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• 48-60% of cells in CD19-cTCR transduced cultures were CD8+ T cells, with 
34-44% of the population CD4+ T cells.  CD56+ NK cells made up 10-18% of 
the total culture. 
• Transduced T cells were able to kill CD19+ L591 and LCLs at a significantly 
higher rate than mock transduced T cells. 
• The CD56+ NK cell fraction within the transduced population was responsible 
for high levels of lysis of the CD19- L1236 and K562 target cells when both 
transduced and mock transduced effector cells were used. 
• CD34-enrichment of transduced cells enhanced specific lysis of L591 and LCL 
target cells, but not K562 target cells. 
• Freezing had a minimal effect on the ability of transduced cells to lyse L591 
and LCL target cells. 
• Reactivation of transduced cells improved lysis of L591 and LCL target cells, 
as well as lysis of K562 target cells. 
• EBV-specific HLA matched CTL lines lysed autologous LCLs and the HL cell 
line L591, but not the GC cell line NUGC3-EBV or the NPC cell line C666.1. 
• HLA matched CTLs administered sc or CD19-cTCR transduced cells 
administered iv did not significantly halt sc outgrowth of L591 cells in SCID 
mice. 
• CD19-cTCR transduced cells administered sc were abl to completely prevent 
L591 tumour formation in SCID mice, which was a significant treatment effect 
(p=0.001). 
• CD19-cTCR transduced cells administered iv to SCID mice with established sc 
L591 tumours were able to mediate complete tumour reg ession in 50% of 
cases, which was a significant treatment effect (p=0.011). 
• HLA matched CTLs administered sc did not prevent tumo r formation in 
SCID mice injected with C666.1 cells. 
• CD19-cTCR transduced T cells in L591 injected mice and EBV-specific CTLs 
in C666.1 injected mice were able to traffic to theumours. 
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4.5 Discussion 
In addition to the HL cell killing observed in the current project, CD19-specific 
cTCR expressing T cells have shown cytotoxic potential against B cell NHL, B-CLL 
and B-ALL (Brentjens et al, 2003; Cooper et al, 2003; Cheadle et al, 2005).  In 
contrast to B cell NHL, expression of CD19 is not cnsistently observed in HL, 
although a variable percentage of classical HL biopsies (0 to 75%) and cell lines (20 
to 30%) express the marker (Herbst et al, 1989; Schmid et al, 1991; Drexler, 1992; 
Drexler, 1993).  Thus, a proportion of HL patients are eligible for treatment with 
CD19-specific therapies.  This project demonstrated hat activated PBMCs 
transduced with a retroviral vector express a cTCR specific for CD19, are capable of 
specific lysis of CD19+ target cells in an in vitro cytotoxicity assay, and can mediate 
tumour regression in an i vivo model of HL.  
 
It has been reported previously that transgene expression in therapeutic T cells 
decreases after 10 to 14 days in vitro culture (Eshhar et al, 2001).  Transgene 
expression levels were measured for 11 days post transduction, and peak expression 
was not seen immediately following transduction, but instead increased steadily over 
the first nine days and then remained relatively stable on days 10 and 11 when the 
experiment was terminated (Figure 4.5).  This indicates that there may be a window 
of opportunity for therapeutic use of such cells, when transgene expression is at its 
height.  An additional consideration when planning treatment using therapeutic cells 
is the time required to expand cells in vitro in order to obtain sufficient numbers for 
therapeutic use.  Delayed treatment resulting from the initial use of conventional 
therapy may reduce impact of the therapeutic cells in some cases.  Thus, in order to 
best meet requirements for large numbers of cells available on demand, the ability of 
therapeutic cells to withstand storage at -70°C with their cytotoxic potential intact 
was tested.  The freeze/thawing process had minimal effect on the ability of 
transduced cells to lyse CD19+ target cells (Figure 4.15), and thus it may be possible 
to either store a patient’s own cells that have been transduced and expanded against 
possible need, or create a bank of allogeneic therapeutic cells available on a best 
HLA match basis (to prevent host killing of the therapeutic cells).  
 
Levels of retrovirus transduction varied between 6-20%, with a mean 13%±6% cells 
expressing CD34 as a marker of transduction (Figure 4.4).  This was slightly lower 
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than the mean 27%±12% (range 12-43%) transduction rates reported by our 
collaborators using the same virus construct (Cheadle et al, 2005).  However, fresh 
virus was made for each transduction experiment, and although every effort was 
made to standardise virus production techniques, titrations were not routinely 
performed.  It is therefore possible that the disparity in transduction rates was partly a 
result of variations in virus concentration.   
 
Increasing the fraction of transduced cells in the total population by selection with 
anti-CD34 coated magnetic beads improved levels of pecific lysis (Figure 4.14), 
however it was not a simple relationship between number of CD34+ cells and level 
of specific lysis.  Others have also observed that levels of T cell transduction do not 
correlate with absolute levels of target cell lysis (Cheadle et al, 2005).  It may not be 
necessary to achieve expression of the cTCR on as many as the 82% of cells seen 
after CD34 selection (Figure 4.13), and optimisation to improve transduction rates 
may suffice.  The bearing of low transduction rates and specific lysis in 51Cr release 
assays on the in vivo effect of engineered cells is unclear.  A recent trial using EBV-
specific CTLs to treat PTLD showed no correlation between levels of specific lysis 
as measured by 51Cr release assays and tumour response (Haque et al, 2007).  
Equally, such a correlation was not observed in experiments investigating CTL 
treatment in SCID models of PTLD (personal communication, Dr Ingolfur 
Johannessen).  It remains to be seen if the weighted importance of in vitro results is 
maintained when the therapeutic cells are directed against a single epitope via a 
cTCR compared with the multiple specificities of the CTLs used in previous trials. 
 
As reactivation has been shown to counteract the loss of transgene expression over 
time during in vitro culture (Eshhar et al, 2001), thawed cells were reactivated with 
anti-CD3 (to provide activation signal 1) and anti-CD28 (signal 2) antibodies to 
offset the potential detrimental effect of freeze/thawing on cTCR expression.  
Reactivation improved levels of specific lysis above and beyond those seen with 
unfrozen effector cells for both L591 and LCL target c lls (Figure 4.15).  Therefore, 
incubation of therapeutic cells with anti-CD3 and anti-CD28 antibodies immediately 
prior to administration may improve anti-tumour effects.  Additionally, as similar 
increases in lysis were also seen for the K562 NK target cell line, NK cells may need 
to be removed prior to reactivation. 
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Much work has been done to discover the optimum combination of activation and 
stimulation signals for T cells in order to enhance th ir cytotoxic effect.  Culture 
medium for CTLs is generally supplemented with IL-2 for T cell survival and 
proliferation (Morgan et al, 1976; Miyazaki et al, 1995), but other cytokines have 
been used both individually and in combination to achieve peak T cell activation and 
proliferation, including IL-7, IL-15 and IL-21 (Schluns et al, 2000; Brentjens et al, 
2003; Zeng et al, 2005).  Where CTLs have been engineered to express cTCRs, other 
techniques to enhance T cell activation have also been tested, such as restimulation 
of engineered cells through their endogenous TCR.  This has applications not only 
when tumour cells express both the cTCR target (TAA) and the native TCR target 
(viral antigen) (Savoldo et al, 2007), but also where engineered APC presenting the 
native TCR target can be co-administered with the therapeutic T cells (Cooper t al, 
2005).  As the exact rules governing signal propagation through cTCRs have not yet 
been fully deciphered, additional attention has been given to providing improved 
signal 1 and 2 transduction from within the cTCR itself.  Addition of lck tyrosine 
kinase or OX40 signalling domains to cTCR constructs already containing CD28 and 
ζ moieties did not compromise the effector function of engineered cells, and may 
improve long term proliferation and activation of engineered T cells (Geiger et al, 
2001; Pule et al, 2005). 
 
The persistence and proliferation of engineered T cells in vivo is advantageous in 
cellular immunotherapy.  Therapeutic cells should ideally have immediate effect in 
reducing tumour burden and also be able to localise to metastatic cells and protect 
against disease relapse.  The conditions used to activate T cells are crucial in 
determining therapeutic outcome (Brentjens t al, 2003).  Until the optimum culture 
environment for engineered T cells is established, an alternative approach entails in 
vivo proliferation of administered T cells rather than reliance on ex vivo expansion.  
For the treatment of cancer, administration of an excess of therapeutic cells risks 
tumour lysis syndrome, which results from the rapid destruction of malignant cells 
and consequent release of intracellular ions, nucleic acids, proteins and their 
metabolites into the extracellular space, overwhelming the body's normal 
homeostatic mechanisms and potentially leading to life-threatening complications 
such as renal failure, arrhythmias, and seizures.  In contrast, a paucity of transferred 
cells risks inadequate clinical response.  Cells capable of expanding in the patient to 
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meet individual need are therefore a major asset.  Such in vivo expansion may also 
clarify why tumours in the SCID treatment model continued to increase in size for up 
to 10 days after infusion of engineered cells before beginning to regress (Figure 4.18), 
and why CD8+ T cells were not detectable in tumours by immunostaining until day 
11 post infusion (Figure 4.19).  Although the engineered cells used to treat establi hed 
SCID tumours had the highest transduction levels seen during this project, the 
transduced cells still needed to traffic to the tumo r site and expand before reaching 
sufficient numbers to effect a clinical response.  Cells engineered with a CD19-
specific cTCR were able to effect complete tumour regression in 50% of SCID mice 
carrying an established HL tumour, a significant trea ment effect (p=0.011) (Figure 
4.18).  The animals which did not respond to treatment were culled due to necrosis of 
the skin at the tumour site, as opposed to excessiv tumour growth.  It is possible that 
a more rapid treatment effect may avoid this complication.  Delays in tumour 
regression have been observed in other cellular therapy models.  During experiments 
in which Rag-/- mice (targeted mutations of the recombination-activ ting genes result 
in mice with complete ablation of functional T and B cells) bearing murine 
thymomas engineered to express the influenza epitope NP(366-374) were treated 
with NP(366-374)-specific engineered T cells, tumour growth continued for an 
average of eight days following T cell administration before initiation of regression 
(Kessels et al, 2001).  Increasing the number of transduced cells, ither by improving 
transduction rates or manually enriching transduced lls based on a selectable 
marker may produce a more immediate effect.  This could in turn improve overall 
treatment responses in the SCID HL model.   
 
Immunophenotyping of activated PBMC cultures following transduction with a 
CD19-cTCR revealed a population of predominately CD8+ T cells (mean 57%±6%), 
with CD4+ T cells contributing the next largest fraction (39%±4%) (Figure 4.6).  
Addition of IL-2 to the culture medium, which is standard procedure for in vitro 
culture of T cells, does tend to favour the establishment of majority CD8+ CTL lines 
(Wilkie et al, 2004).  B cells constituted less than 1% of the total population.  A 
substantial fraction of NK cells was also detected in all cultures tested, averaging 
14%±4% of the total population.  This is consistent with CTL lines at early time 
points in their development into specific effectors (Vanhoutte, 2006).  High levels of 
K562 lysis mediated by NK cells has also been seen in PBMCs transduced with an 
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unmodified LMP2-specific TCR (Orentas et al, 2001).  For patient use, CTL 
expansion in vitro involves multiple rounds of antigenic stimulation, which increases 
cell line specificity but also has the effect of sub tantially decreasing the NK fraction 
(Wilkie et al, 2004; Comoli et al, 2005; Straathof et al, 2005a).  It has also been 
shown previously that transduction does not alter th  CD3, CD4, CD8 or CD56 
immunophenotype of CTL lines (Savoldo et al, 2007). 
 
The presence of NK cells in the therapeutic cell cultures is interesting in light of their 
involvement in the lysis of the HL L1236 cell line in 51Cr release assays (Figure 4.12).  
As mentioned previously, the L1236 cell line has been definitively identified as 
derived from EBV-negative HRS cells (Kanzler t al, 1996a). However, in their 
native HL environment HRS cells utilise a number of mechanisms to avoid killing by 
NK cells.  The extensive inflammatory infiltrate characteristic of classical HL 
consists primarily of Th2 and T regulatory cells (Tregs) and is generally devoid of Th1 
cells, CD8+ T cells and NK cells (Poppema, 2005). HRS cells appe r to maintain this 
composition by the secretion of Th2 type chemokines such as the thymus and 
activation regulated chemokine (TARC) (van den Berg t al, 1999), as well as 
cytokines that inhibit Th1 responses for example IL-10 (Herbst et al, 1996), leading 
to a decreased anti-tumour immune response.  An associ tion between areas in the 
HLA class I region of the genome and EBV-positive HL suggests polymorphisms in 
this area may affect proper EBV peptide presentation to CD8+ T cells facilitating 
immune escape (Diepstra et al, 2005).  HRS cells in EBV-negative HL can lose HLA 
class I expression, thus escaping CTL detection but potentially becoming NK targets.  
However, expression of HLA-G in HL has been associated with EBV-negative, 
MHC class I-negative status (Poppema, 2005), and HLA-G expression has been 
implicated in evasion of CTL- and NK cell-mediated cytotoxicity (Carosella et al, 
2003).  L1236 was derived from a patient with EBV-negative HL, and FACS 
analysis indicates surface expression of HLA class I (Wolf et al, 1996).  Thus, NK-
mediated killing occurs through an alternative mechanism, possibly indicating a role 
for NK cells in cellular immunotherapy of HL.  Although NK cells are inhibited by 
self-HLA molecules, they hold cytotoxic potential for cancer cells (Ruggeri et al, 
2002), and NK cells expressing cTCRs are capable of specific lysis of leukaemia 
cells in vitro (Imai et al, 2005). 
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In conclusion, the results presented in this chapter showing the ability of CD19-
cTCR engineered T cells to specifically lyse CD19+ HL target cells supports the 
central hypothesis of this thesis, and is in line with the data of others in the field 
(Brentjens et al, 2003; Cooper et al, 2003; Cheadle et al, 2005).  Given these 
encouraging results, it is to be hoped that phase I trials of CD19-cTCR engineered T 
cells will soon commence, with a view to CD19-cTCR engineered T cells becoming 
a future treatment option for CD19+ leukaemia and lymphoma patients who relapse 







5 Identification of LMP2-Specific scFv 
Using Phage Display 
 
In Chapter 4, T cells were redirected against HL cells with a cTCR specific for the B 
cell marker CD19.  Due to the modular nature of cTCR construction, the CD19-
specific scFv could potentially be replaced with a scFv specific for any cell surface 
antigen.  To utilise this feature, a scFv specific for LMP2 was required, as the EBV 
latent protein was selected as a suitable target for redirecting T cells to EBV-
associated malignancies.  Antibody phage display technology was chosen as the 
method by which to isolate this LMP2-specific scFv.  Phage libraries displaying 
antibody fragments have been used to select scFv or Fab specific for a range of 
targets.  Indeed, a TNFα-specific antibody derived from a fragment isolated by phage 
display has been approved for use in autoimmune arthritis (Hoogenboom, 2005).  
Therefore, scFv specific for the extracellular peptide loops of LMP2 (Figure 1.5) were 
sought for the creation of an LMP2-specific cTCR to direct T cells against EBV-
associated malignancies.  Initially, selections were performed using the Tomlinson 
I+J human single fold scFv phage library, although later experiments employed the 
ETH2Gold scFv and RotMar Fab libraries.   
 
5.1 Standardisation experiments 
5.1.1 Library characterisation 
Initially, frozen aliquots of the Tomlinson I+J libraries (Geneservices) were thawed 
and amplified to create working stocks.  To confirm the presence of full length scFv 
inserts, 10 clones from each library were screened using PCR.  Agarose gel 
electrophoresis of the PCR products is shown in Figure 5.1.   
 
For Library I, three reactions amplified no product and the remaining seven of 10 
reactions amplified full length inserts, with bands of the expected 935 bp size.  For 
Library J, one reaction amplified no product and the remaining nine of 10 reactions 
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amplified full length inserts.  There were no reactions which resulted in bands of 329 
bp, the size of PCR product amplified from clones lacking a scFv insert. 
 
 
Figure 5.1: scFv inserts in Libraries I+J. 
PCR screening of Library I and Library J clones (clones 1-10 in lanes 1-10) 
showed all clones which amplified products were of the expected 935bp full 
length size.  No product was amplified from the no template control (-).  




5.1.2 Selections with control phage 
Next, test selections using controls supplied with the Tomlinson I+J libraries were 
carried out to ensure the phage display technology worked in our hands.  Controls 
were TG1 bacteria infected with a polyclonal phage population which had been 
subjected to one round of selection against either BSA or ubiquitin by the supplier.  
Phage was made from the control aliquots, and a second round of selection 
performed using 100µg/ml BSA or ubiquitin as target.  Polyclonal phage ELISA was 
used to assess enrichment of specific phage. 
 
Both BSA and ubiquitin selections showed enrichment of specific phage (Figure 5.2).  
Absorbance (A) increased by at least two-fold in both populations, as was expected 
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Figure 5.2: Selection with control phage. 
Polyclonal ELISA analysis of one round of phage selection using previously selected 




5.1.3 Selection with control targets 
Test selection using a target protein (BSA) and peptid  (c-myc) to which monoclonal 
antibodies have been produced (Apple et al, 1984; Evan et al, 1985) were also 
performed to verify that the unselected libraries could be enriched for specific clones.  
BSA and c-myc at 100µg/ml were used for three rounds of selection with Library J, 
with a polyclonal ELISA for assessment of specific phage enrichment. 
 
For selection with BSA, after three rounds of panning a polyclonal ELISA showed 
the absorbance of phage bound to BSA was almost three-fold higher than the 
absorbance of the same phage population bound to the control antigen (Figure 5.3).  
There was also an enrichment of binders for c-myc, with absorbance increasing over 
the three rounds from 0.36 to 1.57.  However, there was also a concomitant increase 
of phage binding to the control antigen, with a rise in absorbance from 0.15 in round 
1 to 1.30 in round 3.  Phage titres between the two selections were comparable, with 
no increase in phage output compared to controls (Table 5.1).  Therefore, Tomlinson J 
could be enriched for clones specific for BSA but not c-myc. 




Figure 5.3: Library J selection using BSA and c-myc as targets. 
Polyclonal ELISA analysis of three rounds of Library J phage 
selection using BSA and c-myc as targets.  ELISA controls are BSA 




Table 5.1: Phage titres of Library J selection using BSA and c-myc as targets. 
target round phage titre 
    input output control 
BSA 1 1x1013 2.1x107 9.1x106 
 2 1.1x1010 1.5x108 1.6x108 
 3 1.9x1010 6.8x109 9.2x109 
c-myc 1 1x1013 6.2x106 9.1x106 
 2 1.5x1010 6.4x107 1.4x108 
  3 1.6x1010 4.4x109 4.8x109 
 
 
5.2 Panning the libraries 
5.2.1 Target peptides 
In order to identify target LMP2 peptides, the Swiss-Prot database at the Swiss 
Institute of Bioinformatics was searched (www.expasy.org).  Input of LMP2 as the 
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keyword yielded sequence from Epstein Barr virus strain B95-8 (entry name: 
LMP2_EBV; primary accession number: P13285; reference: Baer et al, 1984).  The 
feature aligner tool in Swiss-Prot gave six potential extracellular domains.  These 
were compared with published sequence annotated with po ential transmembrane 
domains (Sample t al, 1989).  One extracellular sequence of four aa was discarded 
as too short to use for phage selection, as antibody epitopes are generally five to 
eight aa.  The remaining five sequences were used to synthesise the peptides shown 
in Table 5.2 and indicated in Figure 1.5.  To create the biotinylated (designated b) and 
biotinylated cyclised (designated bc) peptides, sequences were lengthened by three to 
six aa using the flanking protein sequences. 
 
Table 5.2: Target peptides for phage library selections.   
Peptides used as targets for phage library selections, t gether with label, configuration, 
sequence, length, and aa position in the LMP2 protein s quence from EBV B95-8 
(Baer et al, 1984).  [* designates point of cyclisation] 
label configuration and sequence length aa position 
2.1 SCFTASVS 8 142-149 
b2.1 biotin-ßAlaßAla-AASCFTASVSTV 12 140-151 
bc2.1 biotin-ßAlaßAla-Q*AASCFTASVSTVK* 14 140-151 
2.2 RIEDPPFNS 9 199-207 
b2.2 biotin-ßAlaßAla-TWRIEDPPFNSLL 13 197-209 
bc2.2 biotin-ßAlaßAla-Q*TWRIEDPPFNSLLK* 15 197-209 
2.3 DAVLQLSP 8 260-267 
b2.3 biotin-ßAlaßAla-IVDAVLQLSPL 11 258-268 
bc2.3 biotin-ßAlaßAla-Q*IVDAVLQLSPLK* 13 258-268 
2.5 SILQTNFKSLSSTEFIPN 18 374-391 
b2.5 biotin-ßAlaßAla-SILQTNFKSLSSTEFIPN 18 374-391 
bc2.5 biotin-ßAlaßAla-Q*SILQTNFKSLSSTEFIPNK* 20 374-391 
2.6 SNTLLSA 7 444-450 
b2.6 biotin-ßAlaßAla-VMSNTLLSAWI 11 442-452 
bc2.6 biotin-ßAlaßAla-Q*VMSNTLLSAWIK*  13 442-452 
 
 
5.2.2 Selections using unmodified peptides 
Using the peptide panel (Table 5.2), two pools of unmodified peptides were used for 
the selection of Library I and Library J in parallel.  Pool 1 contained peptides 2.1, 2.2 
and 2.3, while pool 2 contained peptides 2.5 and 2.6. Three rounds of selection were 
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performed, with peptides at a final concentration of 100µg/ml.  Polyclonal phage 
ELISA was used for assessment of specific phage enrichment, and monoclonal phage 
ELISA was used for screening of individual clone spcificity. 
 
Phage panned on pool 1 but not pool 2 showed a slight enrichment of binders by 
polyclonal ELISA (A=0.62) (Figure 5.4).  However, this enrichment did not appear to 
be specific for the peptides as phage also bound to BSA (A=0.42).  Phage titres for 
neither pool showed any increase in phage output compared to control (Table 5.3). 
 
 
Figure 5.4: Library I and J selections using pools of 
unmodified peptides as targets. 
Polyclonal phage ELISA analysis of three rounds of Library I 
and J selection using peptide pools of 2.1, 2.2 and 2.3 (A) or 2.5 
and 2.6 (B) as targets.  ELISA controls are BSA specific phage 
and unselected Library phage. 






Table 5.3: Phage titres of Library I and J selections using pools of unmodified peptides. 
targets Library round phage titre Library round phage titre 
      input output     input output 
2.1, 2.2, 2.3 I 1 1x1013 5.6x105 J 1 1x1013 1.5x106 
  2 1.1x1010 7x108  2 1.3x1010 4.9x108 
  3 1.1x1010 3.3x108  3 2x1010 1.8x109 
2.5, 2.6 I 1 1x1013 5.6x105 J 1 1x1013 3.8x106 
  2 1.x1010 2.1x108  2 7.2x109 3.1x108 





Monoclonal ELISA screening was performed on 80 round three output clones from 
each of the four selections.  This yielded two clones with higher absorbance on target 
peptide compared with BSA.  Clone G11 was from pool 1 and Library J selection, 
with absorbances of 2.13 on the peptides and 1.49 on BSA.  Clone H10 was from 
pool 2 and Library J selection, with absorbances of 0.33 on the peptides and 0.16 on 
BSA.  These clones were rescued, and their specificity tested by phage ELISA using 
BSA, ubiquitin, individual peptides and human serum as targets (Figure 5.5).   
 
Clone G11 bound to all targets tested with absorbances greater than 2.0, except for 
BSA, against which it had an absorbance of 1.5 (Figure 5.5 panel B).  On the 
individual antigens, clone H10 bound most strongly to peptide 2.5 (A=0.87), 
although it bound more strongly still to human sera (A=1.26) (Figure 5.5 panel C).  
The BSA positive control bound only to BSA of the individual antigens (A=2.77), 
although it did also bind though less strongly to human sera (A=1.12).  Therefore 
neither clone H10 nor clone G11 was specific for any LMP2 peptide.  
 






Figure 5.5: Specificity testing of clones from Library I and J selections using 
unmodified peptide pools. 
BSA control (A), and two clones from the third round of Library J phage selection using 




5.2.3 Selections using biotinylated peptides 
To make peptides more available to phage during the panning process, sequences 
were lengthened slightly and biotinylated (Table 5.1).  The biotin tag would adhere to 
streptavidin or avidin pre-coated immunotubes, leaving peptides free for phage 
binding.  Immunotubes were coated with 500ng/ml streptavidin or avidin, and 
100µg/ml biotinylated peptide bound to this.  Indivi ual peptides b2.1, b2.2, b2.3, 
and b2.5 (Table 5.2) were used for three rounds of selection of Library I and Library J 
in parallel.  Polyclonal phage ELISA was used for assessment of specific phage 
enrichment, and monoclonal phage ELISA for screening of individual clone 
specificity.  A polyclonal phage population binding, but not specific, to streptavidin 
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was used as a positive control for ELISAs with streptavidin.  Selections in this 
section were performed by Mr Matthew Seah (University of Edinburgh). 
 
Selection experiments using Library I and Library J and peptides b2.1 and b2.2 
showed enrichment of binders in a non-peptide-specific manner (Figure 5.6).  After 
three rounds of selection, similar levels of absorbance were seen for phage binding to 
streptavidin and peptide (target), compared with streptavidin alone (control): Library 
I selected on peptide b2.1 - target A=1.91, control A=1.85; J+b2.1 - target A=1.20, 
control A=1.14; I+b2.2 - target A=2.37, control A=2.23; J+b2.2 - target A=1.84, 
control A=1.65.  Peptide b2.3 also showed non-peptid -specific enrichment with 
Library I by round 3 (target A=2.65, control A=2.65), but no increase in binders with 
Library J.  Peptide b2.5 showed no increase in binders with Library J.  By round 
three with Library I, peptide b2.5 appears to have  substantial increase in specific 
peptide binders (target A=2.50, control A=0.10); however in this ELISA the no 
phage (A=1.45) and unselected Library I (A=1.12) also appeared reactive with the 
target peptides. 
 
Monoclonal phage ELISA analysis was performed on the round three outputs shown 
in Figure 5.6.  Results from the Library I and b2.5 screenings, which are 
representative of those seen for all library/peptide combinations, are shown in Figure 
5.7.  Target peptides b2.1, b2.2, b2.3, and b2.5 had 47, 80, 44 and 51 clones 
respectively positive for target binding in the screen, however all clones also bound 
to streptavidin alone.  Therefore, no clone specific for biotinylated, linear LMP2 
peptides was isolated from the Tomlinson I and J librar es. 
 





Figure 5.6: Library selection using biotinylated, linear peptides. 
Polyclonal ELISA analysis of three rounds of Library I and J selection using 
biotinylated, linear peptides 2.1 (A,B), 2.2 (C,D), 2.3 (E,F) and 2.5 (G,H) as targets. 
 





Figure 5.7: Screening of clones from selections using biotinylated, linear 
peptides. 
Monoclonal ELISA screening of 80 clones from the third round output of Library I 
selection using biotinylated linear peptide b2.5 as a target. 
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5.2.4 Selections using biotinylated cyclised peptid es 
As the extracellular sequences of LMP2 in their natural configuration will be looped 
to allow insertion of the flanking domains into the c ll membrane, the biotinylated 
peptides were cyclised in an effort to mimic this conformation.  Individual peptides 
bc2.1, bc2.2, bc2.3, bc2.5 and bc2.6 (Table 5.2) were used for three rounds of 
selection of Library I or Library J.  Polyclonal phage ELISA was used for assessment 
of specific phage enrichment, and monoclonal phage ELISA for screening of 
individual clone specificity.   
 
Figure 5.8: Library selection using biotinylated, cyclised peptides. 
Polyclonal ELISA analysis of three rounds of selection using Library J and 
biotinylated, cyclised peptides 2.1 (A), 2.2 (B), 2.3 (C), 2.5 (E) and 2.6 (F), or 
Library I and 2.5 (D) as targets. 
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Selection experiments with all combinations of Library and peptide showed 
enrichment of binders in a non-peptide-specific manner (Figure 5.8).  After three 
rounds, similar levels of absorbance were seen for phage binding to streptavidin and 
peptide (target), compared with streptavidin alone (control): Library J selected on 
peptide b2.1 - target A=1.71, control A=1.90; J+b2.2 - target A=2.01, control 
A=2.00; J+b2.3 - target A=1.72, control A=1.71; I+b2.5 - target A=2.50, control 
A=2.48; J+b2.5 - target A=2.54, control A=2.53; J+b2.6 - target A=2.09, control 
A=1.79.  Phage titres for all combinations of Library nd peptide showed no increase 
in phage output compared to controls (Table 5.4).  However, the overall titre of both 
phage output and control did rise dramatically in the second and third rounds for all 
selections.  If no selection was occurring, then the titres for both control and phage 
output would remain at the lower levels seen in the first round.  If the selection was 
specific for the target peptides, there would be an increase in the phage output titres 
but no increase in the control titres.  As there is an increase in both phage output and 
control titres, this suggests that selection pressur  is resulting in the retention of 
strongly binding non-specific phage.  
 
 
Table 5.4: Phage titres of Library I and J selections using biotinylated, cyclised peptides. 
Library + round phage titre Library + round phage titre 
target   input output control target   input output control 
J+bc2.1 1 1x1012 4x103 4x104 J+bc2.2 1 1x1012 2.4x104 4x104 
 2 7.5x1010 4x108 2.8x109  2 4x109 1x109 8x109 
 3 1.3x1010 5.2x108 7.6x109  3 9.6x109 1x109 8x109 
J+bc2.3 1 1x1012 1.8x105 5.2x105 I+bc2.5 1 1x1012 1.2x105 2x105 
 2 1.8x1010 1.8x108 3.2x109  2 3.5x1010 2x107 2.5x108 
 3 2.2x1010 4.4x108 1.1x1010  3 5x1010 8.4x108 3.6x109 
J+bc2.5 1 1x1012 1.3x105 3.6x105 J+bc2.6 1 1x1012 1.2x105 5.2x105 
 2 9.6x109 1.4x108 3x108  2 3x1010 1.6x108 1.2x109 




Monoclonal phage ELISA analysis was performed on the round three outputs shown 
in Figure 5.8.  Results from the Library J and bc2.6 screenings, which are 
representative of those seen for all library/peptide combinations, are shown in Figure 
5.9.  Target peptides bc2.1, bc2.2, bc2.3, bc2.5, and bc2.6 had 20, 45, 23, 7, and 17 
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clones respectively with A>0.5 for peptide binding i  the screen, however all clones 
also bound to streptavidin alone.  Therefore, no clone specific for biotinylated, 
cyclised LMP2 peptides was isolated from the Tomlinson I and J phage libraries. 
 
 
Figure 5.9: Screening of clones from selections using biotinylated, cyclised peptides. 
Monoclonal ELISA screening of 80 clones from the third round output of Library J 
selection using biotinylated cyclised peptide 2.6 as a target. Clones labelled a-j were 
taken for further analysis. 
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In light of the above results, 10 clones (designated -j) were selected at random from 
the monoclonal screening of Library J and bc2.6 for further analysis of clone 
diversity.  Clones were screened by PCR for full length inserts (Figure 5.10 panel A).  
Restriction enzyme digest fingerprinting of the PCR products was used as an 
indication of clone diversity (Figure 5.10 panel B), and sequencing reactions of the VH 
and VL regions of each of the clones were also performed.   
 
DNA from all 10 clones amplified PCR products of the expected 935bp size, 
indicating full length scFv inserts, although clone g also had a second band of 
roughly equal intensity at approximately 700 bp (Figure 5.10 panel A).  Nine of the 10 
clones (a-h, j) had identical fingerprints, with clone i alone being unique.  The 
secondary band from the clone g PCR did not distinguish its fingerprint from clones 
a-f, h and j. 
 
 
Figure 5.10: scFv inserts and clone diversity in bc2.6 selected phage. 
PCR screening for full length inserts (A) and restriction enzyme digest 
fingerprinting for diversity (B) of 10 clones (a-j) from the third round of 
Library J selection using biotinylated cyclised peptide bc2.6 as target 
antigen.  PCR negative control (-) contained no template DNA and 
positive control (+) was unselected Library J phage. 




Sequence alignment of nine clones identified four which were identical (a, c, h, j), 
while the remaining five were unique (b, d, e, f, i).  The overrepresentation of a 
single clone after three rounds of panning suggests some form of selection is 
occurring, in line with the data from the selection titres.  The sequence of clone g 
was of poor quality, presumably due to interference from the second PCR band, and 
hence was excluded from analysis.   
 
5.2.5 Selection protocols incorporating negative se lection for 
streptavidin binders 
In order to discourage binding of streptavidin-specific clones, a negative selection 
step was incorporated at the beginning of each round of panning (see 2.6.5).  
Individual peptides bc2.1, bc2.2, bc2.3 and bc2.6 were used for two rounds of 
selection of a premixed population of Library I+J.  Polyclonal phage ELISA was 
used for assessment of specific phage enrichment, and monoclonal phage ELISA for 
screening of individual clone specificity. 
 
Selection experiments with all peptides showed enrichment of binders in a non-
peptide-specific manner (Figure 5.11).  After two rounds, similar levels of absorbance 
were seen for phage binding to streptavidin and peptid  (target), compared with 
streptavidin alone (control) for bc2.2 (target A=0.95, control A=1.14), bc2.3 (target 
A=1.04, control A=1.12), and bc2.6 (target A=0.53, control A=0.47) and a higher 
level of absorbance for streptavidin alone compare to streptavidin and peptide for 
bc2.1 (target A=0.90, control A=1.66).  Phage titres for all combinations of Library 
and peptide showed no increase in phage output compared to controls, and there was 
no enrichment of clones containing full length insert  (Table 5.5). 
 





Figure 5.11: Library selection using biotinylated, cyclised peptides with negative 
selection for streptavidin binding phage. 
Polyclonal ELISA analysis of two rounds of phage selection using Library I+J and 




Table 5.5: Phage titres and PCR screening of Library I+J selections using 
biotinylated, cyclised peptides with negative selection for streptavidin binding phage. 
target round phage titre PCR screening 
    input output control inserts / clones 
bc2.1 1 1x1012 8x103 2x104 6 / 8 (75%) 
 2  1.2x109 1.4x109 8 / 8 (100%) 
bc2.2 1 1x1012 1.6x104 2x104 4 / 4 (100%) 
 2  1.4x108 2.1x108 5 / 10 (50%) 
bc2.3 1 1x1012 8x103 8x103 7 / 10 (70%) 
 2  8.4x107 1x108 3 / 8 (38%) 
bc2.6 1 1x1012 4x103 8x103 5 / 10 (50%) 
  2   2.2x108 1.5x108 5 / 9 (56%) 
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Monoclonal phage ELISA analysis was performed on the round three outputs shown 
in Figure 5.11.  No individual clone from selections on bc2.2, bc2.3, and b2.6 had an 
A>0.5 for either streptavidin alone or streptavidin a d peptide.  Nine clones from 
bc2.1 selections had A>0.5 on streptavidin and peptid , however all clones also 
bound to streptavidin alone.  Therefore, although incorporating a negative selection 
step for streptavidin binders did appear to reduce the overall number of streptavidin 
binding phage in monoclonal ELISA analysis of selection, it did not appear to 
encourage selective enrichment of LMP2 binding phage, nd no phage clone specific 
for biotinylated, cyclised LMP2 peptides was isolated. 
 
5.2.6 Selections using streptavidin coated beads 
In a parallel experiment also aimed at reducing the enrichment of streptavidin 
binding phage, selections using streptavidin-coated b ads in place of immunotubes 
were performed.  A µMACS Streptavidin Kit for Phage Display (Miltenyi Biotec) 
was used according to the manufacturer’s instructions, with peptide bc2.5 as target 
for two rounds of Library I and Library J selection.  Polyclonal phage ELISA was 
used for assessment of specific phage enrichment, and monoclonal phage ELISA for 
screening of individual clone specificity. 
 
For Library I, selection using streptavidin coated beads had the effect of removing all 
binding phage, while the results for Library J once again showed enrichment in a 
non-peptide-specific manner (Figure 5.12).  Similar levels of absorbance were seen 
after two rounds of selection for phage binding to streptavidin and peptide compared 
with streptavidin alone (peptide A=1.06, control A=1.24).  Phage titres for the two 
libraries were also similar (Table 5.6). 
 
Monoclonal ELISA analysis was performed on 80 round two output clones from 
each Library I and Library J selection.  No individual clone showed an A>0.5 for 










Figure 5.12: Library selection using a biotinylated, cyclised peptide 
with streptavidin coated beads. 
Polyclonal ELISA analysis of two rounds of Library I or Library J selection 







Table 5.6: Phage titres of Library I and J 
selections using streptavidin coated beads. 
Library round phage titre 
    input output 
I 1 1x1011 4x103 
 2 1.8x1010 1.6x107 
J 1 1x1011 3.6x104 
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5.3 Selection experiments using alternate libraries  
To test if phage libraries other than the Tomlinson I+J would yield specific clones 
after selection with LMP2 peptides, two new libraries were examined.  Like the 
Tomlinson I+J, the ETH2Gold is a scFv phage library with a diversity of 3x109 
(Silacci et al, 2005).  The RotMar library is in Fab format with a diversity of 
5.36x109. 
 
5.3.1 ETH2Gold phage library 
Selections using peptide bc2.1 and the ETH2Gold library were performed by Ms 
Lynda Robson at UCL, London, UK.  After three rounds of selection, phage titres 
and PCR screening showed no specific enrichment of peptide binders compared with 
controls (Table 5.7). 
 
 
Table 5.7: Phage titres of ETH2Gold phage library selection. 
target round phage titre PCR screening 
    input output control inserts / clones 
2.1 1 2x1012 3.3x104 3x104 5 / 10  (50%) 
 2 3x1012 1.3x104 7x103 0 / 9  (0%) 




5.3.2 RotMar phage library 
Selections using peptide bc2.5 were performed by Ms Karen McAulay (University of 
Edinburgh) and Dr Reno Debets (Erasmus-Daniel den Hoed Cancer Centre) at the 
Erasmus-Daniel den Hoed Cancer Centre, Rotterdam, Netherlands.  After three 
rounds of selection monoclonal ELISA showed enrichment of binders in a non-
peptide specific manner (Figure 5.13).  Of the 96 clones screened, 70 had A>0.5, 
however all clones also bound to the streptavidin-bcLMP1 complex, and thus no 
phage clone specific for biotinylated, cyclised LMP2 peptide 2.5 was isolated from 
the RotMar library. 
 





Figure 5.13: RotMar library selection using LMP2 peptide 2.5. 
Monoclonal ELISA analysis of the third round output of RotMar phage library 
selection using biotinylated cyclised peptide 2.5 as target. bcLMP1 is the non-
target peptide ELISA control. 
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5.4 Summary of results 
• PCR screening showed at least 70% of Tomlinson I clones and 90% of 
Tomlinson J clones contained full length scFv inserts. 
• After one round of selection, Tomlinson I+J were enriched for clones specific 
against target proteins BSA and ubiquitin. 
• After three rounds of selection, Tomlinson J was enriched for clones specific 
for the target protein BSA.  Enrichment for target p ptide c-myc was non-
specific. 
• There was a small increase in the number of binding clones after three rounds 
of selection using pool 1 peptides and Library J, but no enrichment using pool 
1 and Library I, or pool 2 and either library.  Enrichment was not specific for 
the peptides when assessed by polyclonal ELISA. 
• Two clones isolated from round 3 pool 1 and Library J selection displayed 
higher absorbance on target peptide compared with BSA in a monoclonal 
ELISA.  Upon further analysis, one clone was non-specific and the other of 
low affinity for the target peptide. 
• There was an increase in binding clones after three rounds of selection in 6 of 8 
combinations using biotinylated linear peptides and Libraries I and J in 
parallel.  Enrichment was not specific for the peptides when assessed by 
polyclonal or monoclonal ELISA. 
• There was an increase in binding clones after three rounds of selection in all 
combinations using biotinylated cyclised peptides and Library I or J.  
Enrichment was not specific for the peptides when assessed by polyclonal or 
monoclonal ELISA. 
• Of nine clones isolated from a round 3 Library J selection with a biotinylated 
cyclised peptide, all contained full length inserts; four represented a single 
clone, whilst the remaining five were unique. 
• There was a comparatively small increase in binding clones after two rounds in 
all selections incorporating a negative selection step and using biotinylated 
cyclised peptides with Library I+J.  Enrichment was not specific for the 
peptides when assessed by polyclonal or monoclonal ELISA. 
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• There was a small increase in binding clones after two rounds of selection 
using streptavidin coated beads and a biotinylated cyclised peptide with 
Library I and J in parallel.  Enrichment was not specific for the peptides when 
assessed by polyclonal ELISA. 
• There was no enrichment of specific clones after three rounds of selection 
using a biotinylated cyclised peptide and the ETH2Gold scFv Library when 
assessed by PCR. 
• There was no enrichment of specific clones after three rounds of selection 
using a biotinylated cyclised peptide and the RotMar Fab Library when 
assessed by polyclonal ELISA. 
 
5.5 Discussion 
LMP2 was chosen as the target for phage display selections for two reasons; firstly, it 
is a membrane protein with external loops available for targeting via a cTCR, and 
secondly, it is expressed in the EBV latency II phenotype characteristic of HL and 
NPC as well as in a proportion of GC cases.  Peptids entical in sequence to the 
extracellular loops of LMP2 were used as targets rathe  than cells expressing LMP2 
as advice received had highlighted the difficulties of panning on whole cells 
(personal communication, Sir Gregory Winter, MRC Laboratory of Molecular 
Biology, Cambridge, UK).  The abundance of antigens present on any cell means 
that a huge number of clones would need to be screened to identify LMP2-specific 
binders.  Even using a panel of LMP2-positive and -negative cell lines over multiple 
rounds of positive and negative selection, it would be extremely difficult to isolate 
LMP2 specific binders.  Peptides were used in preference to whole purified protein 
as computer modelling to predict antigenic sequences within the LMP2 protein 
returned predominantly transmembrane and intracellular hits 
(http://bio.dfci.harvard.edu/Tools/antigenic.pl).  This suggested that selection using 
whole protein might result in the selective enrichment of clones binding to those 
domains, with clones specific for the external loop sequences lost over progressive 
rounds of selection.  A scFv format was selected for the phage library, as the 
Tomlinson I+J library was readily available as the time this project commenced.  
Also, the scFv configuration was the format most relevant for cTCR construction, 
which was the anticipated initial use for the selected clone. 
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Standardisation experiments demonstrated that the Tomlinson libraries were 
functioning correctly.  By PCR screening, at least 70% of Tomlinson I and 90% of 
Tomlinson J clones contained full length scFv inserts (Figure 5.1).  The library 
specification sheet gave 96% and 88% as the percentag  of full length clones in I and 
J respectively, thus the results were as expected.  The remaining clones did not 
amplify any product, full length or otherwise.  It is possible that the clones do contain 
full length inserts, and that the lack of product was a result of sub-optimal PCR 
conditions.  One possibility is that insufficient DNA was added to the reaction mix 
when bacteria were picked directly from agar plates.  Three rounds of selection using 
Library J and BSA as a target protein confirmed that e library could be enriched for 
phage specific for a target protein (Figure 5.3).  At this point it was decided that 0.5A 
would be the level beneath which phage binding in an ELISA would be classed as 
background.  This was the approximate absorbance value of the third round BSA-
selected phage population binding to c-myc in a polycl nal ELISA (Figure 5.3).   
 
An increase in binding clones was observed during selections using c-myc as target 
(Figure 5.3); however, phage also bound to BSA control wells in the polyclonal 
ELISA.  As the c-myc epitope is 10 aa long and a mAb for c-myc is commercially 
available, c-myc was chosen as a target to test if the library was capable of selection 
against short peptides.  In retrospect, this was not a good choice of target as phage in 
the Tomlinson libraries carry a myc tag for detection, purification or immobilisation 
of the scFv.  Thus, it is possible that phage specific for myc would bind to other 
phage during panning, greatly reducing the selection pressure necessary for specific 
enrichment. However, this was not appreciated at the ime, and selection experiments 
using a more appropriate peptide target were not performed.  Given the slight but 
visible difference between control and test wells in the polyclonal ELISA it was 
decided to continue with the peptide approach (Figure 5.3). 
 
Selections using pooled, unmodified peptides and the Tomlinson libraries in parallel 
did not result in a high enrichment of binding clones.  Only two potential clones with 
clear differences in absorbance when binding to target compared with BSA were 
identified by monoclonal ELISA: clones G11 and H10.  Upon rescue and further 
analysis, clone G11 proved to be an equally strong bi der against the all three pool 
Chapter 5                          Identification of LMP2-Specific scFv Using Phage Display 
 164 
peptides when each was assayed individually (Figure 5.5). It also returned high 
absorbances against ubiquitin, human sera and to a slightly lesser extent BSA, 
demonstrating that it was not specific for target pptides.  Clone H10 bound 
specifically to peptide 2.5 but not 2.6 or BSA.  However, it was also reactive against 
ubiquitin and human sera (Figure 5.5).  Additionally, although the phage used in the 
ELISA had been PEG-precipitated and was therefore of high concentration, 
absorbance was still relatively low (peptide 2.5, A=0.87), suggesting a weak affinity 
for peptide 2.5.  As high affinity scFv show better umour delivery (at least in 
antibody format; Adams et al, 1998), no further analysis of H10 was performed.   
 
Biotinylating peptides had the effect of increasing ‘background’ phage in selections 
using both linear and cyclised peptides (Figure 5.6 and Figure 5.8). That is, overall 
more binding phage were rescued during rounds of selection, as evidenced by 
increased absorbance levels in polyclonal ELISAs.  However, these phage were 
reactive with both target peptides and the streptavidin used to adhere biotinylated 
peptides to immunotubes and ELISA plates.  One polycl nal ELISA showed 
increased absorbance on target peptide compared to streptavidin (Library I and b2.5, 
Figure 5.6 panel G), although the no phage and unselected Library I controls also had 
raised absorbance.  Thus, the most likely explanatio  for the ELISA results is cross-
contamination with other samples, either in the sample aliquots or ELISA wells.  
Subsequent monoclonal ELISA analysis confirmed this wa  not a true positive result, 
as no specific individual clones were isolated from the 80 clones tested. 
 
Sequence analysis of nine clones from a selection using Library J and bc2.6 showed 
that while five clones were unique, the remaining four clones selected represented a 
single scFv (see 5.2.4).  This overrepresentation of a single clone after three rounds 
of panning, together with the high titres returned on both phage output and control 
tubes in the second and third rounds (Table 5.4),` suggests some form of selection is 
occurring, possibly on an epitope common to avidin and streptavidin.  Avidin was 
used to bind target peptide in round 2 and streptavidin was used in rounds 1 and 3.  
Restriction enzyme digests were also used prior to sequencing as an initial screen for 
clone diversity (Figure 5.10 panel B).  In retrospect this was not an appropriate choice 
as the Tomlinson library is based on a single antibody framework, with sequence 
diversity engineered only in the CDR3 and CDR2 regions.  Thus BstNI cleavage 
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sites are not likely to vary even between clones with different specificities.  
Restriction enzyme digests are better suited to screening naïve libraries. 
 
Some background is expected when using phage display, th t is, rescue of phage 
clones not specific for the target may occur.  Only a minority of phage particles 
display scFv.  In the Tomlinson system, it is between 1 in 10 and 1 in 100 (Jensen t 
al, 2003a).  However, these phage would be expected to be non-binders in 
monoclonal ELISAs given that they have no ligand with which to bind to targets.  
Some of the background yet binding clones may be reactive to the milk powder 
contained in the blocking buffer used for both ELISAs and panning.  The problem of 
the streptavidin reactive background generally seen when using biotinylated target 
may have been compounded in this case by the lack of specific phage, with 
streptavidin reactive phage enriched over multiple rounds of selection as there was 
no competing enrichment of target-specific phage. 
 
It remains an open question as to why LMP2 loops were unable to select out specific 
scFv.  Although the peptides were comparatively short, they were long enough to be 
a target.  With the c-myc epitope, only 10 aa are ne ded for specificity.  The 
Tomlinson I+J are relatively old phage libraries, and newer, larger and therefore 
more diverse libraries are currently being constructed, such as the ETH2Gold and 
RotMar libraries.  A major difference between the Tomlinson and ETH2Gold 
libraries compared with the RotMar library, is that the RotMar is a naïve library.  
This means that diversity is incorporated over the entire antibody fragment and not 
just in the CDR regions where antibody residues directly contact the antigen.  Indeed, 
the Tomlinson and ETH use the same VH framework (DP47).  This may affect the 
size and shape of the antigen binding cleft of the antibody, with consequences for the 
range of targets able to be bound.  As with the Tomlinson selections, panning using 
the ETH2Gold library and bc2.1 did not isolate peptide-specific clones (Figure 5.7).  
However, although a similar result was seen using the RotMar library and bc2.5 
(Figure 5.13), parallel selections using a biotinylated cyclised LMP1 extracellular 
loop peptide (bcLMP1.2) were also performed, and these selections did result in 
specific enrichment (Figure 5.14).  The bcLMP1 sequence is biotin-ßAlaßAla-
LIALWNLHGQALFLG ( Figure 1.4).  Of the 96 clones screened after three rounds of 
selection, 72 specific clones were identified (peptide A>0.24, control A<0.1). 





Figure 5.14: RotMar library selection using LMP1 peptide 1.2. 
Monoclonal ELISA analysis of the third round output of RotMar phage library 
selection using biotinylated cyclised peptide LMP1.2 as target. bc2.5 is the non-
target peptide ELISA control. 
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In addition to differences in library construction, the RotMar library is also in Fab 
format, compared to the scFv format of the Tomlinson and ETH2Gold libraries.  
Rather than a single recombinant antibody fragment fused to the pIII protein, the 
RotMar Fab library has only the antibody heavy chain fused to pIII.  The antibody 
light chain is expressed as a separate molecule, which is secreted into the E.coli 
periplasm where it can pair with the heavy chain.  Fabs tend to be expressed at lower 
levels on phage than scFv, leading to a lower display frequency and lower fraction of 
avid phage.  Therefore, selections using Fab are governed more by affinity (the 
binding strength of an antigenic determinant to a single antigen-binding site) than 
avidity (the sum total binding strength of an antigenic particle to an antigen-binding 
molecule).  Also, Fab do not form multimers when expr ssed as soluble fragments, 
in contrast with scFv which do tend to multimerise.  Thus, Fab libraries are easier to 
use with respect to downstream affinity assays such as using surface plasmon 
resonance technology as crude protein fractions can be utilised without the need for 
purification.  Also, and for the same reason, they are a better option when panning 
for fragments to be incorporated into whole antibody molecules. 
 
Only one peptide each from LMP1 and LMP2 were used to screen the RotMar 
library (Figure 5.13 and Figure 5.14), so it is possible that a Fab specific for an LMP2 
loop may yet be isolated.  Logically, there is no reason why the LMP2 loops 
shouldn’t retrieve specific scFv.  LMP1 and LMP2 loops have been used previously 
to isolate Fab fragments from the de Haard library (personal communication, 
Professor Jaap Middeldorp; de Haard et al, 1999).  Other possibilities for target 
manipulation which could be explored include synthesising peptide repeats to make 
targets longer, and branching peptides to display multiple copies of the same target 
or combinations of targets.  The use of whole cells xpressing LMP2 as targets has 
been discussed previously, and remains an option, albeit  difficult one.  Colleagues 
in our laboratory are currently conducting further analysis on the LMP1 clones 
isolated in Rotterdam, and transferring the RotMar library to Edinburgh in order to 
continue selections using LMP1 and LMP2 peptides as targets.  Initial results are 
encouraging, however further work evaluating the spcificity and affinity of isolated 
clones is ongoing. 
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On a technical note, selections in our laboratory ae now conducted using 
commercially available streptavidin coated beads to immobilise biotinylated targets, 
rather than the immunotube method described here.  Although selections using 
streptavidin coated beads and a biotinylated cyclised peptide with Library I and J in 
parallel did not result in the isolation of an LMP2 specific clone during this project 
(Figure 5.12), this was a single experiment using only one peptid  with no opportunity 
for optimisation or standardisation.  As commercially vailable streptavidin coated 
beads undergo quality assurance testing prior to releas  from the supplier, this format 
reduces variability in streptavidin concentrations across selection experiments with 
obvious implications for the reliability of target concentration (personal 
communication, Dr Reno Debets).  An additional advantage of this method is that it 
allows selections to be performed in smaller volumes than the immunotube format.  
This facilitates the binding of target and specific clone, which is presumably of low 
frequency in the initial library population, by bringing them into closer proximity. 
 
In light of the unsuccessful nature of selections performed with the Tomlinson 
libraries and LMP2 peptides, an evaluation of the approach taken is warranted.  The 
advantage of using the loop peptide targets is that t ey are able to be easily and 
relatively cheaply synthesised, and any phage binding to them is specific for the 
extracellular rather than intracellular or transmembrane portions of the LMP2 
molecule, as required for cTCR construction.  Conversely, the whole protein is 
considerably more difficult and expensive to synthesis  or purify, and as it is a 
membrane protein it would not be in its native conformation.  The major drawback to 
peptide selections is that in general they are not as successful those using whole 
protein targets.  Also, scFv phage specific for peptid s, or indeed whole purified 
proteins, do not necessarily bind targets in their native conformation and 
environment.  ELISA screening using soluble scFv or Fab rather than fragments 
expressed on the surface of phage may give a more accurate indication of 
functionality, and in retrospect this assay should have been performed in the library 
control experiments (5.1.2 and 5.1.3).  Nevertheless, as a starting point peptide 
targets were a reasonable choice.   
 
With the benefit of additional time, it would have b en interesting to also attempt 
selections on whole cells.  Vaccinia constructs could have been assembled containing 
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LMP2, and the addition of a selectable marker would have allowed subtractive 
selection using FACS.  With hindsight, a switch from the peptide target approach to 
whole cell selections, or to using a naïve library, should possibly been taken earlier.  
However given the time limits inherent in the project there is no guarantee that this 
would have led to the isolation of LMP2-specific scFv.  Had a robust monoclonal 
antibody for LMP2 been available, the need for these selections may have been 
obviated, and the LMP2-specific scFv could have been obtained from this source.  
However, this lack is another argument for searching for LMP2-specific antibody 








6 Future Directions 
 
 
“The history of cancer research has been a history of curing cancer in the 
mouse.  We have cured mice of cancer for decades, and it simply didn’t 
work in humans.” 
     - Dr Richard Klausner 
   former director, US National Cancer Institute 
   Los Angeles Times, 6th May 1998 
 
The above quote has been both a goal and a goad throughout this project.  As yet, no 
mouse model has been a good predictor of the human response to immunotherapy 
(June, 2007) although the SCID model of PTLD is a possible exception.  The 
divergent responses seen when using CTLA4-specific antibody blockade are one 
example highlighting the differences between the mouse and human situations.  In 
mice, treatment is well tolerated and induces anti-tumour responses when 
administered in combination with a granulocyte/macrophage colony-stimulating 
factor (GM-CSF)-expressing tumour cell vaccine in a murine melanoma model (van 
Elsas et al, 1999).  Although anti-tumour responses have also observed in humans, 
they were often accompanied by serious autoimmunity (A tia et al, 2005; Blansfield 
et al, 2005).  The recent media furore which accompanied th  hospitalisation of six 
men in Northwick Park as a result of a phase I immunotherapy trial also underscores 
the differences between model systems and the human situation (Suntharalingam et 
al, 2006).  In this case the model animal was the rat, and a novel therapeutic anti-
CD28 mAb (TGN1412) was well tolerated in this setting (Beyersdorf et al, 2005).  
Prior to the trial, the mAb was also tested on human PMBCs in vitro, as well as in 
cynomolgus macaques in vivo (whose CD28 molecule shares 100% homology with 
the intra- and extracellular domains of human CD28), with no adverse effects 
(Hanke, 2006).  In fact, it was anticipated the antibody would preferentially expand 
Tregs (defined by a CD4+CD25
high phenotype) and be useful in the treatment of 
autoimmune disease.  Instead, antibody administration initiated a rapid release of 
proinflammatory cytokines, a so called ‘cytokine storm’, leading to multiple organ 
failure in all six patients, although all eventually recovered (Suntharalingam et al, 
2006).  Whilst this is an extreme case, it emphasises the need for caution in 
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immunotherapy, as many aspects of the immune system have yet to be fully 
understood.  Nonetheless, returning to the quote, curing cancer in a mouse is a 
considerable achievement.  It provides proof-of-principle for novel therapies, and yet 
it falls short of the aim of the majority of cancer r search, which is of course curing 
cancer in humans. 
 
Evaluation of novel therapeutic agents requires complex, biologically relevant 
models in which to study interactions between agent and subject.  Technical and 
ethical constraints limit the use of humans as test subjects, and consequently animals 
fill this niche.  Current guidance from the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH), to which the European Union is a signatory, requires evaluation 
of preclinical data collected from animal experiments prior to the commencement of 
human trials.  Non-human primates most closely represent human biology, yet they 
do not absolutely mimic the human situation, and as mentioned previously, the 
specialist requirements, high expense and adverse public attitude towards primate 
research means it is not feasible for large scale res arch in the UK.  Due to their lack 
of functional T and B lymphocytes, SCID mice can be engrafted with human tissue.  
Such humanised animals are a useful tool in which to study the effects of targeted 
therapies for cancer, providing as it does the actual target cells in a 
microenvironment more akin to human malignancy than in vitro culture.  
Additionally, mouse models are relatively inexpensive and used on such a wide scale 
that mouse biology is well understood in comparison with other mammalian models 
(Hughes, 2003).  Thus, the SCID models of HL, NPC and GC set up during this 
project may be valuable in future investigations of cancer therapy. 
 
As a viral antigen associated with a number of tumors, some attention has been 
focused on LMP2 as a CTL target for immunotherapy of EBV-positive tumours.  
However, LCL-stimulated CTL cultures from healthy EBV-positive individuals 
usually contain less than 1% T cells recognizing LMP2A (Bollard et al, 2004).  
Although only subdominant and no immunodominant LMP2 specificities have been 
identified so far, these CTLs may still be immunologically relevant.  Sun et al (2007) 
used an INF-γ capture assay to enrich CTL cultures for LMP2A-specific effector 
cells.  In vitro, these polyclonal populations were able to specifically lyse fibroblasts 
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expressing LMP2A as well as LCLs expressing the full range of EBV latent antigens, 
and release Th1 cytokines such as INF-γ and GM-CSF following antigen stimulation 
(Sun et al, 2007).  Bollard et al (2007) used an alternative method to enrich CTL 
populations for LMP2A-specific cells.  Rather than use conventional EBV-positive 
LCLs for stimulation and expansion of CTLs, PBMCs were initially stimulated with 
dendritic cells engineered to express LMP2A from an adenovirus vector, with LCLs 
overexpressing LMP2A from the same vector used in subsequent stimulations.  This 
approach resulted in a polyclonal population of LMP2A-specific CTLs, which were 
able to mediate four complete and one partial respon e, with one non-responder, in 
the six patients with relapsed HL or NHL treated using the LMP2A-specific cells 
(Bollard et al, 2007).  This result validates the use of cellular therapies directed 
against LMP2 for the treatment of EBV-associated malign ncies.  However, a major 
disadvantage of the Bollard protocol is that the therapeutic CTLs are generated using 
PBMCs from the patient’s own blood to derive the dendritic cells (DC), LCLs and T 
cells required.  This means that the delay between d cision to treat and actual therapy 
is prolonged, the patient must have LMP2 reactive T cells present in the periphery, 
and ideally PBMCs should not be numerically or functionally defective as a result of 
disease or treatment.  One advantage of the cTCR appro ch undertaken in this 
project is that whilst a patient’s PBMCs could be us d as a T cell source if time and 
facilities permit (as outlined in Figure 1.8), a bank of best match CTLs transduced 
with the cTCR and expanded to clinically relevant numbers could also be created and 
stored, reducing treatment delay and obviating the need for functional patient cells. 
 
Although immunotherapy using cTCRs to direct T cells against cancer cells has great 
potential, there are a number of issues which need to be addressed in order to 
facilitate the transfer of treatment from animal models into the clinic.  Three phase I 
clinical trials using cTCR engineered T cells have be n undertaken to date, and these 
studies have highlighted some of the key issues needi g to be addressed by 
researchers in the engineered cellular immunotherapy field.  The first study 
investigated cells targeting FBP found on ovarian ccers (Kershaw et al, 2006), and 
the second examined cells directed against the L1-cell adhesion molecule (CD171), 
which is overexpressed by neuroblastoma cells (Park et al, 2007).  Both treatment 
regimes were well tolerated by patients.  However, T cell persistence was poor and 
no clinical benefits were observed.  Clinical responses have been correlated with T 
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cell persistence in vivo, at least in adoptive therapy of melanoma using unmodified 
melan-A-specific T cells, suggesting that persistence of therapeutic cells is crucial 
for successful treatment (Meidenbauer et al, 2003).  Neither of the cTCRs used in the 
trials conducted by Kershaw et al or Park et al included a co-stimulatory domain.  
The lag time between laboratory and clinical studies can be as much as 10 years, 
making incorporation of the latest research unfeasible, and thus evaluation of safety 
was the main issue under investigation.  Therefore, as there were no adverse events, 
the results of the trials are encouraging and pave the way for future trials using more 
advanced cTCRs incorporating co-stimulatory domains for improved T cell 
persistence and therapeutic efficacy.  The third cTCR trial targeted carboxy 
anhydrase IX (CAIX), which is overexpressed in more than 90% of primary renal 
carcinoma (Lamers et al, 2006).  Unfortunately, this trial was halted as a result of 
unexpected hepatic toxicity, most likely due to theengineered T-cells trafficking to 
and exerting cytotoxic effect against CAIX-expressing epithelial cells lining the bile 
ducts.  Whilst this is an encouraging display of T cell migration and effect, it 
emphasises the need for careful selection of target antigens.  Lamers et al (2006) also 
saw development of anti-scFv antibodies in patients, a ituation which may need to 
be taken into consideration for future studies, although the mAb source of the scFv 
was in this case murine, and hence likely to be more immunogenic in patients than a 
fully human scFv.  Taken together, the studies demonstrate that engineered T cells 
are capable of trafficking to and killing cells expressing the target antigen.  When 
targets are carefully chosen, treatment is well tolerated by patients.  However, safety 
and efficacy in vivo are areas in which more research is required. 
 
A number of avenues are being explored to make T cells more efficacious, especially 
with regards to activation of therapeutic cells.  The benefits of IL-2 on anti-tumour 
effect when co-administered systemically alongside tumour-specific T cells have 
long been known (Cheever t al, 1982).  However, in the patient setting systemic IL-
2 administration is toxic, and when used in conjunctio  with MART1, melan-A-
specific or gp100-specific CTLs for the treatment of melanoma, minimal clinical 
benefits were observed (Yee t al, 2002).  For a more specific IL-2 mediated T cell 
stimulation in vivo, therapeutic T cells could be transduced with a gene encoding IL-
2.  In vitro, this resulted in constitutive IL-2 expression and prolonged viability of T 
cells specific for a melanoma antigen in the absence of exogenous IL-2 (Liu & 
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Rosenberg, 2001).  Alternatively, a chimeric GM-CSF/IL-2 receptor could be used, 
where stimulation of T cells results in GM-CSF secretion and initiation of an 
autocrine T cell growth loop (Cheng et al, 2002).  Tumours may also secret or induce 
secretion of inhibitory cytokines, for example transforming growth factor (TGF)-β, 
creating a tumour microenvironment which prevents ati-tumour immune responses, 
as is the case in HL (Newcom & Gu, 1995; Gruss & Kadin, 1996).  One strategy to 
defend therapeutic cells against tumour inhibitory factors is engineering them with a 
dominant negative TGF-βII receptor (Bollard et al, 2002).  This has been shown to 
protect EBV-specific CTLs from TGF-β mediated inhibition, whilst their phenotype, 
growth characteristic and ability to specifically lse EBV-positive cells remained 
unaffected (Bollard et al, 2002). 
 
As mentioned previously, safety is a major concern when designing engineered T 
cells for therapy.  Although there has been no evidence so far of insertional 
mutagenesis in clinical testing of cells engineered using viral vectors, as seen with 
the CAIX-targeted trial mentioned above, cross-reactivity with healthy tissue is a real 
risk.  Also, given the interest in the incorporation f additional costimulatory 
moieties intended to enhance T cell proliferation and persistence, uncontrolled 
lymphoproliferation is also a possibility.  To guard against these and other 
unforeseen adverse events, inclusion of suicide gens is a prudent option.  HSV-TK 
has been used for this, where expression of HSV-TK results in the phosphorylation 
of the non-toxic prodrug, ganciclovir. The active, phosphorylated analogue is 
incorporated into the DNA cells causing death by apoptosis.  However, as it is a viral 
protein HSK-TK can provoke an immune response against therapeutic cells, greatly 
reducing efficacy (Ciceri et al, 2007).  Thus, recent work has investigated the 
engineering of suicide genes using endogenous proteins such as caspase 9 (Tey et al, 
2007).  In the inducible caspase 9 system, administration of a synthetic drug (a 
chemical inducer of dimerisation) results in cross-linking and activation of the 
suicide gene product and subsequent apoptosis of the engineered cell (Straathof et al, 
2005b). 
 
Although this project has focused on the use of CD8+ CTLs as therapy, CD4+ T cell 
subsets also have an important role to play in vivo.  The function of Tregs in cancer 
immunity has yet to be fully elucidated. Tregs are, however, enriched in TILs and 
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PBMCs of cancer patients, suggesting they contribute to the suppression of anti-
tumour immune responses (Woo et al, 2001; Griffiths et al, 2007).  CD4+ cells, 
nonetheless, are required together with CD8+ cells to generate an effective response 
in vivo (Dudley et al, 2001; Einsele et al, 2002), as well as for initiation and 
maintenance of CD8 memory (Bevan, 2004).  Therefore, depletion of the entire 
CD4+ T cell subset from therapeutic populations is not an option.  Further research is 
required to find a balance between CD4+ T cell help and suppression of CTL 
responses.  Recent reports point to lymphodepletion prior to adoptive 
immunotherapy as a promising strategy in the clinic (Rosenberg & Dudley, 2004).  
The reasons why this approach enhances the efficacy of therapeutic T cells are not 
entirely clear.  One  possibility is that the creation of immune ‘space’ reduces 
competition between native and introduced cells forstimulatory cytokines, 
alternatively the removal of Tregs may reduce suppression of anti-tumour immunity 
(Wrzesinski & Restifo, 2005). 
 
With so many alternatives potentially able to improve the efficacy of engineered T 
cells, the biggest challenge facing scientists is ascertaining which options are useful 
and complementary, and subsequently incorporating these into treatment regimes.  
Cancer immunotherapy treatments will need to be multifactorial in order to fully 
harness the enormously complex human immune system. However, there is much yet 
to be learned with regard to gene modified T cells, and hopefully the understanding 
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